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Abstract 
Introduction: Alzheimer’s disease (AD) is a complex neurological disease, characterized by 
two protein aggregate forms, namely extracellular amyloid-beta (Aβ) plaques and intracellular 
neurofibrillary tangles of tau protein. AD is the most common type of progressive dementia 
and is currently poorly treated, which is associated with poor clinical outcomes. Although 
significant insight has been gained regarding AD pathology, limited progress has been made 
in the development of pharmaceutical therapeutics that modify or reverse the debilitating 
effects of this disease. Autophagy is a vital process involved in cellular survival, as it is 
essential for organelle and long-lived protein turnover. As such, it is widely accepted that 
autophagy impairment is a major contributing factor in the development of AD. Gingko biloba 
(GB) and lithium chloride (LiCl) have been reported to be neuroprotective in the context of 
neurodegenerative diseases. Even though some countries readily prescribe GB and LiCl to 
individuals suffering from AD, their mechanism of action, their potency in enhancing 
autophagy and their ability to clear toxic protein aggregates remains largely unclear. We 
hypothesized that treatment with GB will exhibit a concentration dependent effect on 
autophagic activity, and this effect will be further enhanced through combination treatment 
with LiCl. This effect may then translate in the distinct removal of amyloid precursor protein 
(APP) and Aβ, preserving lysosomal function and mitochondrial integrity. The aim of the 
proposed study was therefore to investigate the effect of both GB and LiCl as a single or 
combination treatment intervention on the modulation of autophagy activity, and the 
mitigation of Aβ proteotoxicity in an in vitro model of AD.  
Methods and Materials: Neuroblastomas 2A mouse neural cells, stably expressing AD-
related Swedish mutant form of the APP695 plasmid were utilized and cultured under 
standard conditions. WST-1 assays were utilized to determine suitable drug concentrations. 
Immunoblotting of LC3-II and p62 protein in the absence and presence of the lysosomal 
inhibitor bafilomycin A1 (BafA1) were used to assess autophagy activity. Autophagy 
induction was also characterized using fluorescence microscopy and transmission electron 
microscopy (TEM). Immunoblot techniques were utilized to assess the clearance effect of 
key amyloidogenic and mitochondrial fission/fusion was assessed using a combination of 
immunoblotting and fluorescence microscopy. Lysosomal integrity was assed using an 
acridine orange stain, while the LAMP2a protein expression profile was assessed through 
western blotting. Finally, to assess the protective role of GB, western blot analysis probing for 
cytochrome-c, cleaved caspase-3 and 4HNE was conducted. 
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Results: 48 hrs butyric acid (BA) treatment and subsequent APP overexpression 
significantly decreased reductive capacity, however, a 24-hr pre-treatment with LiCl, GB↓ 
10µg/ml & GB high (↑:200µg/ml) and GB↓ + LiCl preserved reductive capacity. Significantly 
increased LC3-II protein levels were observed following GB low (↓:10µg/ml), GB high 
(↑:200µg/ml), GB low (↓:10µg/ml) + LiCl and GB high (↑:200µg/ml) + LiCl treatment before 
and after BafA1 exposure. Moreover, a significant reduction in APP, BACE, Aβ and 
cytochrome-c protein levels was observed following 24 hrs treatment of LiCl, GB low 
(↓:10µg/ml) and GB high (↑:200µg/ml) in the absence and presence of LiCl. A significant 
increase in p62 protein levels was observed when cells were exposed to GB high 
(↑:200µg/ml) followed by BA and BafA1 treatment, in comparison with control and GB low 
(↓:10µg/ml) treated cells followed by BA and BafA1 treatment, respectively. When the 
induction of autophagy by GB high (↑:200µg/ml) was inhibited, the protein levels of APP, 
BACE, Aβ, cytochrome-c and 4HNE were elevated. This scenario led to impairment in 
mitochondrial and lysosomal function, which was improved by GB treatment in the absence 
and presence of LiCl. 
Discussion and Conclusion: Our results provide clear evidence that GB, and more 
specifically, GB in combination with LiCl, an FDA approved drug, reduces Aβ pathology, 
preserves lysosomal and mitochondrial function and thereby attenuates Aβ-induced cell 
death by upregulating autophagy. In addition, even though both, low and high concentrations 
of GB result in a similar degree of protection, their effect on protein clearance through 
autophagy, and autophagy activity itself is distinct, suggesting that autophagy can indeed be 
finely controlled. We therefore recommend that individuals suffering from AD, or those 
susceptible to AD, are supplemented with the dose of GB which provides the highest 
clearance, highest protection and highest flux, which we reported as GB (↑:200µg/ml). Hence 
a suitably high, yet non-toxic concentration may be recommended as adjuvant treatment. 
Future research may focus on testing patients by using patient derived cells, such as 
fibroblasts, to screen and select most suitable drugs to enhance autophagy and protein 
clearance. 
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Opsomming 
Inleiding: Alzheimer-siekte (AS) is ‘n komplekse neurologiese siekte, gekarakteriseer deur 
twee proteïen aggregate, naamlik ekstrasellulêre amiloïed-beta (Aβ) plaak en intrasellulêre 
neurofibrilêre voue van tau proteïen. AS is die mees algemene tipe progressiewe demensie, 
word huidiglik swak behandel en is bekend vir swak kliniese uitkomste. Alhoewel beduidende 
kennis opgedoen is wat AS patologie betref, is daar beperkte vordering in terme van die 
ontwikkeling van farmaseutiese terapie wat die aftakelende uitwerking van die siekte 
verander of om keer. Outofagie is ‘n noodsaaklik proses betrokke in die oorlewing van selle 
aangesien dit noodsaaklik is vir organel en langlewende proteïen omset. As sulks word dit 
oor die algemeen aanvaar dat outofagie disfunksie ‘n groot rolspeler is in die ontwikkeling 
van AS. Vorige bevindinge dui daarop dat Gingko biloba (GB) en litium chloried (LiCl) ‘n 
neurobeskermende effek het in die konteks van neurodegeneratiewe siektes. Alhoewel 
sommige lande geredelik GB en LiCl voorskryf aan individue wat lei aan AS, is dit steeds 
onduidelik hoe hierdie middele op ‘n meganistiese vlak te werk gaan om die siekte te beveg 
en tot watter mate hul outofagie versnel en toksiese proteïen aggregate verwyder. Ons stel 
voor dat behandeling met GB ‘n konsentrasie afhanklike effek op outofagie aktiwiteit sal toon 
en dat hierdie effek verder versnel sal word in kombinasie met LiCl. Hierdie effek kan 
moontlik oorgedra word tot die verwydering van amiloïed voorganger proteïen en Aβ wat lei 
tot die behoud van lisosomale funktionaliteit en mitochondriale integriteit. Die doel van die 
voorgelegde studie is dus om te ondersoek wat die effek van GB en LiCl, beide op hul eie 
sowel as in kombinasie, sal wees op die modulasie van outofagie aktiwiteit en op die 
verlaging van Aβ proteotoksisiteit in ‘n in vitro model van AS. 
Metodes en materiale: Neruoblastomas 2A muis neurale selle wat die AD-verwante 
Sweedse mutasie van die APP695 plasmied stabiel uitdruk was gebruik en gekweek onder 
standaard kondisies. WST-1 toetse was gebruik om geskikte konsentrasies van di middelste 
bepaal. Immunoblottering van die LC3-II en p62 proteïen in die afwesigheid en 
teenwoordigheid van die lisosomale inhibeerder bafilomisien A1 (BafA1) was gebruik om 
outofagie aktiwiteit te ondersoek. Outofagie induksie was ook gekarakteriseer deur gebruik te 
maak van fluoressensie mikroskopie en transmissie elektron mikroskopie (TEM). ‘n 
Kombinasie van Immunoblotterings- en fluoressensietegnieke was gebruik om die 
klaringseffek van sleutel amiloïedogeniese en mitochondriale fisie/fusie te bestudeer. 
Lisomale integriteit was geannaliseer deur gebruik te maak van ‘n akridien oranje kleurstof 
terwyl die LAMP2a proteïen uitdrukkingsprofiel geannaliseer is deur westerse blottering. 
Laastens om die beskermende rol van GB te assesseer was westerse blotteringsanalisie 
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uitgevoer met die oog daarop om die vlakke van sitochroom-c, gekleefde caspase-3 en 
4HNE vas te stel. 
Resultate: 48-uur butirielsuur behandeling en daaropvolgende APP ooruitdrukking het die 
reduksiekapasiteit aansienlik verminder. Deur ‘n 24-uur pre-behandeling met LiCl, GB↓ 
10 µg/mol + GB hoog (↑:200 µg/ml) en GB↓ + LiCl is die reduksiekapasiteit egter behou. ‘n 
Verhoging in die LC3-II proteïenvlakke is waargeneem na behandeling met GB laag 
(↓:10 µg/ml), GB hoog (↑:200 µg/ml), GB laag (↓:10 µg/ml) + LiCl en GB hoog (↑:200 µg/ml) + 
LiCl voor en na BafA1 blootstelling. Verder is ‘n verlaging in APP, BACE, Aβ en sitochroom-c 
proteïen vlakke waargeneem na 24-uur behandeling met LiCl, GB laag (↓:10 µg/ml) en GB 
hoog (↑:200 µg/ml) in die afwesigheid en teenwoordigheid van LiCl. ‘n Verhoging in die p62 
proteïenvlakke is waargeneem met die blootstelling van selle aan GB hoog (↑:200 µg/ml) 
gevolg deur BA en BafA1 behandeling in vergelyking met die kontrole en met GB laag (↓:10 
µg/ml) behandelde selle gevolg deur BA en BafA1 behandeling onderskeidelik. In die geval 
waar die induksie van outofagie deur GB hoog (↑:200 µg/ml) geïnhibeer was, was daar ‘n 
verhoging in die proteïenvlakke van APP, BACE, Aβ, sitochroom-c en 4HNE. Hierdie 
scenario het gelei tot ‘n verswakking in die mitochondriale en lisosomale funksie wat verbeter 
is deur behandeling met GB in die afwesigheid en teenwoordigheid van LiCl. 
Bespreking en afsluiting: Die resultate verskaf bewyse dat GB, en meer spesifiek GB in 
kombinasie met LiCl, ‘n FDA goedgekeurde middel, Aβ patologie verlaag, lisosomale en 
mitochondriale funksie onderhou en daarby Aβ-geïnduseerde seldood verlaag deur outofagie 
te opreguleer. Alhoewel lae en hoe konsentrasies van GB lei tot ‘n soortgelyke vlak van 
beskerming, is hul effek op proteïenklaring deur outofagie en outofagie-aktiwiteit nie 
dieselfde nie wat daarop dui dat outofagie fyn beheer kan word. Ons stel dus voor dat 
individue wie ly aan AS, of wie vatbaar is vir AS, aanvullings meet krymet die dosis GB 
(↑:200 µg/ml) wat die hoogste klaringsvlak verskaf, die hoogste beskerming en die hoogste 
fluksuasie-koers bied. Dus ‘n geskikte hoë, nie-toksiese konsentrasie kan voorgestel word as 
‘n bykomende middel vir die behandeling of voorkoming van AS. Toekomstige navorsing kan 
fokus op die toetsing van patiënte deur gebruik te maak van patient-afgeleide selle, soos 
fibroblaste, om die mees geskikte middel vas te stel om outofagie en proteïen klaring te 
bevorder. 
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CHAPTER 1: LITERATURE REVIEW 
1 Introduction 
Neurodegeneration (ND) describes the process of steady and progressive degeneration and 
loss of neuronal cells, resulting in the malfunction of the central nervous system. Impaired 
proteostasis, protein misfolding and abnormal protein aggregation are common features of 
most neurodegenerative diseases, invariably leading to neuronal toxicity and cell death 
onset. Hence, there is an urgent need for novel therapies to either halt or reverse the 
progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD), which continue to impose a tremendous societal and economic 
burden (Alzheimer’s Association, 2016). Despite the availability of extensive data from both 
in vitro and in vivo model systems, the precise pathogenic mechanisms leading to the 
development of neurodegenerative diseases remains unclear. To this end, the mechanistic 
understanding of the major molecular and pathological processes implicated in the 
progression of neurodegenerative diseases, may aid in the development of novel disease 
modifying therapeutics. AD is a severe neurodegenerative disease and the most common 
form of senile dementia amongst the elderly, affecting over 46.8 million people globally 
(Alzheimer’s Association, 2016). Age is a major risk factor for the development and 
progression of AD, with the number of people aged 60 years and older projected to more 
than double in the next 35 years and with the prevalence of AD and PD expected to increase 
by a drastic 7.1 million newly diagnosed cases by 2025 (United Nations, 2015). AD is a 
growing concern in developing countries such as South Africa (SA), where the provision of 
services is poor (de Jager et al., 2017). In SA, an estimated 187 000 elderly individuals were 
reported to be living with dementia (Alzheimer’s Association, 2016). This prevalence is 
expected to rise to 250 000 by 2030, with the population concurrently increasing in the 
number of elderly individuals (60 years and older). This is likely to pose an even greater 
societal and economic challenge to resource poor countries, with already-severely stretched 
health and social care systems. 
Although research efforts have intensified in the last decade, AD remains greatly 
understudied and poorly documented in the context of SA. The lack of AD-related research 
focus in SA may be attributed, at least in part, to the high burden of Human 
immunodeficiency virus infection/acquired immune deficiency syndrome (HIV/AIDS) 
pandemic and Tuberculosis (TB), which are currently classified as diseases of major national 
priority. Hence, available resources are largely dedicated to the study and prevention of 
these diseases, while non-communicable diseases such as AD remain largely neglected. AD 
is a complex neurological disease, and the most common type of progressive dementia 
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associated with poor clinical outcomes (Wimo et al., 2017). AD remains an unmet clinical 
challenge and is characterized by the progressive degeneration and eventual loss of 
neurons, particularly in the hippocampal and cerebral cortex region (Jack et al., 2013). 
Clinically, dementia is diagnosed when normal daily living is severely compromised following 
progressive cognitive impairment. Although insight has been shed regarding AD pathology, 
limited progress has been made in the development of pharmaceutical therapeutics that 
modify or reverse the debilitating effects of this disease.  Currently, all approved treatment 
options for AD are primarily symptomatic. This includes acetylcholinesterase inhibitors, as 
well as N-methyl-D-aspartate (NMDA)-receptor antagonist which treat symptoms but not the 
underlying molecular dysfunction and cause (Anand et al., 2014). Despite advances in 
unravelling the biological underpinnings of AD pathology, to date there are still no disease-
modifying therapies available for those affected. This highlights the substantial need for 
dedicated research efforts toward the development of better targeted AD therapeutic 
interventions that are strongly aligned with the molecular defect and may potentially modify 
the progression of the disease. In this literature discussion, I will therefore provide an in-
depth background of the molecular mechanisms that have been identified to play a key role 
in the disease onset and progression. These may present novel targets, which may hold 
potential for the development of therapeutic interventions in the treatment of 
neurodegenerative diseases such as AD, PD etc.  
Recently, the role of proteotoxicity and macro-autophagy (hereafter referred to as autophagy) 
in the context of neurodegeneration has received major attention. The autophagy process 
will be discussed in greater detail in the context of proteolytic systems. Therefore, in 
particular the molecular mechanisms that govern protein degradation and neuronal cell death 
will be highlighted. It is in this context, that two drugs, namely Gingko biloba (GB) and lithium 
chloride (LiCl) have been reported to be neuroprotective (Kanowski, et al., 1996; Baldessarini 
et al. 1999). Importantly, in some countries, both drugs are often prescribed to individuals 
suffering from AD, however, their mode of action of action remains largely unclear. LiCl is a 
promising compound that has been shown to modulate the activity of the autophagy pathway 
(Sarkar et al., 2005), and has been approved and used clinically, primarily in the treatment of 
depression.  However, drugs that modulate autophagic activity, and thereby impact the 
removal of toxic protein aggregates have not been fully explored for translation at the clinical 
level, largely due to limited knowledge about drug concentration ranges that affect and 
control autophagy. Similarly, GB is currently recommended as a supplement for AD patients, 
but questions related to its clinical application in the context of AD remain unclear. GB is 
known to have beneficial neuroprotective properties, but it is currently unclear to what extent 
it induces autophagic activity. Interestingly, these two drugs have been shown to impact 
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proteolytic clearance of toxic proteins such as amyloid beta (Aβ) by modulating the 
autophagy pathway, thus making these drugs favourable candidate compounds for 
therapeutic intervention in AD. However, it is unclear which concentration of GB or LiCl 
would maximize protein degradation and hence favour neuronal cell survival. It is also not 
clear whether a combination of both drugs could further enhance protein degradation through 
enhanced autophagic activity. In order to understand the underlying molecular mechanisms 
which are involved in steering the onset and progression of AD, it is important to focus on the 
physiology of functioning neurons with their distinct dependence on protein degradative 
pathways, and the precise control and regulation of these pathways. Accordingly, the basic 
molecular mechanisms, proteolytic production and Aβ degradation will first be discussed. 
1.1  AD pathology: basic molecular mechanisms  
In the year 1906, the neuroscientist Alois Alzheimer, studied post-mortem brains of women 
who had died from gradual behavioural and cognitive dysfunction (Hardy and Higgins 1992). 
In 1968, a relationship between the magnitude of Aβ plaques in brain tissue of the elderly 
and the risk of developing dementia was first described (Hardy and Higgins 1992). It has 
been suggested that prior to the deposition of Aβ1-42 peptides in the formation of amyloid 
plaques, Aβ initially forms oligomers and later forms insoluble fibrils (Ahmed et al., 2010). 
The regions that are characterized by an accumulation of amyloid plaques have been shown 
to be surrounded by neurons that contain neurofibrillary tangles (NFTs). Controversy exists 
about the order of events in the pathogenesis of AD, and the molecular mechanisms that 
govern the relationship between NFTs and amyloid plaques. For many years, the amyloid 
cascade hypothesis (ACH) has been suggested as a key underlying mechanism for AD 
pathology, which suggests that the presence of Aβ may be the first histological feature in AD, 
with other secondary features arising later in disease progression (Hardy and Higgins, 1992). 
The ACH suggests that the deposition of amyloid plaques (mainly containing Aβ peptides) is 
the causative factor in AD pathology, and that the formation of NFTs, vascular damage, 
neuronal cell loss and dementia occur due to increased Aβ deposition (Hardy and Higgins 
1992). 
Pathologically, AD is characterized by the presence of senile plaques, composed mainly of 
Aβ peptides and NFTs composed of hyperphosphorylated cleaved forms of microtubule-
associated protein tau (Paradis, Koutroumanis and Goodyer, 1996). However, the 
accumulation of Aβ peptides in the brain appears to be the main contributor to the 
pathogenesis of AD. Moreover, the aggregation of toxic proteins has shown to be critical in 
most neurodegenerative diseases, including PD and Huntington’s disease (HD). Protein 
aggregation is defined as the clumping of misfolded, aggregate-prone proteins (Hartl and 
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Hayer-Hartl, 2009). Interestingly, very recently these protein aggregates have also been 
proposed to offer protective properties (Swart et al., 2014).  Moreover, whether neurotoxicity 
originates from the misfolded protein intermediates or the aggregate bodies themselves 
remains unknown. One hypothesis is that misfolded proteins become toxic, and therefore are 
predisposed to aggregation in brain areas mostly implicated in AD (Swart et al., 2014).  
Although the majority of AD cases manifests as a late onset sporadic form (LOAD), the role 
of genetic factors in the pathophysiology of AD is increasingly recognised in early onset AD 
(EOAD) or Familial AD cases (Alzheimer’s Association, 2016). Familial AD occurs before the 
age of 65 and is thought to be a rare form of the disease which is usually due to hereditary 
mutations (Alzheimer’s Association, 2016). LOAD accounts for more than 95% of all AD 
cases and occurs in individuals older than 65 years. In Familial AD, genetic mutations in 
coding genes of proteins participate in the breakdown of amyloid precursor protein (APP) 
and production of Aβ (i.e. the APP gene, the presenilin1 (PSEN1) gene and the presenilin 2 
(PSEN2) gene) (Folch et al., 2015). These mutations favour and trigger the formation of 
neurotoxic species of the Aβ peptide, primarily Aβ42 peptide. PSEN1 mutations have also 
been shown to cause autophagy defects (Chong et al., 2018). The sporadic form of AD is 
influenced by both genetic and environmental factors (i.e. epigenetic factors), which impact 
the clearance of neurotoxic Aβ peptides, and may thereby contribute to the complex 
pathology of AD. 
The ACH suggests an imbalance between the production and clearance of Aβ, with a 
decrease in the clearance of Aβ in sporadic AD and increased Aβ production in the familial 
form of AD (Hardy and Higgins 1992). Familial and sporadic AD patients have been shown to 
be clinically indistinguishable, and increased Aβ deposition and neurotoxicity is thought to 
represent the most consistent feature, suggesting that both AD forms may share common 
underlying molecular mechanisms (Bali et al., 2012). Amyloids are defined as tissue deposits 
of extracellular fibrils (Hardy, 1997), which are present in low quantities under physiological 
conditions, and play an important role in synaptic physiology (O’Brien and Wong, 2011). 
Strikingly, the role of its precursor protein, APP remains unclear, although it has been shown 
that the expression of APP confers overall beneficial effects such as neuronal growth and 
increased cellular viability (O’Brien and Wong, 2011). Consequently, studies have focused 
on the production and the degradation of Aβ with AD progression (Hyttinen et al., 2014). 
1.2  APP processing, Aβ production and degradation 
APP can be metabolized rapidly in a series of complex processes by a group of secretase 
enzymes (Fig.1.1) (Hardy and Higgins, 1992). APP is sorted in the Golgi apparatus and the 
endoplasmic reticulum, and further transported to the axon, where it is delivered to the 
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synaptic terminals (cell surface) by the trans-Golgi network, which is a crucial site for the 
processing of APP (Lodish et al., 2000). Following transport along the trans-Golgi network, 
APP can further be transported directly to endosomal compartments or to the surface of the 
cell (Lodish et al., 2000). The precise intracellular localization of APP processing is a vital 
factor determining whether Aβ is produced. Following the amyloidogenic pathway, APP is 
incorporated into endosomal components through clathrin-coated vesicles and is initially 
cleaved by beta-site APP-cleaving enzyme 1 (BACE1) (Hardy and Higgins, 1992). This 
cleavage, results in the generation of a soluble N-terminal fragment termed sAPPβ. The C-
terminal fragment of APP (C99), which is bound to the cell membrane, is further cleaved by 
the y-secretase-presenilin complex at Aβ sites between Aβ40-Aβ44 (Hardy and Higgins, 
1992). This process leads to the production of Aβ peptides and the intracellular APP domain 
(AICD) (Takahashi et al., 2002). Several peptide isoforms ranging in length from 39 to 43 
amino acids are formed during the amyloidogenic cleavage of APP, with Aβ40 and Aβ42 
being the most-commonly found isoforms. Aβ42 is the more neurotoxic isoform, as it 
aggregates more rapidly and forms insoluble plaques that lead to neuronal cell death and 
cognitive defects (Kellett and Hooper, 2009). In the context of AD, the abnormally increased 
production of Aβ occurs through the amyloidogenic processing of APP. It is important to note 
that the formation of Aβ peptides is an ongoing, gradual process, thereby explaining why AD-
associated pathology is evidenced decades prior to its clinical manifestation (Alzheimer’s 
Association, 2015).  
Alternatively, APP can be metabolized through the non-amyloidogenic pathway, where it is 
initially cleaved by α-secretases (Fig.1.1) (Kellett and Hooper, 2009). During this process, 
APP is sorted in the Golgi apparatus and the endoplasmic reticulum, and further transported 
to the axons’ surface where it is cleaved by γ-secretase to form non-pathogenic soluble 
products, including P3 fragments (O’Brien and Wong, 2011). α-secretase cleavage occurs in 
the Aβ domain of APP, thereby inhibiting the production of Aβ. Notably, the target protein 
sequence identified by α-secretase is closer in proximity to the cell surface than those of 
BACE1, as a result the non-amyloidogenic pathway is generally more favoured under 
physiological conditions (O’Brien and Wong, 2011). 
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Figure 1.1: Amyloidogenic and non-amyloidogenic pathway of APP processing. APP is internalized 
into the endosome membrane where it is cleaved by BACE1 releasing CTF- and insoluble APPβ. The 
latter is subsequently cleaved by γ-secretase that releases AICD+Aβ. Consequently, the insoluble 
APPβ is released to the extracellular space via exocytosis. Thereafter, Aβ peptides that are 42 amino 
acids long aggregate into plaques and induce neurotoxicity. Abbreviations: Aβ = amyloid-beta, APP = 
amyloid precursor protein, AICD = intracellular APP domain, C99 = C-terminal fragment, COOH = 
carboxylic acid terminal, NH2 = NH2 terminal (Adapted from Ntsapi et al., 2017). 
Estus and colleagues suggest that APP can also be processed by the endosomal-lysosomal 
pathway, after recycling of membrane-bound APP and possibly via an intracellular metabolic 
route (Estus et al., 1992). The endosomal-lysosomal pathway has been shown to be involved 
in the processing of APP following the recycling of the membrane-bound APP (Wirak et al., 
1991). This alternative processing pathway of APP can produce carboxyl-terminal segments 
comprising the complete Aβ peptide, which may ultimately lead to increased Aβ deposition 
(Estus et al.,1992). This points towards the importance of the lysosomal system in the 
context of APP processing, which is important since lysosomal dysfunction is also a hallmark 
of AD.  
1.3  Mechanisms of Amyloid-Beta-induced toxicity  
The contribution of Aβ in the progression of AD is well established. However, studies have 
shown that Aβ peptide also mediates several physiological process, such as calcium and 
potassium regulation (Kellett and Hooper, 2009). Kellet and Hooper further highlighted the 
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fact that Aβ only becomes toxic when its levels increase above physiological levels, due to 
the imbalance in production and clearance, as evidenced in AD. In sporadic forms of AD, the 
amyloidogenic processing of the APP pathway is accelerated as a result of increased protein 
expression and enhanced BACE1 activity (O’Brien and Wong, 2011). Since BACE1 is the 
rate-limiting step in the production of Aβ, an increase in its protein expression and activity 
influences the protein levels of Aβ peptide. In a neuroblastoma 2A (N2a) mouse neural cell 
line that stably expresses the AD-related Swedish mutation (APPswe), the levels and activity 
of BACE1 were shown to increase markedly following treatment with APP-transgene inducer, 
butyric acid. Consequently, the expression of the APP was increased, resulting in increased 
production of Aβ (Shin et al., 2016). 
Studies have extensively reported several molecular disruptions as a direct result of 
increased Aβ protein levels (Behl et al.,  1994). In an in vitro study by Behl et al. (1994), 
absolute cell death was demonstrated in cultured rat pheochromocytoma PC12 cells and rat 
cortical neurons exposed to exogenous Aβ fibrils for 24 hrs. This finding revealed that Aβ 
fibrils are acutely neurotoxic (Behl et al., 1994). Mouse models overexpressing mutant 
human APP displayed increased Aβ deposition within four to six months and manifested 
sequential injury of neuronal cells, synaptic dysfunction and inflammatory damage (O’Brien 
and Wong, 2011). In these mouse models, numerous caspases (3, 6, 7, and 9) were shown 
to be activated, contributing to the demonstrated death of neuronal cells via apoptosis. Aβ 
has also been shown to directly contribute to tau pathology, which is also a major hallmark in 
AD pathology (Mawuenyega et al., 2011). Studies have shown that soluble Aβ promotes 
hyperphosphorylation and cleavage of tau, resulting in the generation of NFTs. Furthermore, 
extracellular Aβ has been shown to activate Glycogen synthase kinase 3 beta (GSK3β), 
which is a key regulator for tau phosphorylation (Hyttinen et al., 2014). The intracellular NFTs 
are composed of hyperphosphorylated microtubule-associated tau protein aggregates 
present in several neurons (Perl and Perl, 2010). Tau protein is vital in the stabilization of the 
microtubule network of the cytoskeleton (Fontaine et al., 2015), and its phosphorylation 
regulatory process have been shown to be controlled by the activity of GSK3. In AD states, 
GSK3 activity has been demonstrated to increase, resulting in the hyperphosphorylation and 
aggregation of tau (Avila et al., 2004). A more recent study revealed that the reduction of Aβ 
peptides prevents the development of spatial memory impairment and inhibits tau pathology 
(Vanden et al.,  2017). Taken together, these studies suggest that Aβ neurotoxicity may be a 
mediator of tau pathology in AD. 
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1.4  NFTs and BRAAK staging  
Although the diagnostic criteria for AD was initially developed by Alois Alzheimer (Alzheimer, 
1911), it was pioneering work by Braak and Braak (1991) that led to the establishment of a 
staging system to monitor the progression of the disease. This monitoring system is termed 
the “Braak staging of Alzheimer disease-associated neurofibrillary pathology” and is based 
on the progressive region-specific protein aggregation (Braak and Braak, 1991). The 
progression of AD is typically slow and develops in three-sub-divided stages, namely mild 
(early-stage), moderate (middle-stage), and severe (late-stage) (Alzheimer’s Association, 
2015). Early in the AD stages, the hippocampus undergoes atrophy (Caselli and Reiman, 
2013), leading to failure in cognitive function, specifically memory formation. This contributes 
to the significant link between AD and dementia.  
1.5 Proteolytic systems  
1.5.1 Autophagy  
The disruption of proteostasis and the dysregulation in protein degradative pathways is 
associated with the onset of AD (Komatsu et al., 2006). The presence of protein aggregates 
in AD illustrates a failure in the neuronal cells’ protein quality control systems (Hyttinen et al., 
2014). Therefore, the maintenance of proteostasis and a tight equilibrium between protein 
synthesis and degradation is vital in the removal of abnormal, aggregate-prone proteins 
(Sarkar et al., 2009). Neuronal cells rely heavily on protein quality control systems to meet 
their metabolic demands during periods of energy/ nutrient deprivation (Rubinsztein, 2006). 
The maintenance of proteostasis is accomplished by two degradative processes, including 
the ubiquitin-proteasome pathway (UPP) and the autophagy-lysosomal pathway (ALP). The 
UPP primarily targets short-lived cytosolic and nuclear proteins whereas the ALP degrades 
long-lived cytoplasmic proteins and impaired organelles  (Mizushima et al., 2010). Given that 
99% of intracellular proteins are long-lived, the maintenance of proteostasis depends 
primarily on ALP in neuronal cells (Mizushima et al., 2010).  
The ALP comprises of three sub-divisions based on how cargo is transported for degradation 
to the lysosome. The sub-types include microautophagy, autophagy, and chaperone-
mediated autophagy (CMA) (Mizushima et al., 2010). CMA involves the selective recognition 
and delivery of cytosolic proteins harbouring a pentapeptide amino acid sequence (the CMA 
targeting motif - KFERQ) to the lysosomal surface, where upon unfolding, they are 
internalized through a membrane translocation complex involving lysosome-associated 
membrane protein type 2A (LAMP-2A) for subsequent degradation by lysosomal proteases 
(Kaushik and Cuervo, 2015). Microautophagy involves the direct engulfment of cytoplasmic 
material that is trapped by the vacuole of lysosomes through a process termed membrane 
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invagination (Nixon, 2011). Finally, autophagy is defined as a process that results in the 
sequestration of cytoplasmic material into double-membraned vesicles termed 
autophagosomes, which in turn fuse with lysosomes or late endosomes to acquire hydrolytic 
activity, forming the autolysosome compartment in which the sequestered cargo is 
subsequently degraded (Mizushima, 2007). This process leads to the generation of amino 
acids which can be reused by the cell to adapt to fluctuations in nutrient supply, to produce 
adenosine triphosphate (ATP) to drive energy-dependent processes such as protein 
synthesis (Loos et al., 2013). Autophagy also  removes damaged organelles such as 
mitochondria and thereby prevents the stimulation of cell death processes emanating from 
increased reactive oxygen species, decreased cellular antioxidant mechanisms, as well as 
protecting cells against proteotoxic stress (Rabinowitz and White, 2010). The turnover of 
organelles and cellular macromolecules may be indicative of the essential role of autophagy 
in various physiological processes, including differentiation, normal growth, cellular survival 
and during starvation (Kabeya et al., 2000). The first direct evidence linking proteostasis 
control and autophagy in the nervous system came from studies in which genetic deletion of 
essential autophagy genes Atg5 (Hara et al., 2006) or Atg7 (Komatsu et al.,2006) in the 
central nervous system caused spontaneous neurodegeneration, promoting extensive 
neuronal loss, the accumulation of protein aggregates, and premature death in mice. Most 
cell types show a low level of basal autophagic activity which plays a prominent role in the 
intracellular turnover of proteins and organelles (Funderburk et al., 2010). However, 
autophagic activity may be enhanced by diverse stress signals such as nutrient starvation, or 
hypoxia, or through the use of various pharmaceutical drugs such as rapamycin and 
spermidine (Rabinowitz and White, 2010).  
Disruptions in the autophagy pathway have been shown to enhance abnormal protein 
aggregation in neurodegenerative diseases, as well as contribute to the development of 
various pathologies including cancer, cardiovascular diseases and lysosomal storage 
disorders (Nixon and Yang, 2011). It is important to note that neurons are highly sensitive to 
fluctuations within the autophagy process due to their post-mitotic characteristics, and 
thereby require tight regulation of proteostasis. As such, defects within the autophagic 
system is associated with the onset of neurodegenerative diseases, including AD (Wong and 
Cuervo, 2010). 
1.5.1.1 The autophagy machinery and its regulation  
The autophagic process is regulated by a class of conserved autophagy related (Atg) genes 
that were primarily identified in yeast (Mizushima et al., 2011, Klionsky and Ohsumi, 1999). 
The autophagy process can be mechanistically organised into several sequential steps, 
namely: initiation, autophagosome membrane expansion, autophagosome maturation, and 
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lysosomal degradation, as illustrated in Fig 1.2. Firstly, during initiation, a process termed 
nucleation occurs. Nucleation results in the formation of a phagophore which matures into an 
autophagosome (Simonsen and Tooze, 2009). This process involves a multiprotein complex, 
which consists of a mammalian homolog of Atg6 (beclin1), class III phosphatidylinositol 3-
kinase (PI3K). Here the activation of PI3K by ULK/Atg1 complex leads to the association of 
Atg13-FIP200 members to an isolated membrane (phagophore), thereby forming an 
autophagosome (Simonsen and Tooze, 2009) (Fig 1.2). The ULK-Atg13-FIP200 complex 
plays a role in the induction of autophagy. 
Next, a ubiquitin ligase (E3), associated with one of the two ubiquitin-like conjugation 
systems Atg16, is required to complete the formation of an autophagosome (Ohsumi, 2001). 
The selective process of cargo degradation via autophagy requires the adaptor protein p62 
(sequestosome 1/SQSTM1), which selectively binds to ubiquitin-tagged proteins and marks 
proteins for degradation. The binding of p62 and microtubule-associated protein 1A/1B light 
chain (LC3) allows the targeted and selective degradation of cytosolic proteins via 
autophagy. This is followed by the formation of the Atg5-Atg12 complex that then binds to the 
first of the two ubiquitin-like conjugation systems (Fig 1.2). This process promotes 
transformation of LC3-I to LC3-II through lipidation with phosphatidylethanolamines (PE) 
(Ohsumi, 2001). LC3-II associates with the autophagosome membranes, hence the number 
of autophagosomes is indicative of the extent of LC3 bound to autophagy vesicles (Kabeya 
et al., 2000).  
Autophagosome membrane expansion includes the conjugation of two ubiquitin molecules. 
In brief, Atg4 processes the C-terminal 22 fragments of LC3-I to generate LC3-II, a soluble 
form of LC3 which in turn leads to the exposure of the C-terminus glycine segment (Kabeya 
et al, 2000). The exposed C-terminal of LC3-I is further conjugated by a ubiquitin system, 
comprising of Atg7 (enzyme E1), Atg3 (enzyme E2) and the Atg12-Atg5-Atg16L complex 
(enzyme E3) to PE. Finally, for the cargo engulfed by the autophagosomes to be degraded, 
the autophagosomes are required to fuse with lysosomes which contain hydrolase enzymes 
and can subsequently degrade the cargo (Fig 1.2). The fusion of autophagosomes with 
lysosomes results in the formation of autolysosomes (Mizushima, 2007). The 
autophagosome may either fuse with the lysosome to generate an autolysosome or it can 
fuse with late endosomes to produce an amphisome. Subsequently, the degradation of 
engulfed cytosolic contents is initiated by hydrolase enzymes that are contained within the 
autolysosome. A protein pump termed vacuolar [H*] ATPase is responsible for crucial events 
including the acidification of autolysosomes, cathepsin protease activation, and effective 
substrate proteolysis (Yoshimori et al., 1991). This proton pump is located on the lysosomal 
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membrane. The fusion between lysosomes and autophagosomes is continuous and includes 
the digestion of contents within the autolysosomes and ultimately lysosomal restoration 
(Mizushima, 2007). 
 
 
 
 
 
 
 
 
Figure 1:2 Regulation of autophagy. The distinctive stages within the autophagy process are shown to 
be functionally linked. The formation of autophagosomes (i.e. the initiation phase) and the final steps 
of the process (i.e. lysosomal restoration) are controlled by mTORC1. Autophagy can be induced by 
the inhibition on mTORC1, which is mediated by the PI3K signalling pathway. Abbreviations P= 
Phosphorylation, ATG=Autophagy-related protein, LC3 = microtubule-associated protein 1A/1B light 
chain, ATP = Adenosine triphosphate, mTORC1 = mammalian target of rapamycin complex, PE = 
phosphatidylethanolamines, ULK1/UNC-5 like autophagy activating kinase 1 (ULK1)). (Adapted 
from Meléndez and Levine, 2009). 
1.5.1.2 Autophagy and metabolism 
One of the primary roles of the autophagic process is to supply nutrients and metabolic 
substrates to cells especially during adverse conditions such as nutrient starvation, in order 
ensure cell survival. This is achieved mainly through the metabolism of endogenous nutrient 
reserves which may be used in the production of ATP (Loos et al., 2013). Starvation-induced 
autophagy is mainly regulated by the (mammalian target of rapamycin) mTOR signalling. The 
mTOR nutrient signalling pathway has been widely studied and shown to be a major 
regulator of the autophagic process (Ravikumar et al., 2010). mTOR is a conserved protein 
kinase that plays a key role in controlling a balance between protein synthesis and 
degradation and interacts with several proteins to form two distinct complexes: the mTOR 
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complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Tchevkina and Komelkov, 2012). 
mTORC1 consists of Rag, a protein belonging to the family of Ras-like small GTPases which 
are key mediators of amino acid–induced mTORC1 activation, bound together with a 
regulator protein called RAPTOR (Rabinowitz and White, 2010).  Several stimuli, including 
amino acids, growth factors (insulin) and energy (in the form of ATP) can cause the 
activation of mTORC1 which in turn inhibits the initiation of autophagy (Ravikumar et al., 
2010). Controlled proteostasis is vital for neuronal functioning, and mTORC1 signalling has 
been shown to play a pivotal role in controlling this process since mTORC1 promotes 
anabolic cellular metabolism to supply the necessary building blocks for cell growth and 
proliferation. mTORC2 is insensitive to rapamycin (Wullschleger et al., 2006), but the 
molecular mechanism of mTORC2 regulation by upstream effectors is largely unknown. 
However, mTORC2 has been implicated in the control of cellular morphology through the 
modulation of actin function (Cuervo et al., 2005). Increasing studies have revealed that 
aging is associated with the augmentation of abnormal proteins, and that this can be caused 
by a decline in the autophagic activity (Cuervo et al., 2005).  
Under low energy levels, the autophagic process serves as an energetic sensing mechanism 
(Loos et al., 2013). This is achieved through three main pathways involved in the sensing of 
energy, linked to the autophagic machinery. These pathways include  protein kinase A 
(PKA), adenosine monophosphate-activated protein kinase (AMPK) and mTORC1, and act 
as important regulators of metabolism, energy sensing and consequently vulnerability to cell 
death (Loos et al., 2013). The activation of mTORC1 inhibits autophagy, promotes protein 
synthesis and nucleotide synthesis as illustrated in (Fig 1.3). An increase in energy in the 
form of ATP causes a reduction in the AMPK signalling pathway which in turn causes an 
increase in the activity of mTORC1. In turn, activated AKT directly phosphorylates and 
thereby inhibits tuberous sclerosis tumour suppressor complex1/2 (TSC1/2), resulting in 
dissociation of TSC1/2 from the lysosome, where Rheb is localized, promoting formation and 
activation of the TSC/Rheb complex. Since Rheb is an activator of mTORC1, inhibition of 
TSC1/2 by AKT dependent phosphorylation results in mTORC1 activation. mTORC1 can 
also inhibit transcription factor EB (TFEB), a master transcriptional regulator of lysosomal 
and autophagy genes which inhibits the biogenesis of lysosomes which in turn negatively 
regulates the autophagy process (Rabinowitz and White, 2010). DNA damage activates p53 
which subsequently triggers TSC2 and thereby activates autophagy. Subsequently, 
extracellular signal-regulated kinase 2 (ERK1/2) is activated, which inhibits TSC2, thereby 
activating mTORC1, resulting in the down-regulation of autophagy activity (Ravikumar et al., 
2010). This pathway is stimulated when insulin binds to the receptor on the cell surface, 
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resulting in the activation of mTORC1 and thereby the inhibition of autophagy (Fig 1.3) 
(Sarkar, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Autophagy metabolism is regulated by three main pathways involved in the sensing of the 
energic status of the cell. These include, protein kinase A, adenosine monophosphate-activated 
protein kinase (AMPK) and mTORC1 which inhibits the ULK1 complex by phosphorylating complex 
components. These pathways are important regulators of metabolism, energy status and thereby 
impact vulnerability to cell death (Adapted from Loos et al., 2013). Abbreviations: AMPK = adenosine 
monophosphate-activated protein kinase, TSC2 = tuberous sclerosis complex 2, AKT/PKB = 
Protein Kinase B, TFEB = Transcription factor EB, PTEN = Phosphatase and tensin Phosphatase and 
tensin homolog deleted on chromosome 10, ULK1 = Serine/threonine-protein kinase UNC-5 like 
autophagy activating kinase, mTORC = mammalian target of rapamycin complex, PI3K= 
phosphatidylinositide 3-kinase. 
1.5.1.3 Current techniques to measure autophagic flux 
The autophagic flux is defined as the rate of protein degradation through the entire 
autophagy pathway (Klionsky et al., 2016; du Toit et al., 2014). Increased or decreased 
autophagic flux may be associated with a higher or lower autophagosome pool size. The 
selective process of cargo degradation via autophagy requires the adaptor protein p62, 
which interacts with cargo targeted for degradation. For example, p62 binds to LC3 through 
the LC3 interacting region (LIR), which is necessary for degradation of the protein. Hence, 
the total expression of p62 within a cell may be inversely correlated to the status of the 
autophagic flux.  
There are a wide range of tools and techniques used to assess autophagy. In in vivo and in 
vitro studies, autophagy can be induced through treatment with pharmacological drugs such 
as rapamycin (Boland et al., 2008). Stress signals such as nutrient deprivation or hypoxic 
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conditions also induce autophagic activity. Subsequently, the level of autophagic activity can 
be inferred by measuring the difference in LC3II levels between samples in the presence and 
absence of autophagy fusion inhibitors (Mizushima and Yoshimori, 2007). Such autophagy 
inhibitors include lysosomal protease inhibitors E64d and pepstatin A, as well as the vacuolar 
H+-ATPase inhibitor bafilomycin A1, which directly affects lysosomal pH and thereby inhibits 
the fusion of autophagosomes and lysosomes (Mizushima and Yoshimori, 2007). Western 
blotting techniques can be used to assess LC3-I to LC3-II conversion due to the distinct 
electrophoretic mobility of these LC3 isoforms as the abundance of LC3-II reflects the 
number of autophagosomes. The “flux” of LC3 puncta, as in the immunoblotting-based 
assay, can also be determined using fluorescence microscopy, where the increase in the 
number of LC3 puncta in the presence, compared to that in the absence of a 
autophagosome/lysosome fusion inhibitor, represents the number of autophagosomes that 
would have been degraded during the treatment period (Klionsky et al., 2016). Importantly, 
upstream inhibitors, such as 3-Methyladenine, would not work, as they would just decrease 
the synthesis. 
Autophagosomes have been shown to be present at low levels within healthy neurons 
(Boland et al., 2008). Initially it was thought that this was due to low autophagic activity within 
neurons. Mizushima and colleagues developed transgenic mice that systemically express 
green fluorescent protein (GFP) attached to LC3 and used fluorescence microscopy 
techniques to analyse the extent of autophagy induction by nutrient starvation in different 
tissues (Mizushima et al., 2004). This is an excellent technique to assess autophagy activity 
in in vivo studies as it facilitates the visualization of autophagosomes. Using this approach, 
autophagy induction was found to be distinct in different organs (tissues) in response to 
nutrient starvation, suggesting that autophagy is constitutively active in tissues and highly 
efficient in healthy neurons (Mizushima et al., 2004). However, it should be noted that 
although LC3-II is a good marker for autophagosomes, the amount of LC3-II itself at a given 
time point does not necessarily estimate the autophagic activity, because not only autophagy 
activation but also inhibition of autophagosome degradation greatly increases the amount of 
LC3-II. It is therefore necessary to measure the autophagic flux. 
Electron microscopic (EM) analyses have also been used to examine autophagy in in vivo 
and in vitro model systems. Regrettably, this method is time consuming and requires various 
skills, and it is sometimes challenging to morphologically distinguish autophagic vacuoles 
from other structures. However, EM may be used to assess the degradation of organelles 
such as mitochondria, which can be visualised in the nervous system, ideally employing the 
perfusion fixation to avoid changes in autophagy (Davis et al., 2014). Although EM-based 
techniques do not allow to assess the dynamic nature of the autophagy pathway, flux can be 
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inferred by fixing tissue at different time points in the presence, compared to that in the 
absence of an inhibitor (Klionsky et al., 2016). Transmission electron microscopy (TEM), can 
also be employed to semi-quantitively measure autophagy. TEM allows to measure the 
number of autophagosomes that are produced and allows to quantify the surface area of 
autolysomes (Eskelinen et al., 2011). 
Recently, a new probe referred to as the GFP-LC3-RFP-LC3ΔG probe, which is a fusion 
protein of GFP-LC3 and RFP-LC3 was developed by Kaizuka et al. (2016) to assess 
autophagic flux. In brief, this protein is translated as one fusion protein, and is subsequently 
cleaved by endogenous ATG4 proteases and produces equal amounts of GFP-LC3 and 
RFP-LC3ΔG proteins in the cytosol. RFP-LC3ΔG serves as an internal control by remaining 
stable in the cytosol, while GFP-LC3 is degraded through the autophagic process. This probe 
offers simple quantitative evaluation of the autophagic flux (Kaizuka et al., 2016). 
Interestingly, studies are currently underway to develop mice strains stably expressing GFP-
LC3-RFP-LC3ΔG to monitor both basal and induced autophagy, the currently available mice 
have only been shown to sufficiently express GFP-LC3-RFP-LC3DG in muscles (Kaizuka et 
al., 2016). 
1.6  Lysosomal function  
Lysosomes are specialized membrane-enclosed organelles that digest large molecules using 
an array of hydrolytic enzymes (Settembre et al., 2015). These vesicles are vital in the 
functional execution of protein and organelle degradation through the autophagy pathway. 
The lysosomal membrane consists of transport proteins that enable transportation of proteins 
found inside and outside of the cell, and also control lumen acidification and the fusion of this 
vesicle with other lysosomal structures such as autophagosomes (Settembre et al., 
2015).The role of lysosomes in the degradation of substrates or cellular waste is well 
established (Settembre et al., 2013). However, lysosomes have recently been implicated in 
several physiological processes such as the repair of the plasma membrane, signalling 
mechanisms and energy metabolism (Saftig and Klumperman, 2009). 
1.7  Autophagy and lysosomal dysfunction 
Given the essential role of functional lysosomal activity in the autophagy process, these 
organelles are increasingly recognised as pivotal role players in the regulation of many 
cellular processes. Thus, the effective functioning of lysosomes is crucial in the context of 
health and disease (Settembre et al., 2013). In a study by Maejima et al. (2013), suppression 
of autophagy has been shown to block the biogenesis of lysosomes under conditions of 
injured lysosomes in vitro. This highlights that autophagy is also able to sequester damaged 
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lysosomes, a process termed lysophagy, to control lysosomal biogenesis (Maejima et al., 
2013). The degradative capacity and low pH of injured lysosomes is recuperated in an 
autophagy-dependent manner. Pathogenic invasion of cells can cause lysosomes to rupture, 
leading to oxidative stress, and the onset of apoptotic or necrotic cell death (Maejima et al., 
2013). The rupture of lysosomes causes cellular contents to leak, including the leakage of 
cathepsins from the lysosomal lumen into the cytosol (Boya and Kroemer, 2008). LAMP1 
and LAMP2 are specific lysosomal membrane associated proteins which prevent the 
lysosomal membrane from being digested by the hydrolase enzymes because they are 
glycosylated (Eskelinen, 2006). The permeabilization of lysosomal membranes leads to the 
liberation of proteases into the cytosol from the lumen, which further triggers cell death onset. 
Under these conditions, proteases are released from the lysosomal lumen, which in turn 
results in the activation of a controlled mode of cell death (Terman et al., 2006). 
Several cellular processes which are dependent on functional lysosomal activity, are also 
affected by lysosomal rupture, which also leads to DNA damage, and a decrease in the 
lysosome’s degradative capacity (Boya and Kroemer, 2008). The rupture of lysosomes also 
stimulates the nucleotide-binding domain and leucine-rich repeat (NLRP3) inflammasome, 
which causes the secretion of pro-inflammatory cytokines such as IL-1B, thereby enhancing 
inflammation and promoting disease pathogenesis (Maejima et al., 2013). Hence, the rupture 
and injury of lysosomes is harmful and induces cellular stress. Several in vivo studies have 
demonstrated how cytosolic substrates including Aβ, bacteria and lipids can contribute to the 
impairment of lysosomal membranes. The lysosomal membrane has been shown to be 
impaired by various elements including mineral crystals and lysosomotropic compounds. 
These compounds are involved in the pathology of many diseases, including 
neurogenerative diseases such as AD (Boya and Kroemer, 2008). Galectin-3 (Gal-3) is a 
recently discovered marker for damaged endomembranes, including lysosomes (Paz et al., 
2010). Gal-3/Mac-2 forms part of the Galectin family members, which belongs to the family of 
lectin proteins (Paz et al., 2010). These protein families are recognized by a preserved 
sequence and by their high affinity for β-galactosides. While Gal-3 is found in the nuclear 
region as well as the cytosol, only β-galactose-containing glycoconjugates are present on the 
surface of cells and in the lumen of the Golgi apparatus, the post-Golgi secretory apparatus 
and endocytic components. Therefore, the rupture of endosomal membranes permits the 
release of Gal-3 to enter the glycoproteins present in the lumen of these compartments (Paz 
et al., 2010). In a study by Boya and Kroemer (2008), it was shown that lysosomal damage 
caused by oxidative stress leads to the recruitment of Gal-3 to LAMP1 and increased 
colocalization with LC3 (Fig 1.4), suggesting that Gal-3 may be effectively used as a 
common marker of lysosomal damage.  
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Figure 1.4: Schematic diagram of the fate of Galectin-3 following its recruitment to damaged 
lysosomes. Abbreviations: LAMP = lysosomal associated membrane proteins, ATPase = 
adenylpyrophosphatase, H
+
= hydrogen ion. Adapted from (Maejima et al., 2013). 
1.8  Extensive autophagy pathology in AD 
It is widely accepted that autophagy impairment is a major contributing factor in the 
development of AD (Nixon, 2007). Increasing evidence indicates that autophagy is 
compromised in ageing, and this impairment in turn contributes to further deterioration of 
biological functions (Hyttinen et al., 2014). Defects in the autophagy process are associated 
with a rise in the vulnerability of the cell to undergo cell death (Ntsapi et al.,2017).  The 
relationship between autophagy dysfunction, the changing rate of protein degradation in the 
specific pathology, and the aggregate prone behaviour of specific candidate proteins remains 
unclear. The maintenance of the equilibrium between protein synthesis and degradation of 
aggregate-prone cytotoxic proteins is vital for proper functioning and growth of the cell 
(Ntsapi et al., 2017).  
In an electron microscopy study on post mortem human brain samples from patients with AD, 
Nixon et al. (2005) revealed the massive accumulation of autophagic vacuoles that appeared 
to accumulate in dystrophic neurites. The dystrophy in neurons was shown to be associated 
with amyloid plaques (Nixon and Yang, 2011). The accumulation of autophagic vacuoles can 
be the result of enhanced autophagy induction, impairment of autophagosome maturation, or 
impaired fusion of lysosomes with autophagosomes, which is linked to a reduction in the 
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formation rate of autophagosomes (Nixon and Yang, 2011). In AD patients, the expression of 
beclin-1, which is an important regulator of autophagy induction, was found to be decreased 
(Pickford et al., 2008). Since beclin-1 expression is an essential protein in autophagy 
initiation and induction, a decrease in its expression causes an impairment in autophagy 
induction, thereby contributing to the build-up of toxic protein aggregates and contributes to 
AD pathology. Furthermore, in neurons isolated from PS1-deficient mice, substrate 
proteolysis and autophagosome clearance during autophagy was found to be prevented and 
impaired due to the selective impairment of autolysosome acidification and cathepsin 
activation (Lee et al., 2010). 
Furthermore, in AD brains, electron-dense autolysosomes were shown to accumulate, 
suggesting a  failure in lysosomal function within the proteolytic pathway (Lee et al., 2010). 
The use of lysosomal inhibitors and the suppression of certain cathepsins was found to result 
in the accumulation of autophagic vacuoles due to the inhibition of lysosomal proteolysis. 
Most importantly, the critical role of the autophagy process in neuronal function is highlighted 
in Atg5 or atg7 knockout mouse models (Komatsu et al., 2006, 2007). In these studies, the 
occurrence of neurodegeneration was shown to occur independent of the presence of 
cytotoxic proteins. This highlights the role of dysfunctional autophagy in neuronal disease 
progression and pathology. The ongoing removal of cytoplasmic constituents via basal 
autophagic activity is vital to avert the build-up of misfolded, aggregate-prone proteins which 
may interfere with proper neuronal functioning, and consequently result in neurodegeneration 
(Hara et al., 2006). The accumulation of autophagic vacuoles has been ascribed to a 
deficiency in autophagic vacuole removal rather than a marked induction of autophagy 
(Boland et al., 2008). In contrast, during the early stages of AD, induction of autophagy has 
been demonstrated to be upregulated (Ginsberg et al., 2010). Accumulated autophagic 
vacuoles represent a common feature in AD, and represent the presence of undigested, or 
partially degraded protein clumps which are an immense burden to the autophagy system. Of 
note, the accumulation of misfolded undigested proteins is also a central theme in lysosome 
storage disorders (Mizushima et al., 2008). 
1.9  Localization of autophagy defects 
It has been argued that during early stages of lysosomal system abnormalities, the response 
of the endoplasmic pathway is dysfunctional, while in later stages there is a gradual 
impairment of the autophagy process (Lipinski et al., 2010). This leads to an immense 
augmentation of undegraded materials in dystrophic neurons. Current evidence 
demonstrates a failure in the impaired autophagosome-lysosome fusion resulting in 
disturbances in substrate proteolysis (Nixon and Yang, 2011). Immunogold labelling and 
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ultrastructural studies on neocortex biopsies of AD patients have shown that dystrophic 
neurites consist of dense lysosomes that are composed of different autophagic vacuoles, 
including autophagosomes (Nixon and Yang, 2011). These represent the intermediate 
stages in autophagy progression, suggesting that in AD, the autophagic process is 
insufficient to mediate clearance. The ability to pinpoint the site or stages at which the 
autophagy process may be impaired has led to the suggestion that the precise modulation of 
localized dysfunctional stages within this process may serve as a promising therapeutic 
intervention in AD pathology. 
The inhibition of lysosomal proteolysis in AD has been reported to selectively impair 
transportation of autophagy-associated vesicles along axons. This leads to AD-type axonal 
dystrophy, which is characterized by selective accumulation of autophagic vacuoles (Nixon 
and Yang, 2011). In the brain of healthy individuals, the presence of autophagic vacuoles in 
neurons is not apparent (Nixon et al., 2005). Since autophagosomes are intermediate 
structures in the autophagy process, their presence in cells is indicative of the dynamic 
balance between their rate of sequestration (formation) and degradation by lysosomes 
(Nixon and Yang, 2011). If the rate of autophagosome clearance is greater, or matches the 
rate of autophagosome formation, the presence of autophagic vacuole intermediates is 
barely detectable (Boland et al., 2008). Therefore, the pathology of autophagy reflected in 
AD is thought to be caused by the disrupted degradation of autophagic vacuoles instead of 
rapid induction of autophagy alone (Boland et al., 2008). Therefore, targeting the late stages 
of the autophagy process may be a promising therapeutic target in AD.  
1.10 Autophagy and Amyloid-Beta 
Autophagy is a vital process in cellular survival, as it is essential for organelle and long-lived 
protein turnover. In the PS1/APP mouse model of Aβ-amyloidosis, the extracellular 
deposition of Aβ has been shown to occur following impaired neuronal autophagy induction 
in early stages of AD (Yu et al., 2005). Sequentially in dystrophic dendrites, late autophagic 
vacuoles and autophagosomes accumulate and thereby the ‘maturation of autophagosomes 
and subsequent fusion with lysosomes’ is impaired. In post-mortem studies assessing the 
brains of AD patients, autophagosomes have been identified as a site for intracellular Aβ 
production and subsequent accumulation through immunolabelling techniques (Yu et al., 
2005). In a study by Caccamo et al. (2010), it was demonstrated that the accumulation of Aβ 
causes an increase in mTORC1 signalling, while the expression of Aβ was reduced when 
mTORC1 signalling was decreased, suggesting that Aβ levels may modulate autophagy 
induction. Indeed, when the production of Aβ was blocked by inhibiting the γ-secretase 
activity in 7PA2 cells, the kinase activity of mTORC1 was restored (Caccamo et al., 2010). 
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These results suggest that Aβ and not APP intermediates may increase mTORC1 signalling, 
thereby decreasing autophagy activity (Caccamo et al., 2010). In agreement, studies 
conducted on microglia and neuronal cells have demonstrated that the increase in PI3K-AKT 
signalling pathway is stimulated by Aβ levels, and thereby modulates mTORC1 activity 
(Wullschleger et al., 2006). It has particularly been shown that an increase in the PI3K-AKT 
signalling pathway may be caused by Aβ oligomers and not monomers. Indeed, autophagy 
impairment is associated with the formation of Aβ aggregates, and this association is thought 
to play a role in AD pathology.  
1.11 The role of mitochondrial dysfunction in AD 
Mitochondria generally occur as a reticular network to create an interconnected system 
which provides energy and metabolites for the cell (Lee et al., 2004). Extensive studies have 
reported that mitochondrial irregularities associated with their form or distribution may play a 
role in the progression of neurodegenerative diseases such as AD. Mitochondria are 
cytosolic double membraned organelles which serve as essential modulators of many 
signalling pathways, and have several functions including the maintenance of synaptic 
plasticity, generation of neurotransmitters, and energy production in the form of ATP (Pagani 
and Eckert, 2011). Mitochondria generate ATP through oxidative phosphorylation and the 
tricarboxylic acid (TCA) cycle. Through a series of enzymatic reactions, the TCA cycle leads 
to the generation of photons from NADH and FADH (Laura et al., 2014). This is followed by 
redox reactions comprising of protein complexes (complex I, complex II, complex IV and 
complex V) that generate a proton gradient. The last step of oxidative phosphorylation results 
in the generation of ATP (via the phosphorylation of ADP to ATP). This step is regulated by 
complex V through the ATP synthase machinery. Mitochondrial function is necessary for 
cellular metabolism, as sustained ATP synthesis is integral to maintaining normal cellular 
function, cellular viability and homeostasis. In addition, important physiological functions, 
such as regulating calcium concentration, scavenging free radicals, triggering cell death and 
regulating variations in redox reactions in the cell are key features of mitochondrial activity 
(Pagani and Eckert, 2011). 
The unique physiological features of neuronal cells and high energy demands make them 
extremely dependent on the normal functioning of mitochondria (Palmer et al., 2011). 
Fundamentally, any functional abnormalities in mitochondria may be detrimental to the 
functioning of neurons. Current literature supports a role for mitochondrial dysfunction and 
oxidative damage in the pathogenesis of AD, indicating that mitochondrial dysfunction plays 
an early and prominent role in AD (Pagani and Eckert, 2011). According to the mitochondrial 
cascade hypothesis, mitochondrial dysfunction is the primary event that causes Aβ 
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deposition, synaptic degeneration, and NFT formation (Pagani and Eckert, 2011). 
Pathophysiological events such as dysregulation of calcium homeostasis, production of free 
radicals and respiratory chain uncoupling which are a consequence of dysfunctional 
mitochondria, contribute to the triggering of neuronal cell death (Pagani and Eckert, 2011). 
Mitochondria are central in the execution of intrinsic apoptosis. This process is triggered by 
inherent protein signals such as caspase activation, which leads to the permeabilization of 
the mitochondrial membrane, causing the mitochondrial permeability transition pore to open. 
Similarly, the mitochondrial membrane potential declines, resulting in the production of free 
radicals (Kerr et al., 1972). Dysfunctional mitochondria are also central role players in 
bioenergetic sensing (Kroemer et al., 1998). During the distressed state, this can result in the 
activation of necrosis or apoptosis, both of which will be discussed at a later stage.  
1.12  Mitochondrial morphology  
The regulation of mitochondria through fusion and fission reactions enables these dynamic 
organelles to undergo continuous remodelling. Several biological processes such as cellular 
metabolism, proliferation and cell death are regulated by mitochondria (Laura et al., 2014). 
Therefore, the maintenance of mitochondrial homeostasis is essential for the resultant fate of 
the cell and is regulated by the opposing fission and fusion events. Fission state is defined as 
when a single organelle like mitochondria divides into more independent constitutions and 
fusion is the opposite reaction (Westermann, 2010). These processes are crucial not only for 
the preservation of mitochondrial function, but also the removal of damaged mitochondria 
(Laura et al., 2014). The fusion of an impaired mitochondrion to an adjacent healthy 
mitochondrion prevents the deleterious effects associated with mitochondrial dysfunction 
(Laura et al., 2014). This process permits the mixture of healthy mitochondrial DNA and the 
exchange of macromolecules (proteins, lipids, metabolites), which thereby dilutes the 
impaired mitochondria population. In contrast, the removal of damaged mitochondria may be 
achieved through the fission process whereby damaged mitochondria are separated into 
smaller fragments, thereby making it simpler for these organelles to be targeted for 
degradation through autophagy, in a process referred to as mitophagy (Laura et al., 2014). It 
is important to note that the fusion of mitochondria can be prevented by the loss of the 
mitochondrial membrane potential, which may be the result of a high population of impaired 
mitochondria. The fusion event thus relies on the internal potential of the mitochondrial 
membrane which ultimately allows the cell to undergo these processes (Laura et al., 2014). 
During the fission state, mitochondria take up a rod or spherical shape caused by 
fragmentation and are transported by the tubulin network. When the mitochondria are 
healthy, there is an equilibrium between the fusion and fission state, which enables their 
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intracellular movement (Laura et al., 2014). Mitochondrial fusion favours the distribution of 
ATP in metabolically active cells making fusion events beneficial to the cell. In contrast, the 
fission events of mitochondria are more evident in quiescent cells (Westermann, 2010). The 
fragmentation of mitochondria during fission is a trigger for cell death, whereas the fusion of 
mitochondria facilitates the preservation of a healthy pool of mitochondria and proper 
functioning of mitochondria (Chan, 2006).  
The dynamic network of mitochondria is regulated by distinct proteins which are part of the 
dynamin family. The primary set of proteins responsible for the fission events are dynamin 
related protein 1 (DRP1) and fission protein 1 (Fis1) (Reddy, 2009). DRP1 is prominently 
found in the cytoplasm, however, the fragmentation of mitochondria is promoted by the 
interaction of DRP1 with the outer membrane of mitochondria. Fis1 is confined to the 
mitochondrial outer membrane and is stimulated by free radicals which in turn induces the 
fission of mitochondria. The mitofusin (Mfn) proteins are primarily responsible for the 
regulation of the fusion events. These proteins include Mfn1 and Mfn2, which are both 
localized on the outermost mitochondrial membrane (Reddy, 2009). Opa1, an additional 
fusion protein, is present on the innermost mitochondrial membrane. Mfn1 facilitates the 
interaction process between Mfn compounds next to mitochondria, resulting in fusion of 
adjacent mitochondria (Reddy, 2009). Fission is favoured during apoptosis, moreover, Fis1-
deficient cells have been shown to be resistant to apoptotic cell death and display a high 
degree of fusion states instead (Reddy, 2009). Several studies have demonstrated that cells 
deficient in fusion proteins (i.e. Mn1) are susceptible to apoptotic cell death, and such cells 
display mitochondria that favour the fission state, hence extensive fragmentation (Lee et al., 
2004).  
1.13 AD and mitochondrial dysfunction 
Recent research in sporadic AD cases suggests that APP expression, processing of APP, 
and Aβ accumulation are all affected by the functioning of mitochondria (Swerdlow et al., 
2014). Aβ protein aggregates are implicated in the pathology of AD and appear to impair 
mitochondrial function (Diana et al., 2008). Indeed, Aβ was shown to be targeted to 
mitochondria, consequently resulting in the onset of apoptosis, and eventually leading to 
neurodegeneration (Diana et al., 2008). This process is initiated by the accumulation of Aβ 
within the mitochondrial membrane, which further disrupts the functioning of the 
mitochondria, by either damaging mitochondrial enzymes or by impairing mitochondrial DNA 
(Pagani et al., 2011). Subsequently, these events lead to an increase in mitochondrial 
membrane permeabilization and lipid peroxidation, which causes the production of reactive 
oxygen species that further disturb synaptic function (Pagani et al., 2011). This eventually 
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leads to the unwanted generation of NFTs, ultimately causing the synapse to fail, causing 
apoptosis, and eventually neurodegeneration (Pagani et al., 2011). Aβ can also target 
components of the electron transport chain, such as the mitochondrial matrix TCA cycle 
enzymes which further disturb metabolic processes associated with the mitochondria. Aβ has 
been reported to promote the activity of mitochondrial fission protein Fis1, causing the 
fragmentation of mitochondria (Pagani and Eckert, 2011).  
1.14 Cell death and its classical categorization 
Current literature suggests that the progressive loss of neurons in vulnerable brain regions, 
such as the hippocampus and cortex, is a key feature of AD (Stadelmann et al., 1999). 
However, the exact mechanism of neuronal loss remains unclear. Neuronal cell loss in 
certain regions of the brain, including the hippocampus, is thought to occur via the induction 
of apoptosis (Stadelmann et al., 1999). The clinical presentation of AD has been shown to 
correlate with the extent of neuronal loss in certain brain regions including the hippocampus 
and neocortex. In vitro studies of AD reveal that hippocampal neurons subjected to 
exogenous Aβ peptides indeed display primarily features of apoptotic cell death (Calissano, 
et al., 2009). In vivo, these features are accompanied by synaptic failure, protein aggregation 
and macroscopic changes such as enlarged ventricles and an atrophied hippocampal region 
(Apostolova et al., 2012).  
Cell death has traditionally been categorized into three modes, including: apoptosis, necrosis 
and autophagic cell death (ACD) (Galluzzi et al., 2017). They are respectively categorized as 
type I, II or III modes of cell death (Clarke, 1990). These forms of cell death are highly 
dependent on the cell’s ability to withhold or mitigate the encountered stress and its ability to 
recuperate (Fulda et al., 2009). In the past twenty years, intensive research efforts have 
been directed towards the study of cell death, because of the involvement of this process in 
pathophysiological diseases such as cancer and neurodegenerative diseases. Very recently, 
the Nomenclature Committee on Cell Death (NCCD) has established widely accepted 
definitions and classifications of cell death from biochemical, functional and morphological 
viewpoints (Galluzzi et al., 2017). This has caused a shift from the traditional separation of 
the cell death modalities. Previously, necrosis and apoptosis were highlighted as the major 
forms of cell death. However, each cell death type was studied separately, and thereby 
considered to inherently operate independently. Current operational definitions, classify 
apoptosis, autophagy dependent cell death (ADCD), and necrosis as regulated cell death 
(RCD) (Galluzzi et al., 2017). RCD is caused by the activation of signal transduction 
regulators and can thus be modulated genetically or pharmacologically (Galluzzi et al., 
2017). RCD has been shown to play a chief role in multiple physiological conditions, 
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including inflammation, embryo development, tissue homeostasis, and neurodegeneration 
(Delbridge et al., 2016). Details of the underlying RCD mechanisms and their involvement in 
AD progression will be subsequently discussed. 
1.14.1 Apoptosis 
Apoptosis is typically termed programmed cell death, as this process frequently occurs 
during development and in response to cell injury during morphogenesis (Kerr et al., 1972). 
For cell demise to be morphologically categorized as apoptotic, nuclei fragmentation, 
membrane blebbing, chromosomal DNA cleavage, and cell shrinkage should be evident 
(Edinger and Thompson, 2004). It was further shown that mitochondrial morphology remains 
unchanged. During apoptotic cell death, the cell is eventually removed through phagocytosis, 
and thereby no immune response is elicited. The apoptosis process relies on a series of 
molecular events and can be further distinguished into intrinsic and extrinsic pathways but 
concludes in the same execution process (Bibel and Barde, 2000). Apoptosis is regulated by 
a family of cysteine proteases termed caspases, including caspase 8 and 3 (Song et al., 
2017). 
The activation of the death receptors including, tumour necrosis factor-alpha (TNFα) and Fas 
(CD95/APO1) located on the cell surface, leads to the transmission of cell death signals 
which in turn activate the signalling of intracellular pathways (Elmore, 2007). This process 
represents the extrinsic pathway. These death receptors further interact with their ligands 
and form clusters. Subsequently, the formation of a death-inducing signalling complex 
(DISC) occurs, triggering the autocatalytic activation of pro-caspase 8 which forms caspase 8 
(Elmore, 2007). The execution of the extrinsic pathway is stimulated by caspase 8. Finally, 
the interplay and the execution of both the intrinsic and extrinsic pathway is the activation of 
caspase 3. This process results in the fragmentation and condensation of DNA, and 
cleavage of Poly ADP-ribose polymerase (PARP) (Tewari et al., 1995). Interestingly, in 
neurodegeneration, caspase 3 has been shown to play a key role in the execution of 
apoptosis, with caspase 3 activity being reported to be involved in the processing of APP 
(Gervais et al., 1999). Importantly, the intrinsic pathway involves the functioning of 
mitochondria (Kroemer et al., 2007). Stimuli, including hypoxia, free radicals and toxins serve 
as positive signals for the activation of intrinsic apoptosis. During intrinsic apoptosis, inherent 
protein signals such as caspases are activated by certain stress signals leading to the 
permeabilization of the mitochondrial membrane, causing the mitochondrial permeability 
transition pore to open (Friedlander, 2003). This damages the mitochondria and leads to 
cytochrome c release into the cytosol, which serves as a proapoptotic signal (Green, 2005). 
Next, the cytoplasm and nucleus begin to condense (pyknosis), leading to mitochondrial 
aggregation (Friedlander, 2003). Similarly, the mitochondrial membrane potential declines, 
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resulting in the production of free radicals (Kerr et al., 1972). Next, cytochrome c binds and 
triggers the formation of a complex, termed the apoptosome, involving apoptotic protease 
activating factor 1 (Apaf1), pro-caspase 9 and ATP utilization. The latter leads to the 
activation of caspase 9. The members of β-cell lymphoma 2 (Bcl-2) play an essential role in 
the regulation and control of apoptosis. These members serve as a survival mechanism as 
they inhibit the activation of pro-apoptotic proteins Bak/Bax, which act on the mitochondrial 
membrane potential (MMP) and lead to the release of cytochrome c, further leading to the 
generation of ROS (Behl, 2000). The Bcl-2 family, which includes Bcl-2 and Bcl-xl, serves as 
anti-apoptotic proteins which in turn together with BH3 inhibit the activation of pro-apoptotic 
proteins (Behl, 2000).  
1.14.2 Necrosis 
Necrosis is triggered during an acute ischemic state or neuronal cell injury in the central 
nervous system (Emery et al., 1998). It involves a cascade of events, including the osmotic 
swelling of cells, swelling of mitochondria, release of cytoplasmic substances into the 
extracellular space and, at a late stage, nuclear pyknosis. During the process of necrosis, 
Los et al. (2002) showed that cell death could be triggered intrinsically through an 
inflammatory response and via the release of the pro-inflammatory cytokine interleukin-1 
beta (IL1β) (Zong and Thompson, 2006). The formation of excitotoxins and production of free 
radicals emanating from sudden biochemical disruptions contribute to the morphological 
cellular changes evident in necrosis (Friedlander, 2003). The mitochondria are highly 
affected by the sudden biochemical disruptions and tend to swell as a result (Aranovic et al., 
2012). The ATP produced by mitochondria also serves as the initial activator of the 
inflammasome response during necrosis (Iyer et al., 2009). Subsequently, the nucleus also 
swells, as a result, the chromatin network surrounding the nucleus begins to condense 
(Friedlander, 2003). This process can further cause the nucleus to rupture (karyorhexis), and 
the DNA becomes degraded; collectively causing the plasma membrane to rupture and well 
(Schweichel and Merker, 1973). Since necrosis does not typically occur during development 
or results via activation of caspases, it has not been identified or considered as a 
programmed cell death mode. However, Proskuryakov et al. (2003) described a process 
termed necroptosis which suggests a ‘programmed’ process of necrosis, whereby cells 
exhibit features of both necrosis and apoptosis. This notion is supported by a study that 
found that neurodegenerative diseases display cell death onset in the form of necroptosis, 
which results following an ischemic state or several infections (Nikoletopoulou et al., 2013). It 
is now generally accepted that necroptosis is indeed a bona fide cell death modality (Galluzzi 
et al., 2017). 
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1.14.3 Autophagy dependent cell death  
Autophagy is active in atrophic and homeostatic conditions, and thereby forms part of the 
normal physiological process. In contrast, autophagy dependent cell death (ADCD) can be 
defined as unregulated form of autophagic activity which fails to terminate the cell before it 
collapses leading to unregulated degradation of cellular contents (Lockshin and Zakeri, 
2004). This leads to the production of many undigested autophagic vacuoles. Moreover, 
when the induction of autophagy is not controlled, beclin1 and Atg1 can be overexpressed in 
mammalian cells and Drosophila (Scott et al., 2007), which could indicate ADCD due to the 
cells’ inability to endure untargeted degradation of huge substances found in the cytoplasm. 
However, the concept of ADCD remains controversial, as several studies have demonstrated 
that increased autophagy prior to cell demise acts as a pro-survival mechanism to prevent 
cell death onset (Shen et al., 2012).  
1.14.4 Cell death dynamics: cross talk between apoptosis, necrosis and autophagy 
The notion that apoptosis, necrosis and autophagy occur in isolation has become 
increasingly controversial. Several studies suggest that these pathways are linked through 
intrinsic factors and molecular interplay mechanisms. Indeed, apoptotic cell death has been 
shown to initiate with autophagy, and autophagic failure can in turn induce apoptosis 
(Lockshin and Zakeri, 2004). Autophagy has been implicated as the crucial link between 
necrosis and apoptosis through its ATP production role (Edinger et al., 2004). Distinctive to 
apoptosis, necrosis is noted to be the end result of ATP depletion above a threshold level at 
which the cell cannot manage or recuperate from. A reduction in ATP by 50% has been 
reported to induce necrosis and activation of apoptosis is ATP dependent. Indeed, 
autophagy can postpone the occurrence of either necrosis or apoptosis, depending on how 
much ATP is generated (Loos and Engelbrecht, 2009). Autophagy has also been shown to 
induce apoptosis by preventing the stimulation of apoptosis-associated caspases, which in 
turn decreases cellular injury (Song et al., 2017). Autophagy is also reported to assist in 
inducing apoptosis through the activation of apoptosis-related proteins. Moreover, the 
inhibition of autophagy through the activation of apoptosis-related proteins has been shown 
to degrade Atg proteins such as Atg4, Atg5 and Beclin1 (Song et al., 2017).  
 
1.15 Therapeutic interventions  
The prevalence of AD significantly rises with age. As a result of improved medical care, the 
global elderly population has increased, particularly in developing countries such as SA 
(Honig and Boyd, 2013). Although extensive research in the AD field is ongoing, no 
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treatment interventions have been proven to stabilize, reverse or modify the progression of 
this disease (Honig and Boyd, 2013). AD is currently poorly treated and has a very poor 
clinical outcome. The following factors contribute to the susceptibility of AD: age, 
cerebrovascular disease, family history, level of education/literacy, vascular complications, 
previous head injuries/trauma and genetic mutations (e.g. presence of the APOE-4 allele). 
Importantly, low levels of education play an additional role in the development of AD in 
countries such as SA (de Jager et al., 2017). The available treatment options are however 
limited, with treatment only improving cognitive and behavioural symptoms, but not 
modulating the underlying molecular dysfunction causing the pathology. 
The US Food and Drug Administration (FDA) has approved five treatment therapies for the 
management of AD (Alzheimer’s and Dementia, 2016). These medications offer moderate 
improvement in cognitive and behavioural functions. The approved FDA medications include, 
four acetylcholinesterase inhibitors (based on neurotransmitter agents) and an NMDA-
receptor antagonist (Honig and Boyd, 2013). Other, more recent and promising therapeutics 
include the use of pharmaceutical drugs which upregulate autophagic activity (e.g. 
rapamycin), but these drugs are not prescribed to AD patients. Hence, there is still a major 
need for more targeted therapeutic interventions that can modify the progression of the 
disease upstream and downstream of the molecular mechanisms. A brief outline of the 
therapeutic options that are presently available will be provided, supplemented with the 
disconnection that exists between the therapeutic action and the molecular dysfunction that 
underlies AD pathology. 
1.15.1 Neurotransmitter based therapies 
Reduction in cortical choline acetyltransferase activity is associated with cognitive decline in 
AD (Lleó, 2007). This led to the development of acetylcholinesterase inhibitors (AChEIs) as a 
treatment option in this context. This treatment is based on the cholinergic hypothesis, 
developed about two decades earlier. The AChEIs act by suppressing cholinesterases, and 
thereby enhance the availability of acetylcholine for brain synaptic processing (Lleó, 2007). 
Clinical trials have clearly demonstrated that these compounds are beneficial for both 
cognitive and behavioural defects in AD patients. Between 1993 and 2001, the U.S. FDA 
approved and standardized four AChEls compounds for AD treatment: donepezil, 
galantamine, rivastigmine and tacrine. Of those four, tacrine hydrochloride has received the 
least attention because it exhibits hepatotoxic side effects (Lleó, 2007). Donepezil 
hydrochloride is frequently prescribed as it is only taken once daily. Later, galantamine 
hydrobromide and rivastigmine tartrate were also approved, and used in a once daily 
dosage. Another recommended drug is memantine hydrochloride that blocks chronic hyper-
activation of NMDA receptors, thereby acting as a NMDA antagonist (Honig and Boyd, 
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2013). Memantine offers further beneficial symptomatic effects when combined with AChEIs 
inhibitors. The overactivation of the NMDA type glutamate receptors or overexposure to the 
neurotransmitter glutamate leads to neuronal cell demise, and disproportionate influx of 
calcium (Lipton, 2004). Although these drugs offer improved cognitive, behavioural and 
functional properties; they are limited as they only target symptomatic factors and fail to 
target the progression of the disease. Yet, to date, the only prescribed medications to AD 
patients are neurotransmitter-based drugs (Chou, 2014). These data indicate that while 
current treatment options offer transient symptomatic relief to those affected, they offer little 
targeting of the molecular defects in AD and have not yet been successfully exploited for the 
overall treatment of the disease.  
1.15.2 Vitamin E, antioxidants and anti-inflammatory agents 
The build-up of free radicals and the existence of oxidative stress are triggers of AD and 
common features in the brains of AD patients. This has led to the assumption that 
antioxidants may be used as a potential treatment option for AD. A widely used antioxidant-
based therapeutic approach involves the use of vitamin E (α-tocopherol). A dose of 2000 
IU/day is recommended for AD patients; however, this high dose is associated with an 
increase in mortality (Valory et al., 2009). Hence, the safety of this concentration and the 
overall efficacy of vitamin E in the treatment of AD has been questioned and is not widely 
used.  
1.15.3 Immunotherapy 
The anti-amyloid therapy aims to improve the removal of Aβ deposits by using a vaccine 
approach. In transgenic mouse models of AD, Aβ42 immunization has been shown to 
prohibit the presence of Aβ pathology and prevents memory defects (Schenk et al., 1999). In 
transgenic AD mice models, the overexpression of APP has been shown to be decreased 
when immunized with Aβ. In some clinical cases, patients displayed improved cognitive, 
behavioural effects and a reduction in Aβ deposits, while other patients experienced 
autoimmune reactions (Morgan, 2011). This treatment option has only been implemented as 
part of clinical trials and has not been approved by the FDA.   
1.15.4 Physical exercise 
Epidemiological studies have shown an inverse proportional relationship between the extent 
of exercise/physical activity and the risk of suffering from neurodegenerative diseases such 
as AD (Paillard et al., 2015). Indeed, physical activity has been reported to enhance cognitive 
function (Hillman et al., 2008). Moreover, autophagy has been shown to be activated by 
exercise in peripheral tissues, the brain, skeletal muscle, pancreas, adipose tissue, and the 
liver (Levine et al., 2012). Interestingly, aerobic exercise has been shown to encourage 
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angiogenesis and to trigger the release of neurotrophic factors, which in turn facilitates 
synaptogenesis and neurogenesis, and memory is linked to cognitive function (Paillard et al., 
2015). The efficacy of exercise as a treatment intervention is however still being researched 
(He et al., 2012a; García-Mesa et al., 2011).  
1.16 Autophagy inducers as promising treatment intervention  
The underlying molecular mechanisms governing AD progression have been widely studied 
and are increasingly understood. Accumulating evidence suggests that the production of Aβ 
oligomers is a major feature in AD pathology and triggers several events which result in 
synaptic failure and neuronal dysfunction (Selkoe and Hardy, 2016). Therefore, the 
development of drugs should be directed towards targeting the clearance of Aβ, which may 
be promising in modifying disease progression and AD pathophysiology. Hence, this 
approach should centre around increasing the clearance or decrease the generation of Aβ. 
The latter can be achieved by modulating the APP processing in favour of the non-
amyloidogenic pathway, while the former can be enhanced by inducing autophagy activity 
above basal levels with disease progression (Salminen et al., 2013). This approach has 
recently received major attention.  
1.16.1 Rapamycin 
Rapamycin is an antibiotic that targets mTORC1 by inhibiting its kinase activity and thereby 
induces autophagic activity. It exerts its inhibitory effect by directly inhibiting the mTORC1 
(Cai and Yan, 2013). By inhibiting mTORC1, rapamycin treatment in vivo has been shown to 
mitigate tau and Aβ pathology in transgenic mice (Caccamo et al., 2010). It has been 
demonstrated that administration of 2 mg/ml of rapamycin for 15–48 hrs displays protective 
effects in cell culture models of neurodegenerative diseases, including AD (Berger et al., 
2006). Rapamycin is also used as an immune-suppressant and has been approved by the 
FDA (Cai et al., 2012). Rapamycin treatment has been shown to protect hippocampal 
neurons from Aβ-induced synaptotoxicity by increasing the activity of pre-synapses (Ramírez 
et al., 2014). Autophagy induction has been shown to markedly decrease the accumulation 
of neurotoxic protein aggregates, including Aβ, and promotes the removal of mutant proteins 
such as mutant HD protein (Rubinsztein, 2004). Therefore, the upregulation of autophagy by 
rapamycin can modulate the metabolism of APP, and thereby reduce the levels of Aβ in 
favour of neuroprotection. Although, rapamycin treatment has shown promising results in 
vivo no successful human trails have been reported to date. Importantly, as rapamycin is 
also an immune-suppressant, it may in turn be harmful to the immune system when used for 
an extended period. The use of rapamycin as treatment agent for AD is still in its infancy 
(Caccamo et al., 2010). However, it remains a promising treatment option.  
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1.16.2 Rilmenidine  
The screening of drugs approved by the US FDA for their autophagy-inducing potential led to 
the identification of rilmenidine as a potential treatment for HD and other neurodegenerative 
diseases (Rose et al., 2010). Rilmenidine is a safe, and efficient drug currently used to treat 
hypertension. In a HD mouse model and primary neuronal culture, rilmenidine has been 
shown to attenuate toxicity caused by polyglutamine peptides (Rose et al., 2010). The 
protective effect of this drug is achieved through its autophagy inducing properties, possibly 
acting in an mTOR independent manner. Rilmenidine has also been shown to lower the 
levels of cAMP (Rose et al., 2010). A clinical study on individuals that clinically manifested 
HD, revealed that treatment with rilmenidine was relatively safe and well tolerated 
(Underwood et al., 2017). This effect was presumed to be mediated by rilmenidine’s effect on 
autophagy activity.  
1.16.3 Lithium chloride and neurodegeneration 
For the past 50 years, LiCl salts have been extensively used in the treatment of key 
psychiatric disorders, particularly bipolar and mood related disorders (Baldessarini et al., 
1999). LiCl has been shown to pass the blood–brain barrier which makes its use in a clinical 
setting very important, since many drugs do not pass the blood–brain barrier (Manji and 
Lenox, 1998). Its mode of action is thought to be mediated through targeting of downstream 
molecules, resulting in the regulation of autophagy related genes and modulation of 
intracellular signalling (Forlenza et al., 2012). LiCl is a glycogen synthase kinase-3 beta 
(GSK3β) inhibitor. GSK3β is a serine-threonine kinase that modulates signalling pathways 
such as the Notch and Wnt signalling pathways and cell cycle regulation (Forlenza et al., 
2012). LiCl can inhibit the enzymatic activity of GSK3β via two mechanisms, firstly via direct 
inhibition by competing at the cationic binding site for magnesium, which is necessary for its 
enzymatic stimulation (Chalecka-Franaszek and Chuang, 1999); and secondly, via indirect 
inhibition, by PKB activation via the Akt pathway which responds to insulin signalling or 
growth factors. LiCl’s collective effects on several intracellular signalling pathways eventually 
leads to the inhibition of apoptosis, the enhancement of neurotrophic factor synthesis and the 
facilitation of synaptic plasticity mechanisms and neurogenesis (Fornai et al., 2008). This is 
also associated with memory enhancement in animal studies (Fornai et al., 2008). LiCl’s 
inhibitory effect on inositol monophosphatase (IMPase) was shown to result in the depletion 
of free inositol, thereby leading to a reduction of myoinositol-1,4,5-triphosphate (IP3) levels 
(Sarkar et al., 2005). This effect was later shown to upregulate autophagy activity. Although 
LiCl’s autophagy inducing potential may not be relevant in the treatment of mood disorders, 
this effect is critical in the treatment and prevention of neurodegenerative diseases (Sarkar et 
al., 2005).  
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Moreover, in human studies, LiCl dietary supplementation has been shown to enhance 
neuroprotective factors such as brain-derived neurotrophic factor (BDNF) synthesis, anti-
apoptotic gene expression, thickening of the cortical region, oxidative stress inhibition and 
enlarged hippocampal and grey matter density (Forlenza et al., 2012). A recent clinical trial 
with amnestic mild cognitive impaired patients, revealed that long-term supplementation with 
LiCl, potentially slowed the progressive decline in functional and cognitive capabilities, and 
further attenuated tau hyperphosphorylation (Forlenza et al., 2012). Although reports from 
clinical trials appear promising thus far, further studies are necessary, particularly large-scale 
clinical trials to evaluate LiCl’s potential neuroprotective effects in the treatment of cognitive 
deficits among elderly individuals.  
1.16.3.1 Neuroprotective effects of Lithium chloride: evidence from preclinical and 
clinical studies 
Treatment with LiCl has also been shown to attenuate Aβ induced cell death in neuronal cells 
and animal studies that were exposed to exogeneous Aβ peptide (Su et al., 2004). The 
increase in GSK3β enzymatic activity is an early hallmark of AD pathophysiology, which 
stimulates various downstream cellular events, in turn resulting in the enhancement of Aβ 
production and tau hyperphosphorylation. LiCl treatment also enhances anti-apoptotic 
protein expression such as Bcl-2 which results in the inhibition of cytochrome c release from 
the mitochondrial membrane, thereby regulating mitochondrial permeability and maintaining 
calcium homeostasis (Chen et al., 2006). These cellular events are vital for the maintenance 
of cellular integrity, and cell survival. Treatment with LiCl has also been demonstrated to 
modulate the processing of APP and to reduce the generation of Aβ through the suppression 
of GSK3β in APP-mutated transgenic mice (Phiel et al., 2003). Moreover, LiCl has been 
shown to possess anti-inflammatory properties, as evidenced by a reduction in interleukin-1β 
and tumour necrosis factor-α production in glial cells exposed to LiCl treatment (Li et al., 
2011). Therefore, LiCl holds therapeutic potential in the mitigation of inflammatory cell 
responses.  
A clinical study was conducted in patients with mild to moderate AD, to evaluate the efficacy 
of LiCl, the results were negative in the initial studies (Dunn et al., 2005). In fact, patients that 
were treated with LiCl were found to have a greater risk for developing dementia, with an 
increase in risk associated with an increase in the dosage of LiCl prescribed (Dunn et al., 
2005). In a clinical trial of a single-blind placebo-controlled group consisting of 71 AD 
patients, 10-week treatment duration with LiCl was demonstrated to not have any significant 
benefits on cognitive function (Hampel et al., 2009). GSK3β enzymatic activity was not 
significantly inhibited by LiCl, and Aβ42, tau protein and cerebrospinal fluid (CSF) biomarker 
levels were not altered. However, a reduction in the levels of CSF phosphorylated tau was 
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displayed in the LiCl group. LiCl has also been studied in other neurodegenerative diseases 
including PD, HD and amyotrophic lateral sclerosis (ALS). In the context of ALS, 
supplementation with LiCl has revealed neuroprotective effects associated with autophagy 
activation, an increase in mitochondrial number in motor neurons and inhibition of reactive 
astrogliosis (Fornai et al., 2008).  
As detailed in the sections above, the long-term neuroprotective effects of LiCl 
supplementation have been widely documented in treatment of psychiatric disorders and AD 
model systems. However, the use of this drug in a clinical setting may be challenging as 
there are safety precautions concerning long-term usage amongst the elderly. However, 
further research is required to confirm the efficacy, safety and long-term use of LiCl to 
achieve the best therapeutic outcomes possible. 
1.16.3.2 Lithium chloride and autophagy 
LiCl has been demonstrated to induce autophagy in a mTOR-independent manner. This 
induction process occurs through the inhibition of IMPase and inositol transporters and 
receptors (IP3R). Suppression of IMPase activity leads to a reduction in free inositol levels, 
resulting in lowered IP3 and myo-inositol-1,4,5 triphosphate levels (Sarkar et al. 2005). 
Additionally, activation of IP3 and its respective receptor has been shown to inhibit 
autophagy (Criollo et al. 2017). However, Sarkar and colleagues (2008) have further 
investigated the inducing effects of LiCl on autophagy and observed that LiCl-induced 
autophagy can also occur in an mTOR-dependent manner. LiCl has also been shown to 
promote the removal of mutant huntingtin and α-synuclein protein (Sarkar et al., 2005). The 
mTOR-independent induction of autophagy has been demonstrated in response to co-
treatment with rapamycin and LiCl, which revealed greater reduction of pathological prion 
proteins in murine neuroblastoma cells compared to cells only treated with rapamycin alone 
(Sarkar et al.,2005). However, the observed reduction was comparatively less significant 
than cells treated only with LiCl. LiCl induced autophagy holds much promise as a 
therapeutic avenue in the removal of aggregate prone-proteins involved in the pathology of 
many neurodegenerative such as AD (Heiseke et al., 2009). This is reflected in a study 
where LiCl induced autophagy resulted not only in the reduction of pathological prion 
proteins, but also in a slight reduction in cellular prion protein levels (Heiseke et al., 2009). 
This was reflected by an increase in LC3-II protein levels in cells treated with LiCl. The 
reduction in pathological prion proteins was observed in a dose- and time-dependent manner 
in murine neuroblastoma cells, where the clearance of pathological prion proteins was 
revealed at a concentration of 10 mM of LiCl treatment (Heiseke et al., 2009).  
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In N2aswe cells either untreated or treated with LiCl for 24 hrs and analysed for endogenous 
levels of LC3-II, an increased amount of LC3-II protein levels was observed in cells treated 
with LiCl (Heiseke et al., 2009). To exclude the possibility that the observed increase in LC3-
II levels upon LiCl treatment did not result from impaired autophagosome-lysosome fusion 
(also leading to an increased level of LC3-II protein expression), the amount of LC3-II was 
measured in the presence and absence of bafilomycin A1 treatment (Yamamoto et al. 1998). 
This led to an increase in LC3-II protein signal, indicating that LiCl indeed upregulates 
autophagic activity above basal levels. 
1.16.4 Gingko biloba and neurodegeneration  
Gingko biloba (GB) is a phytopharmacon and is commonly cultured for its leaf and for its 
nuts. The GB-producing tree can tolerate urban and industrial environments and has great 
resistance against fungal, viral and bacterial infection (Oken et al., 1998). The GB leave 
extract has been used for decades in traditional Chinese medicine for various purposes. GB 
has successfully been used as treatment and in the prevention of vascular and cerebral 
disorders including AD. The main properties of GB include gingko-flavanols (mainly in the 
form of isorhamnetin, kaempferol and quercetin) which make up to 22–27% and 5–7% 
terpenoids (Augustin et al., 2009). The terpenoids comprise of bilobalide and the ginkgolides 
A, B, C, J and M; which are synthesized from 20 carbon cage molecules enclosed by six 5-
membraned rings (Oken et al., 1998). The ginkgolides have several physiological properties 
and ginkgolide B is a platelet-activating factor (PAF) antagonist. PAF has been shown to 
directly affect the function of neurons. In the hippocampal region, ginkgolide J has been 
shown to protect cells against neuronal cell death and irregular hippocampal long-term 
potentiation which is induced by Aβ accumulation (Vitolo et al., 2008). Ginkgolide B has 
specifically been shown to inhibit Aβ25–35 induced neurotoxicity via the upregulation of 
BDNF expression in hippocampal neurons (Xiao et al., 2010).  
Flavonoids are the main components of the GB extract and lend their anti-oxidant properties 
and ability to scavenge free radicals. This makes GB a suitable natural treatment for cellular 
oxidative stress related diseases, including AD (Chan et al., 2007). In numerous studies GB 
has been demonstrated to decrease lipid peroxidation in cell membranes, protect neuronal 
cells against peroxidation induced oxidative stress and reduce injury of neurons following 
ischemia (Wieraszko et al., 1993). Earlier studies have shown that in AD, supplementation 
with EGb761 (standardised GB leave extract) is associated with anti-oxidative properties, 
scavenging of free radicals, anti-amyloidogenic properties, regulation of neurotransmitters 
and anti-apoptotic properties (Horakov et al., 2003). Therefore, EGb761 can be viewed as a 
multivalent agent with the potential to serve as preventive treatment for diseases with 
complex aetiology such as AD (Bastianetto et al., 2000). In a study by Stark and Behl (2014), 
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the proteasome catalytic activity and the protein degradative activity was found to be 
enhanced by EGb761 treatment in cultured cells. The authors further investigated this effect 
in the context of an HD cell culture model using cells that expressed pathologic variants of 
polyglutamine protein. In this context, treatment with EGb761 was found to lead to an 
increase in proteasome activity, thereby stimulating enhanced degradative capacity of short-
lived proteins (Stark and Behl 2014). These findings could suggest that EGb761 promotes 
the degradation of short-lived, misfolded proteins via the proteasome degradative pathway. 
However, since most intracellular proteins are long-lived, to more efficiently target the 
degradation of protein aggregates in neurodegenerative diseases would require a better-
quality control system such as the autophagy pathway. However, further studies are 
warranted to clarify the role of EGb761 in neuroprotection as variable results have been 
reported on the beneficial properties of EGb761 in the treatment of neurodegenerative 
diseases (Moosmann and Behl 2002; DeKosky et al., 2008).  
1.16.4.1 Gingko biloba and AD 
It is well established that ageing is a major contributor to AD pathophysiology. Due to its 
ability to combat age-associated oxidative stress and inflammation, GB can be used as an 
effective treatment of AD (Tchantchou et al., 2009). This is due to GB’s anti-inflammatory 
and antioxidant properties, evident from several clinical studies reporting the efficacy of 
EGb761 in the treatment of dementia and AD (Le Bars et al., 2000; Kanowski, et al., 1996). 
However, work by DeKosky et al. (2008) revealed that treatment with GB (120 mg) twice a 
day did not significantly decrease the overall incidence rate of AD or dementia. Although 
standardized GB extracts have been shown to be neuroprotective in the context of 
neurodegeneration, the mechanism of actions remain unclear. In AD transgenic mice, Aβ 
aggregation and oxidative stress induced by Aβ has been shown to be attenuated by 
EGb761 supplementation (Shi, 2010). Recent in vivo studies have demonstrated that genes 
encoding proteins implicated in the pathogenesis of AD are influenced by short-term 
treatment with EGb761 (Watanabe et al., 2001). This is exemplified in work by Schindowski 
et al. (2001) which demonstrate that treatment with EGb761 in vivo and in vitro has anti-
inflammatory, antioxidant properties and leads to enhanced cerebral blood flow. In addition, 
treatment with EGb761 has also been shown to attenuate Aβ aggregation (Luo et al., 2002) 
and oxidative stress induced by Aβ (Smith and Luo, 2003) in transgenic cells and animal 
models. In the brain tissue of transgenic mice, chronic treatment with EGb761 (300 mg/kg) 
has been shown to differentially influence protein levels involved in the processing and 
metabolism of APP (Augustin et al., 2009). This study also revealed that long-term EGb761 
dietary supplementation leads to a significant decrease in human APP levels in the cortex 
and hippocampus regions, which could potentially indicate that APP is molecularly targeted 
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by EGb761. Augustin and colleagues ultimately concluded that supplementation with 
EGb761 did not affect the levels of APP expression in young mice, suggesting that the 
duration of GB treatment and/or the animal’s age may impact the efficacy of treatment 
(Augustin et al., 2009). 
1.16.4.2 Gingko biloba and autophagy 
GB dietary supplementation results in robust autophagic induction, as revealed by an 
increase in LC3-II protein levels and beclin1 expression in the brains of APP-transgenic mice 
(Liu et al., 2015). Similarly, in microglia cells the protein expression of LC3-II and beclin1 was 
elevated and associated p62 levels were decreased following GB EGb761 treatment, 
suggesting that GB treatment upregulates autophagy activity. Another GB extract (EGb1212) 
consisting of a greater quantity of bilobalide and ginkgolide B has been reported to inhibit 
autophagy in the ischemic brain (Yin et al., 2013). However, the overall extent of autophagic 
flux modulation in response to GB treatment remains unknown. 
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1.17 Rationale of the study  
Two distinct features of proteotoxicity are observed in the brains of AD patients at autopsy, 
namely extracellular deposits of senile plaques composed of Aβ peptide deposition, and 
intracellular aggregation of NFTs composed of hyperphosphorylated tau protein, with Aβ 
deposition being widely recognized as the major contributor to AD pathogenesis (Aging, 
2011). Accumulating evidence suggests that autophagy, a major lysosome-based 
degradation pathway is critical for stress-induced and constitutive removal of long-lived 
proteins and is the primary pathway responsible for maintaining normal Aβ homeostasis 
amongst other important physiological functions (Musiek and Holtzman, 2015). The 
modulation of autophagic activity is therefore thought to be a promising therapeutic strategy 
towards the alleviation of Aβ-associated neurotoxicity in AD, which is often accompanied by 
extensive mitochondrial damage. Current literature supports a role for mitochondrial 
dysfunction and oxidative damage in the pathogenesis of AD, indicating that mitochondrial 
dysfunction plays an early and prominent role in AD pathogenesis (Pagani and Eckert, 
2011). According to the mitochondrial cascade hypothesis, mitochondrial dysfunction is one 
of the primary events that causes Aβ deposition, synaptic degeneration, and NFT formation. 
As a result of insufficient degradation of oxidatively damaged macromolecules and 
organelles through autophagy, neurons progressively accumulate cytotoxic proteins and 
organelles that could exacerbate neuronal dysfunction (Nixon and Yang, 2011). Since 
autophagy is the major pathway involved in the degradation of protein aggregates and 
damaged organelles, there is an intense interest in developing autophagy-related 
therapeutics given the molecular link between autophagy dysfunction and AD pathogenesis. 
1.18 Problem statement 
LiCl is a promising modulator of autophagic activity, however, the relationship between its 
concentration, duration of exposure and potency to induce autophagy is largely unclear as its 
use has been limited to the treatment of bipolar disorders. Moreover, a fine or precision 
control of autophagy activity through LiCl treatment has not yet been achieved. Similarly, GB 
is used as a dietary supplement in AD patients, but it has not been standardized for clinical 
use. Although it is thought to have positive impact on neuronal proteostasis, it is not known to 
what extent it can induce autophagy. Moreover, it is not known whether GB exhibits a 
concentration-dependent effect on autophagy activity and whether a combination approach 
together LiCl would maximize protein clearance and neuronal protection in an in vitro model 
of Aβ induced neuronal toxicity.  
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1.19 Aims and objectives  
The aim of the proposed study was therefore to investigate the effect of both GB and LiCl as 
a single or combined treatment intervention on the modulation of autophagy activity, and the 
mitigation of Aβ proteotoxicity in an in vitro model of AD.  
We specifically aimed to assess the following parameters: 
1. whether GB exhibits a dose-dependent effect on autophagic activity or whether a 
combination treatment approach with LiCl could further enhance autophagy activity 
above basal levels 
2. whether high and low GB concentrations can attenuate Aβ toxicity distinctively, in the 
presence and absence of LiCl treatment 
3. whether high and low GB concentrations can preserve lysosomal function and 
mitochondrial network morphology distinctively, in the presence and absence of LiCl 
treatment 
1.20 Hypothesis  
We hypothesize that treatment with GB will exhibit a concentration-dependent effect on 
autophagic activity, and this effect will be further enhanced through combination treatment 
with LiCl. This effect will translate in the distinct removal of APP and Aβ, by preserving 
lysosomal function and mitochondrial integrity.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 General consumables and reagents  
Bio-smart Scientific (Edgemead, Cape Town) supplied 15 ml (50015) and 50 ml (50050) 
falcon tubes, and flat bottom 96 (30096), 48 (30048), 24 (30024) and 6 (30006)-well dishes. 
NUNC 8-well chambered glass dishes (154534) were supplied by Thermofisher. Sterile cell 
culture flasks including, 175 cm2 (431080, 75 cm2 (708003) and 25 cm2 (707003), were 
supplied by White-head Scientific (Stikland, Cape Town). Sterile 5ml (326001), 10 ml 
(327001) and 25 ml (328001) serological pipettes were supplied by B&M Scientific (Parrow, 
Cape Town). B&M Scientific (Parrow, Cape Town) also supplied pipette tips and 0.5- and 2-
ml Eppendorf tubes. 
Table 2.1. List of reagents and sources. 
Reagent  Company purchased 
2- 2-Mercaptoethanol  Sigma Aldrich (M6250) 
APS Sigma Aldrich (A3678-25G) 
Bromophenol Blue Sigma Aldrich (SAAR1437500CB) 
Bovine serum albumin (BSA) Sigma Aldrich (10735078001) 
Cell Scrappers Nest Biotechnology (710001) 
Clarity ECL Western Blotting Substrate Bio-Rad Laboratories (170501) 
Complete Protease Inhibitor Sigma Aldrich (11573580001) 
Coverslips Sigma Aldrich (Z692263) 
Cryovials Scientific Group (430658) 
Dulbecco’s modified Eagle’s medium (DMEM) Life Technologies (41965-062) 
Dimethyl sulfoxide (DMSO) Whitehead Scientific (D2650) 
Foetal bovine serum (FBS) Biocom Biotech (FBS-G1-12A) 
Glycerol Merck (SAAR2676520) 
Hoechst 33342 Stain solution Sigma Aldrich (H6024) 
Microscope slides Sigma Aldrich (BR474701) 
Mounting Media Diagnostech (S302380) 
NA3VO4 Sigma Aldrich (S6508) 
NaF Merck (193270) 
NP40 Sigma Aldrich (74385-1L) 
n-Pentane Merck (1.07177.1000) 
Opti-MEM Reduced Serum Media Thermo Fisher Scientific (31985047) 
Stellenbosch University  https://scholar.sun.ac.za
  39 
Reagent  Company purchased 
PenStrep antibiotic (15140122) Life Technologies (15140-122) 
PMSF Sigma Aldrich (93482-50ml-F) 
Potassium Chloride Merck (SAAR5042020EM) 
Prestained Protein Ladder Biocom Biotech (PM007-0500) 
Running buffer Bio-Rad Laboratories (161-0772) 
Sodium dodecyl sulphate (SDS) Sigma Aldrich (L3771) 
Sodium Chloride Merck (1.10732.0100) 
Sodium hydroxide Sigma Aldrich (S5881-500G) 
Spar Fat Free Long-Life Milk Local Spar 
TEMED Merck (1.10732.0100) 
TGX Stain-free Fast Cast Acrylamide Kit, 12% Bio-Rad Laboratories (1610185) 
Trans-Blot Turbo Midi PVDF Transfer Packs Bio-Rad Laboratories (1704157) 
Triton X-100 Sigma Aldrich (T8787) 
Trypsin-EDTA Life Technologies (25200072) 
Tween-20 Sigma Aldrich (P1379) 
2.2 Antibodies  
The primary antibodies probed for in western blot (WB) and Immunofluorescence (IF) 
analysis are presented in the table below (Table 2.2). Primary antibodies were either 
purchased from Cell Signalling Technologies or Abcam. All primary antibodies were diluted in 
1x tris-buffered saline (TBS-T) at a dilution factor of 1:1000 and 1:200 dilution in 1x 
Phosphate Buffered Saline with Tween 20 (PBS-T) solution for WB and IF, respectively. The 
following secondary antibodies were utilized for WB: anti-rabbit IgG HRP (7074S) and anti-
mouse IgG HRP (7076S) purchased from Abcam, anti-mouse IgG (CST7076S) and anti-
rabbit IgG (CST7074S) purchased from Cell Signalling.  
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Table 2.2. List of primary antibodies. 
Primary Antibodies  Host Working 
Dilution  
Company 
purchased 
Size (kDa) 
anti-
SQSTM1/p62(D5L7G) 
mouse 1:1000 Cell Signalling 
Technologies 
(88588S) 
62 
APP rabbit 1:1000 Cell Signalling 
Technology (2450) 
100-140 
Amyloid beta (Aβ) rabbit 1:1000 (Cell Signalling 
Technologies 
(2454) 
5 
cleaved PARP rabbit 1:1000 Cell Signalling 
Technology 
89 
anti-LC3B rabbit 1:1000 Cell Signalling 
Technologies, 
(2775S) 
16;18 
LAMP2a rabbit 1:1000 Abcam (ab18528) 140 
c-Caspase-3 rabbit 1:1000 Cell Signalling 
(9661) 
17;19 
Cytochrome c rabbit 1:1000 Cell signalling 
(4280) 
14 
MNF1 mouse 1:1000 Abcam (ab57602) 89 
DRP1 mouse 1:1000 Abcam (ab56788) 89 
Beta-actin rabbit 1:1000 Abcam (ab91526) 42 
Secondary Antibodies Host Working 
Dilution 
Company 
purchased 
Size (kDa) 
anti-rabbit IgG HRP Donkey 1:10000 Abcam (7074S) - 
anti-mouse IgG HRP Donkey 1:10000 Abcam(7076S) - 
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2.3 Cell Culture  
2.3.1 In vitro study design  
Neuroblastomas 2A (N2a) mouse neural cells, stably expressing AD-related Swedish mutant 
form of the APP695 plasmid (N2aswe) were utilized for all experimental procedures. These 
cells were kindly provided by Professor Sangram Sisodia (Department of Neurobiology, 
University of Chicago, USA). The N2aswe cell line has been extensively utilized as an in vitro 
model system for the study of AD (Lee et al., 2015). 
2.3.2 Maintenance of N2aswe cells 
In accordance with the manufacturer’s instructions, N2aswe cells were was propagated in 
tissue culture flasks under a humidified atmosphere containing 5% CO2 at 37°C. The cultured 
cells were supplemented with media consisting of (DMEM and Opti-MEM™ at a ratio of 1:1), 
1% Penstrep and 5% Fetal bovine serum (FBS). Cells were frozen in media (1 ml FBS, and 
10 µl DMSO) containing approximately 1 x 106 cells per cryovial and then stored in a liquid 
nitrogen freezing chamber. To induce the APP transgene expression, N2aswe cells were 
treated with butyric acid (sodium salt) (BA, 5 mM). The use of 5 mM of BA has been shown 
to significantly enhance the expression of APP following 12 and 24 hours (hrs) treatment, 
with no cytotoxic effects reported thus far (Lo et al., 1995; Shin et al., 2016). 
2.3.3 Thawing of cells 
A volume of 4 ml of pre-heated growth medium were added to a T-25 flask using a sterile 5 
ml pipette. Following this, a cryovial containing approximately 1 x 106 cells was removed from 
long-term liquid nitrogen storage and immersed in the water bath (at 37˚C) for ~3 minutes. 
After ensuring that the cells were adequately thawed, 1 ml of cell-suspension was transferred 
to a T-25 flask containing 4ml of growth medium. The cells were then incubated at 37˚C in a 
5% CO2 atmosphere. After two hrs of incubation, the growth medium was removed, 
discarded and refreshed with 4 ml pre-warmed growth medium. For the rest of the 
experimental procedures, the growth medium was replaced every 48 hrs. Cells were allowed 
to reach a confluency of 80% prior to experimental procedures.  
2.3.4 Seeding of cells for experimental procedures 
When the cells reached 80% confluency, the growth media was removed, the cell monolayer 
was then gently rinsed with prewarmed trypsin-EDTA (2 ml for a T-25 and 3 ml for a T-75). 
An inverted microscope (Olympus CKX41) was used to determine whether the cells had 
completely detached from the flask surface. Once the cells had dissociated from the cell 
surface, an appropriate volume of growth medium (4 ml for a T-25, 12 ml for a T-75, 16-20 ml 
for a T-175, and 6 ml for 90 cm2 petri-dishes) was added, and the suspension was 
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centrifuged at 15000 Revolutions per minute (rpm) for 3 minutes at 37 ˚C. Thereafter, the 
supernatant was decanted, and the cell pellet was re-suspended in 1 ml of growth medium. 
Individual cells were counted by using a haemocytometer, and subsequently seeded for 
experimental procedures at the recommended seeding densities of N2aswe cells based on 
the surface area of culture vessels.  A cell passage number of 10-24 was employed for all 
procedures.  
2.5 Treatment groups for autophagy and cell death analysis  
2.5.1 Treatment reagents 
BA (H6501) (Sigma) was used to induce APP transgene expression. Gingko biloba (GB) 
(Flora force) and lithium chloride (LiCl) (Sigma, CAT) were used as the treatment 
interventions. Bafilomycin A1 (B0025) (LKT Laboratories) was used to inhibit 
autophagosome-lysosome fusion (Yamamoto et al. 1998). Sterile PBS was used as a solvent 
to dissolve all the reagents and prepare stock solutions of the treatment compounds.  
2.5.2 GB treatment 
GB capsules (340 mg) were purchased from Flora Force. For extraction of GB, the 60% 
acetone extraction (w/v) method was used. Briefly, GB capsules were removed from the 
bottle and encapsulated powder was retrieved. A total of 0.5 g GB powder was weighed and 
added to a 60% acetone solution in a volumetric flask. The flask was then placed in an 
ultrasonic bath at 40 °C for approximately 30 minutes and the GB diluted in acetone solution 
was filtered using filter paper under a vacuum. Thereafter, a freeze-dried extract method was 
employed to yield an extracted dry GB residue. The processed GB residue was then 
weighed and diluted in sterile PBS to prepare the desired stock solutions. Working standard 
concentrations of 10, 25, 50, 100, 200 and 400 µg/ml GB were prepared by diluting the 
appropriate volume of stock solutions with prewarmed growth media. All stock solutions were 
stored at -20 ˚C until further use. GB low concentration (10 µg/ml (↓)) and GB high 
concentration (200 µg/ml (↑)) were not found to be cytotoxic to the cells, as determined using 
a colorimetric assay based on the bio-reductive capacity of cells. These concentrations were 
thus used for all experimental procedures. 
2.5.3 Lithium chloride (LiCl) treatment 
A stock solution of 1 M of LiCl was prepared immediately prior to each experiment in sterile 
PBS. Working standard concentrations of 2.5, 5, 10 and 20 mM LiCl was prepared. A final 
working concentration of 10 mM LiCl was determined using a calorimetric assay. 
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Table 2.3. describes the treatment groups including the respective treatment intervention 
period that was used for all the experimental procedures in accordance with the aims of the 
study.  
Table 2.3. Treatment compounds 
Treatment intervention Company Working 
Concentration 
Time 
Butyric acid (BA) Sigma Aldrich 5 mM 48 hrs 
Lithium Chloride (LiCl) Sigma Aldrich 10 mM 24 hrs 
Bafilomycin A1 (BAFA1) Lkt Laboratories 400 nM 4 hrs 
Lysotracker Thermo-fisher Scientific 75 nM 2 hrs 
Hoechst Thermo-fisher Scientific 1 mg/ml 30 minutes 
(min) 
Silica Sigma Aldrich 250 mg/ml 3 hrs 
TMRE Abcam 500 nM 30 min 
The treatment groups were outlined as follows: 
 Control 
 24 hrs LiCl (10 mM) pre-treatment group  
 24 hrs GB (10 and 200 µg/ml) pre-treatment group (GB 10 µg/ml (↓), GB 200 µg/ml 
(↑)) 
 4 hrs BafA1 (400 nM) treatment group 
 48 hrs BA (5 mM) treatment group 
2.6 Experimental procedures  
2.6.1 Cellular Viability assays 
2.6.1.1 Water Soluble Tetrazolium Salts assay to determine viability following Gingko 
biloba and lithium chloride treatment 
The Water-Soluble Tetrazolium Salts (WST-1) bioreductive assay is used to quantify the 
metabolically active cells in a population, and to ensure that the treatment compounds were 
not cytotoxic to the cells, thus giving an indication of cellular viability. This colorimetric assay 
is based on the bioreductive capacity of cells. Metabolically active cells can reduce the 
water-soluble yellow tetrazolium salt WST-1 to water-insoluble purple formazan crystals of 
which the absorbance can be detected spectrophotometrically. The principle of this 
calorimetric assay is based on the cleavage activity of various mitochondrial dehydrogenase 
enzymes. Therefore, WST-1 can also be used as an indicator of mitochondrial reductive 
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capacity of metabolically active/living cells. An increase in the absorbance signal indicates an 
increase in metabolically active/healthy cells, whereas a decrease in the metabolism of 
healthy cells is accompanied by a decrease in the absorbance signal, indicating the potential 
cytotoxic effects of the treatment interventions. N2aswe cells were seeded into 48-well plates 
which contained 200 µ of pre-warmed media and allowed to attach overnight under a 
humidified atmosphere containing 5% CO2 at 37°C. The following day culture media was 
removed from the 48-well plates and cells were exposed to various concentrations of the 
treatment compounds as described in section (2.3). This was performed in order to relate the 
intervention concentrations to those known to be therapeutically achievable in humans. After 
incubation and exposure to various treatment, 10 µl of WST-1 was added to 200 µL culture 
medium in each well and subsequently incubated for 2 hrs (avoiding exposure to light). 
Following the incubation period, the absorbance signal was measured at 450 nm using a 
microplate reader (EL800 universal microplate reader, BioTek Instruments Inc). Under 
control conditions, cellular viability was considered as 100% and the treated groups were 
measured against the control groups.  
2.7 The effects of GB and LiCl on autophagy and amyloidogenic processing  
For western blot purposes, N2aswe cells were seeded at a density of 500,000 cells into 12 T-
75 flasks according to each treatment group. WB analysis of the autophagy markers LC3-II 
and cargo protein p62 was conducted. LC3-II is a functional indicator for autophagic activity 
(Rubinszstein et al., 2009), and p62 is required for the selective binding of ubiquitinated 
proteins and marks the proteins for autophagic degradation. However, to investigate the 
extent of autophagy induction the utilization of autophagosome-lysosomal fusion inhibitors is 
crucial to accurately interpret results related to autophagy activity (Rubinsztein et al., 2009). 
To investigate the extent of autophagy modulation by GB, co-treatment with or without 
bafilomycin A1 was performed (Mizushima and Yoshimori, 2007). This allowed the 
investigation of the dose-dependent effects of the described treatment groups on autophagic 
activity, and allowed for the quantification of the rate of autophagic activity. The degradation 
of cargo through the autophagic pathway was determined by probing for the following 
proteins: APP and Aβ through WB. The western blot results of autophagy flux and cargo 
protein levels of cargo, specifically APP and Aβ, allowed us to correlate the relationship 
between protein degradation through autophagy and the clearance rate of proteinaceous 
cargo.  
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2.7.1 Protein extraction  
Upon completion of the treatment interventions, N2aswe cells were harvested as follows: T-
75 flasks were washed with cold PBS three consecutive times and supplemented with 150 µl 
of cold radioimmunoprecipitation assay (RIPA) buffer (adjusted to pH 7.4) and supplemented 
with 10 µl of Protease and Phosphatase Inhibitor Cocktail. A sterile cell scraper was used to 
gently scrape the cell monolayer and the cell suspension was then transferred to sterile 
Eppendorf tubes and maintained on ice. The cell lysates were then sonicated for 10 seconds 
using the ultrasonic liquid processor (Misonix Sonicator 4000, Connecticut, USA) at a 
frequency of 3 Hertz. Sonification was performed on ice. Subsequently cell lysates were 
centrifuged at 8000 rpm for 10 minutes at 4 °C until the cell lysates were clarified. The 
clarified supernatants were carefully collected and transferred to pre-chilled Eppendorf tubes 
and stored until further analysis at -80 °C.  
2.7.2 Protein determination and sample preparation 
Protein quantification was performed using the Direct Detect® FTIR Spectrometer (Merck 
Millipore, USA). The Direct Detect ® infrared spectrometer is an advanced membrane 
technology, optimized for the detection and quantification of proteins. Briefly, cell lysates are 
applied in a drop-wise manner directly to a card-based hydrophilic polytetrafluoroethylene 
(PTFE) membrane that is transparent in most of the infrared spectral region. Once dried, the 
card-based PTFE membrane is measured by the Direct Detect® system for amide bonds in 
protein chains, thereby accurately quantifying protein content. A minimum protein 
concentration of 0.2-5 mg/mL can be accurately determined from a minimal sample volume 
of 2 μl. RIPA buffer was used as the blank measurement. The card-based PTFE membranes 
were placed on the spotting tray and 2 µL of blank (RIPA buffer) was added on spot 1. 
Subsequently 2µL of each sample were loaded onto the assay-free cards and loaded into the 
loading compartment of the Direct Detect® machine. A protein concentration of 20 µg/ml of 
each sample were prepared using a blend of β-Mercaptoethanol (150 μl) and Laemmli’s 
sample buffer (850 μl). For further analysis, samples were stored at -80 °C 
2.7.3 Sodium dodecyl-sulphate polyacrylamide gel electrophoresis  
Using a 12% Bio-Rad Fast Cast Stain Free-gel (Bio-Rad Laboratories, South Africa), 
equivalent amounts of protein (20 μg) were loaded per lane with a molecular marker being 
loaded in the first lane to assist with orientation and sizing of separated proteins. Proteins 
were separated using the sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE; Mini-PROTEAN® Tetra cell, Bio-Rad) system at a constant voltage of 120 V and 
current of 200 mA (Bio-Rad Power Pac 1000) for approximately 90 minutes. When the 
migration front reached the bottom of the gel, the gel was carefully placed and activated in 
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the ChemiDoc imaging system (Chemi Doc MP, Imaging System). Following activation, the 
gels were immediately transferred onto polyvinylidene fluoride (PVDF) membranes 
(Immobilon-P® Merck Milipore, IPVH00010, Darmstadt, Germany) using the Bio-Rad electro-
transfer system electrotransfer system (Bio-Rad Trans-blot® SD, USA) for 5 minutes. This 
was followed by the activation of the membranes to obtain the total protein and determine 
transfer efficiency using the ChemiDoc imaging system. Subsequently, the membranes were 
rinsed in 100% methanol and allowed to air dry prior to being re-hydrated in 100% methanol 
until translucent (this was performed to immobilize the proteins on the membranes). The 
membranes were then incubated for 1 hour in blocking buffer solution (5% fat-free milk 
diluted in 1x TBS-T). 
 
Each membrane was then cut at the 25 kDa protein marker as the proteins of interest were 
either visualized higher than 25 kDa and lower than 25 kDa. Following the blocking 
procedure, the membranes were probed for several proteins of interest using recommended 
dilutions of (see Table 2.2 for full details). With the exception of anti-LC3B which was 
incubated for two nights, all membranes were incubated overnight at 4°C in primary 
antibodies. The following membranes were washed in 1x TBS-T three times 10 minutes 
each, and subsequently incubated in the appropriate HRP-conjugated secondary antibody 
for an hour at room temperature. The membranes were then washed in 1x TBS-T three times 
for 10 minutes each (this was performed to avoid formation of isoforms, which was a 
constant problem in previous WB analyses). The membranes were then exposed to ECL 
Western Blotting Substrate (Bio Vision, USA, San Francisco Africa) for 1 minute to develop 
and visualize protein bands using the ChemiDoc imaging system (Chemi Doc MP, Imaging 
System). The Bio-Rad Image Lab software was used to quantify the band intensities. The 
percentage band intensity was expressed relative to average β-actin control for each 
respective protein of interest.  
2.8 Cell death analysis 
Western blot analysis of the apoptotic marker cytochrome c was performed. The release of 
cytochrome c into the cytosol serves as a pro-apoptotic molecule (Green, 2005). The aim of 
this analysis was to investigate if GB or the combination with LiCl could attenuate Aβ induced 
toxicity, potentially in an autophagy-dependent manner. These results were correlated with 
the WST-1 cell viability assay findings. Additionally, we aimed to investigate whether GB or 
the combinational with LiCl could potentially attenuate Aβ induced damage. Western blot 
analysis of LAMP1 and LAMP2 was collectively assessed to further investigate the 
hypothesis that Aβ toxicity causes lysosomal damage, whereas/while GB preserves 
lysosomal function. 
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2.8.1 Transient transfection  
This section aimed to investigate whether APP causes lysosomal damage/leakage by 
comparing how many cells are Galectin 3 (Gal-3) (+) (damaged cells) and how many cells 
are LAMP1 (+) (total number of lysosomes). This analysis allowed for the investigation of 
lysosomal stability. N2aswe cells were transiently transfected with GFP-Galectin3 plasmid. 
Gal-3 is recruited to damaged lysosomes, and the rupture of endosomal membranes permits 
the release of Gal-3 to enter the glycoproteins found in the lumen of compartments such as 
lysosomes (Paz et al., 2010). The Lipofectamine 3000 (Invitrogen, L300000) transfection 
solution was prepared as described in Table 2.4. 
Table 1.4. Lipofectamine 3000 transfection solution components. 
Compounds  Eppendorf tube 1 Eppendorf tube 2 
GFP-galectin3 (1/773.8 ng/µl) X (800 DNA concentration) 
= 1µl 
NA 
P3000 1 µl per well NA 
Serum free 
media 
50 ul per well 50 µl per well 
Lipofectamine NA 0.5 µl per well 
 
Briefly, 5x103 N2aswe cells were seeded in NUNC 8-well chamber dishes and transfected 
with green fluorescent protein-galectin-3 (GFP-Gal-3) plasmid (expanded and developed at 
the Department of Human Genetics, Tygerberg, South Africa) (see Appendix for exact 
protocol followed). This was done prior to treatment by using the Lipofectamine 3000 
transfection reagent (Life Technologies, L30000015). Sufficient transfection efficiency was 
achieved using a plasmid concentration of 773.8 ng/µL, diluted in Opti-MEM containing 
P3000 solution (1µL/µg DNA). The DNA-P3000 complex solution was co-incubated with 
Lipofectamine 3000 solution in a 1:1 ratio for 30 minutes to allow for stable complex 
formation. Cells were incubated with Transfection media (10 µL per chamber) for 48 hrs. The 
efficiency of transfection was verified using the Olympus cell system attached to an Ix 81 
inverted fluorescence microscope (Soft imagining system, Olympus Corporation, Tokyo, 
Japan)  
Following transient GFP-Galectin-3 transfection for 48 hrs, N2aswe cells were either treated 
with BA for 48 hrs or treated with Silicon dioxide (also termed Crystalline silica, found in 
nature as quartz or sand) (Life technology). Silicon dioxide has been reported to disturb the 
membrane of lysosomes in alveolar macrophages and trigger inflammation in lungs 
(Hornung et al., 2008), and this compound was also used as a positive control for lysosomal 
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injury. Following the treatment procedure, transfected cells were further supplemented with 
LysoTracker® Red DND-99 (Thermo-Fisher Scientific) which is a red-staining fluorescent dye 
utilized to label and track organelles that are acidic (such as lysosomes) in live cells. This 
was followed by nuclei staining using Hoechst (Thermo-Fisher Scientific) to allow for the 
detection of cell nuclei. Thereafter cells were imaged per group at 100x magnification. Two 
excitation filters were used to capture the images, including, Oregon Green 488 excitation 
and DAPI excitation, and the images were captured using the Olympus Cell software 
(Hamburg, Germany). 
2.8.2 Mitochondrial assessment  
2.8.2.1 Tetramethylrhodamine ethyl ester treatment and live cell imaging 
N2aswe cells (500) were seeded per well into NUNC 8-well chamber dishes and the cells 
were allowed to attach overnight in a humidified atmosphere containing 5% CO2 at 37 °C. 
The following day, the cells were treated with medium (C), LiCl 10mM, GB low (↓:10µg/ml), 
GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl 10mM, GB high (↑:200µg/ml) + LiCl 10mM 
for 24 hrs and then further incubated for 48 hrs in BA (5 mM) treatment. This was followed by 
a refreshment of media comprising of 500 nM tetramethylrhodamine ethyl ester (TMRE; 
Abcam, #ab113852). TMRE is a fluorochrome that is dependent on the potential of the 
membrane, and thus used to stain for polarized mitochondria with intact membranes in living 
cells (Hanley et al., 2002). Cells were stained with Hoechst 33342 at a 1:200 dilution in 
culture media 1 hr prior to imaging. Two excitation filters were used to capture the images, 
including Texas Red excitation and DAPI excitation, and the images were captured using the 
Olympus Cell software (Hamburg, Germany). 
2.9 Immunohistochemistry and confocal microscopy 
N2aswe (500) cells were seeded into a NUNC 8-well chamber dishes containing 200 µl pre-
warmed growth media. The cells were then allowed to adhere overnight. The following day, 
the cells were treated with medium (C), LiCl 10mM, GB low (↓:10µg/ml), GB high 
(↑:200µg/ml), GB low (↓:10µg/ml) + LiCl 10mM, GB high (↑:200µg/ml) + LiCl 10mM for 24 hrs 
and BafA1 treatment for 4 hrs. Following the treatment intervention period, the media was 
removed, and the cells were rinsed with cold PBS. This was followed by a fixative step, 
where cells were incubated at 37 ºC for 15 minutes with a 1:1 fixative solution of 4% 
paraformaldehyde and growth media. The fixative solution was then aspirated, and the cells 
were washed with PBS three times for 5 minutes. This was followed by a permeabilization 
process using 0.1% Triton X-100 in sterile PBS for 6 minutes at room temperature (RT). The 
cells were subsequently washed with 1XPBS three times for 5 minutes and further incubated 
with 5% Donkey serum (Sigma, D9663) for 1 hour which was used as blocking buffer. The 
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blocking serum was then removed, and the cells were incubated overnight at 4 °C with the 
following primary antibodies: ant-APP, anti-Aβ, p62, LC3B, MNF1, DRP diluted in 1XPBS at 
a 1:200 dilution (see Table 2.2 for details). Approximately 50 µl of primary antibody solution 
was added to each well. The following day, the primary solution was removed, and the cells 
were incubated with fluorophore-conjugated secondary antibodies AlexaFluor 568 donkey 
anti-rabbit (ThermoFisher, 10042) and AlexaFluor 488 donkey anti-mouse (ThermoFisher, A-
10037) for 1 hr at RT. This procedure was followed by three times wash step for 5 minutes 
with sterile 1XPBS. This was followed by a nucleur staining for 10 minutes using Hoechst 
33342 diluted in 1XPBS at a 1:200 dilution. After the cells were washed, and allowed to 
airdry for 10 minutes, Dako® fluorescent mounting medium (Dako Cytomation)) was added to 
the individual NUNC 8 chamber wells in a dropwise manner and allowed to airdry for 1 hr. 
Subsequently, the cells were either imaged directly using the Carl Zeiss ELYRA S1 LSM-780 
microscope system or stored at -20 °C for further imaging at a later stage.  
2.10 Acridine orange staining 
Acridine orange (AO) MW (369.94, Sigma) is a fluorescent dye which specifically recognizes 
acidic compartments, such as lysosomes which stand as an indication of the digestive 
capabilities (via autophagy) within a cell.  Briefly, 500 N2aswe cells were seeded into an 8-
chamber dish containing 200 µl pre-warmed growth media. The cells were then treated with 
medium (C), LiCl 10mM, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + 
LiCl 10mM, GB high (↑:200µg/ml) + LiCl 10mM, for 24 hrs and then then treated for 48 hrs 
with BA (5 mM). This was followed by a refreshment of media comprising of AO (1:500; 
Sigma). AO can emit fluorescence after excitation with blue light (466.5 nm) The cells were 
stained with Hoechst 33342 (1:200 dilution in growth media) prior to imaging. Thereafter, 
Dako® fluorescent mounting media (Dako Cytomation) was added dropwise to each chamber 
and left to airdry at -20 ºC overnight. The following day images were acquired using the 
Olympus CellR system attached to an IX 81 inverted fluorescent microscope equipped with 
an F-view-II cooled CCD camera (Soft Imaging Systems). 
2.11 Transmission electron microscopy 
2.11.1 Sample preparation 
N2aswe cells were seeded in duplicate into T-75 flasks and allowed to adhere overnight. 
After reaching a confluency of 80%, cells were treated with medium (C), LiCl 10mM, GB low 
(↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl 10mM, GB high (↑:200µg/ml) + 
LiCl 10mM, and 48 hrs with BA (5 mM). After treatment, 3 ml of trypsin was added to each 
flask and incubated for 5 minutes to all for complete cell detachment from the flask surface. 
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Following this, 6 ml of media was added to each flask, and the cell suspension was 
transferred into 15 ml falcon tubes. The cells were then centrifuged at 1500 RPM for 5 
minutes and thereafter the cell pellet was resuspended in 1 ml of pre-warmed 1XPBS. The 
cell suspension was centrifuged again under the same conditions, and the cell pellet was 
resuspended in 1 ml of pre-warmed 2.5% glutaraldehyde which was used as a fixative 
solution. The cell suspension was further centrifuged for 10 minutes and the cell pellet was 
resuspended in 1 ml 2.5% glutaraldehyde. The cells suspension was then stored at 4°C 
overnight and TEM analysis were performed at the Tygerberg Hospital by National Health 
Laboratory Services. 
2.11.2 TEM sample processing  
The fixative solution was removed, and the cells were washed in 0.1 M sodium phosphate 
buffer 3 times for 5 minutes. This was accompanied by a centrifugation step (1500 RPM) 
between each wash step. The cells were then fixed with 1% osmium tetroxide diluted in 0.1 
M sodium phosphate buffer for 1 hr. Next, the samples were washed in deionised water 5 
times and then transferred to an automated tissue processer, and the samples underwent a 
series of dehydration steps described as follows: 
 15 min in 10% uranyl acetate 
 10 min in 30% ethanol 
 10 min in 50% ethanol 
 10 min in 70% ethanol 
 10 min in 90% ethanol 
 10 min in 95% ethanol 
 10 min in 100% ethanol 
 10 min in 100% ethanol 
Samples were subsequently incubated with a 1:1 solution of 100% ethanol and Spurr’s resin 
for 90 min and then further incubated with 100% Spurr’s resin for 120 min. The samples were 
then embedded for 72 hrs at 60°C in an oven, in 100% Spurr’s resin using BEEM Embedding 
Capsules (Electron Microscopy Sciences). Subsequently, using the Leica EM UC7 
ultramicrotome, the resin-embedded samples were sectioned into 200 nm sections. These 
sections were stretched using chloroform vapor and then placed onto copper grids. Images 
were acquired using a JEOL JEM 1011 transmission electron microscope and analysed 
using the iTEM soft imaging analysis program.  
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2.12 Liquid chromatography-mass spectrometry based quantitative analysis  
Liquid chromatography–mass spectrometry (LC-MS) Q-TOF is a technique that uses 
analytical chemistry to separate components of an organic compound through the 
combination of liquid chromatography, allowing the physical separation of elements, and 
mass spectrometry, used for mass analysis. In order to better understand the Ginkgo extract 
used in this study, LC-MS was performed. This method enables the precise location and 
identification of specific terpene lactones and flavonoid glycosides present in acetonic 
Ginkgo biloba leaf extracts through their different retention times. Upon fragmentation, 
flavonoid glycosides display cleavage sugar moieties (Beck & Stengel, 2016). Components 
are separated in a thin column and the machine scans the compound from 5 Delta to 500 
Delta and generates a peak before indicating an accurate mass of that specific molecule. 
With these two parameters, the exact compound can be identified. 
2.13 Statistical analysis 
Data from at least three independent experiments was analysed by one-way analysis of 
variance (ANOVA) using the Bonferroni post-hoc test. The GraphPad Prism version 5.02 
software was employed to conduct all statistical analysis between treatment groups. A 
p<0.05 was considered as statistically significant. All data are expressed as mean ± standard 
error of the mean (SEM). 
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CHAPTER 3: RESULTS 
Section 3.1: The effect of Ginkgo biloba (GB) and lithium chloride (LiCl) 
treatment on cell viability  
3.1.1 Dose response of lithium chloride and Ginkgo biloba  
One of the main questions in the autophagy field centre around the aspect of whether 
autophagy activity differs in a concentration dependent manner when using an autophagy 
inducing agent. Hence, WST-1 viability assays were conducted after incubating N2aswe cells 
with increasing concentrations of lithium chloride (LiCl) and Gingko Biloba (GB) for 24 hrs 
respectively, in order to determine a suitable low and high, yet non-toxic concentration. With 
the guidance of literature, a suitable concentration range was chosen by conducting a dose 
response to ensure that the desired GB and LiCl working concentrations had no toxic effects 
to the N2aswe cells. 
Literature points to LiCl as a neuroprotective agent (Forlenza & Diniz, 2014). Accordingly, the 
relative reductive capacity of N2a cells after 24 hrs exposure to various concentrations of 
LiCl, including 5 mM, 10 mM, 20 mM, 40 mM, 500 mM, were reported (Fig 3.1.1). Exposure 
to LiCl (10 mM, 20 mM, 40 mM) displayed no significant difference in terms of reductive 
capacity compared to control conditions [0.61 ± 0.06 (p <0.05)]. These results demonstrated 
that LiCl has no neurotoxic effects under these concentration ranges. However, we observed 
that higher concentrations of LiCl (500 mM) appeared cytotoxic by significantly reducing the 
relative reductive capacity compared to control conditions [0.10 ± 0.02 (p<0.05)]. Therefore, 
a lower concentration of LiCl (10 mM) treatment was utilized for all following experiments.  
 
 
  
 
 
 
 
Figure 3.1.1: Relative reductive capacity of N2aswe cells after 24 hrs treatment exposure to various 
concentrations of lithium chloride (LiCl: 24 hrs 5 mM, 10 mM, 20 mM, 40 mM, 500 mM). * p<0.05 vs 
Control (n=3).  
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3.1.2 Concentration-dependent effect of GB on cell viability  
After incubating N2aswe cells with varying concentrations of GB (10, 25, 50, 100 and 
200µg/ml) WST-1 viability assays were performed (Fig 3.1.2). Twenty four hrs 
supplementation with the respective concentration of GB displayed no significant reduction in 
the relative reductive capacity: GB 10 µg/ml [1.1 ± 0.08]; GB 25 µg/ml [0.8971 ± 0.01]; GB 50 
µg/ml [0.87 ± 0.02]; GB 100 µg/ml [0.71 ± 0.03]; GB 200 µg/ml [0.71 ± 0.04] (Fig 3.1.2). This 
demonstrated that GB has no neurotoxic effects on N2aswe cells. However, a significant 
difference decrease was reported between GB 10µg/ml [1.1 ± 0.08]; (p<0.05] and GB 100/ 
200µg/ml [0.71 ± 0.03; 0.71 ± 0.4 (p<0.05)], respectively (Fig 3.1.2). These results showed 
that N2aswe cells display a degree sensitivity with regards to the reductive capacity when 
exposed to GB, however, not reaching significance when compared to non-treated control 
cells. Thus, both a low concentration (10µg/ml: GB↓) and a high concentration (200µg/ml: 
GB↑) was utilized for subsequent experiments. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2: Relative reductive capacity of N2aswe cells after 24 hrs treatment exposure to various 
concentrations of Gingko biloba (GB) (10µg/ml, 25 µg /ml, 50 µg /ml, 100 µg /ml and 200 µg /ml). * 
p<0.05, n=3. 
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3.1.3 Combination treatment of GB and LiCl and effects on cell viability  
Light microscopic examination and WST-1 assays were employed to assess the reductive 
capacity of GB (↓10µg/ml & ↑200µg/ml) in the presence or absence of LiCl (10mM). 
Treatment with GB↓(10µg/ml) [0.36 ± 0.01]; GB↑ (200µg/ml) [0.33 ± 0.01] and LiCl [0.35 ± 
0.01] had no effect on cell viability. Moreover, a similar trend was revealed when the cells 
were exposed to a combination treatment of both GB concentrations with LiCl [0.32 ± 0.01; 
0.32 ± 0.01] (Fig 3.1.3 A). Light microscopic examination revealed no distinguishable 
differences in the general morphology of the N2aswe cells that were exposed to LiCl, GB 
(↓10µg/ml & ↑200µg/ml) in the presence and absence of LiCl compared with the control 
group respectively (Fig 3.1.3 B). Therefore, suitable concentrations were established, and 
used for subsequent experiments to assess autophagic activity and protein clearance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3 A: Relative reductive capacity of N2aswe cells after 24 hrs treatment exposure to Gingko 
biloba (GB↓10µg/ml & GB↑200µg/ml), lithium chloride (LiCl 10 mM) and combination treatment of GB 
(↓10µg/ml +LiCl) and GB ↑200µg/ml +LiCl (10mM) * p<0.05 (n=3). 
 
(A) 
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Figure 3.1.3 B: Micrographs representing the morphological assessment of N2aswe cells (Control) 
after 24 hrs treatment exposure to Gingko biloba (GB↓10µg/ml & GB↑200µg/ml), lithium chloride (LiCl 
10 mM) and combination treatment of GB (↓10µg/ml +LiCl) and GB ↑200µg/ml +LiCl (10mM). (n=3). 
Scalebar: 10µM. 
3.1.4 Gingko biloba pre-treatment confers neuroprotection against amyloid-βeta 
mediated proteotoxicity 
In the following section, results that assessed the effect of LiCl and GB in the context of 
amyloid ß induced neurotoxicity are reported. We hypothesized that supplementation with 
GB and the combination treatment with LiCl would confer neuroprotection due to their likely 
role in upregulating autophagy.  
3.1.4.1 WST1 Reductive capacity 
The relative reductive capacity of N2aswe cells following GB and combination treatment with 
LiCl prior to BA exposure was assessed using WST1 assays (Fig 3.1.4). BA (5mM) is known 
to induce the induction APP transgene expression resulting from increased protein 
expression and activity of BACE, and thereby increasing the production of Aβ (Shin et al., 
2016). 
A significant reduction in the relative reductive capacity of cells was observed following 48 
hrs exposure to BA treatment [0.24 ± 0.01 (p<0.05)] (Fig 3.1.4 A) compared to control 
conditions  This result indicates that 48 hrs overexpression of APP impacts cell viability. 
However, a 24 hrs pre-treatment with LiCl [0.33 ± 0.01 (p<0.05)], GB↓ 10µg/ml (0.34 ± 0.01 
(B) 
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(p<0.05)] & 200µg/ml [0.34 ± 0.01 (p<0.05)] and GB↓ + LiCl [0.30 ± 0.01 (p<0.05)] prior to BA 
exposure caused a higher capacity in the relative reductive capacity, compared to BA only 
treated cells [0.30 ± 0.4 (p<0.05)] (Fig 3.1.4 A). Hence, a rescue effect of LiCl, GB 10µg/ml & 
200µg/ml and GB↓ (10µg/ml) + LiCl treatment was observed, and thereby reducing the 
neurotoxicity caused by the APP overexpression. However, both high and low concentrations 
of GB equally protected neurons from Aβ-induced neuronal toxicity. Exposure to BA caused 
prominent cell loss and alteration of cell morphology, compared to control cells as revealed 
by the corresponding micrographs (Fig 3.1.4 B). In contrast, 24 hrs pre-exposure to LiCl, GB 
(↓:10µg/ml &↑:200µg/ml) in the presence and absence of LiCl prior to BA treatment displayed 
an larger number of cells and an improvement in the morphology of cells compared to BA 
treated cells. In order to further validate the demonstrated neuroprotective role of GB and 
LiCl, western blot analysis of apoptosis markers, namely: cleaved Caspase 3 and 
cytochrome C was conducted.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.4 A: Relative reductive capacity of N2aswe cells following exposure to Gingko biloba (GB) 
(GB↓10µg/ml & GB↑200µg/ml), lithium chloride (LiCl 10 mM) and combination treatment of GB 
(↓10µg/ml +LiCl) and GB ↑200µg/ml +LiCl (10mM) followed by butyric acid treatment (BA, 5mM, 48 
hrs). * p<0.05 vs control; # p<0.05 vs BA, n=3. 
(A) 
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Figure 3.1.4 B: Micrographs representing N2aswe cells (Control) following exposure to Gingko biloba 
(GB↓10µg/ml & GB↑200µg/ml), lithium chloride (LiCl) and combination treatment of GB (↓10µg/ml 
+LiCl) and GB ↑200µg/ml +LiCl (10mM) followed by butyric acid treatment (BA, 5mM, 48 hrs). n=3. 
Scalebar: 10µM. 
  
(B) 
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Treatment groups based on cell viability results 
A summary table of the concentrations and intervention times of the six treatment groups of 
interest which were utilized for all subsequent experiments (Table 3.1) 
Treatment Concentration Intervention Time 
Control (C) - - 
Lithium chloride (LiCl) 10mM 24 hrs 
Gingko biloba low 
(GB↓) 
10µg/ml 24 hrs 
Gingko biloba high 
(GB↑) 
200µg/ml 24 hrs 
Gingko biloba low + 
Lithium Chloride (GB↓ 
+ LiCl) 
GB10µg/ml + LiCl 10 mM 24 hrs 
Gingko Biloba high + 
Lithium chloride (GB↑ + 
LiCl) 
GB200µg/ml + LiCl 10 mM 24 hrs 
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Section 3.2 Characterisation of GB modulation on autophagy and protein cargo 
clearance and its effects on amyloid processing. 
Since significant differences were reported between low concentration GB↓ 10µg/ml [1.1 ± 
0.08] and high concentration GB↑ 200µg/ml [0.71 ± 0.04] (p<0.05)] (Fig 3.1.2 A), we 
hypothesized that treatment with GB will exhibit a dose dependent effect on autophagic 
activity, and that this effect may be further enhanced through combination treatment with 
LiCl. Western Blot analyses were performed to unravel the dose dependent effect of GB and 
its combination treatment with LiCl on autophagic activity and its potential effect on the 
distinct removal of APP and Aβ. Firstly, the dose dependent effect of GB and its combination 
treatment with LiCl on autophagy flux was assessed. Secondly, the protective role of GB 
treatment under neurotoxic conditions was investigated.  
3.2.1 Gingko biloba treatment in the presence and absence of LiCl modulates 
autophagic flux 
In order to asses autophagy, the relative protein expression of LC3-II can be quantitatively 
measured through the utilization of a lysosomal inhibitor, Bafilomycin A1 (BafA1). The 
expression of LC3-II is indicative of the abundance of autophagosome vacuoles following 
BafA1 treatment (Fig 3.2.1. A). BafA1 has only minor effects in control cells, displayed by the 
non-significant changes in LC3-II protein expression compared to BafA1 untreated cells 
[144.3 ± 4.72%]. This suggests that these cells have a relatively low basal autophagy flux. 
Significantly increased LC3-II protein levels were observed for the GB low (↓:10µg/ml) [297.2 
± 14.32% (p<0.05)],GB high (↑:200µg/ml) [321.6 ± 14.79% (p<0.05)], GB low (↓:10µg/ml) + 
LiCl 10 mM [237.3 ± 6.48% (p<0.05)], and GB high (↑:200µg/ml) + LiCl 10 mM [308.8 ± 
19.07% (p<0.05)] groups when compared to their corresponding BafA1 negative group. This 
indicates an increase in autophagosome pool size and an upregulation of autophagy under 
these treatment conditions. Moreover, the results show an enhanced autophagy activity, 
compared to basal autophagy. This is revealed by a significant increase in LC3-II protein 
levels in treated with GB low (↓:10µg/ml) [297.2 ± 14.32% (p<0.05)]; GB high in the presence 
[321.6 ± 14.79% (p<0.05)]and absence of LiCl10 mM [308.8 ± 19.07% (p<0.05)] followed by 
BafA1 treatment, in comparison with cells treated only with BafA1 (basal autophagy) group. 
However, the effect on LC3-II in the combination treatment of GB (↓:10µg/ml) + LiCl 10 mM 
[237.3 ± 6.48% (p<0.05)] was less significant compared to the combination treatment of GB 
(↑:200µg/ml) + LiCl [308.8 ± 19.07 (p<0.05)] in the examined conditions. Although no 
significant difference in LC3-II expression levels was observed between the different 
concentrations of GB in the presence of BafA1 [297.2 ± 14.32%, 321.6 ± 14.79%], there was, 
however, a trend for increased expression in the GB high (↑:200µg/ml) + BafA1 [321.6 ± 
14.32%] and the combination treatment of GB high (↑:200µg/ml) + LiCl + BafA1 [237.3 
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±6.48%] as compared to GB low (↓:10µg/ml) + BafA1 [308.8 ± 19.07%] group. This 
potentially indicates that GB has a dose dependent effect on autophagic activity.  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
(A.1) 
(A.2) 
Stellenbosch University  https://scholar.sun.ac.za
  61 
 
 
 
 
 
 
 
Figure 3.2.1 A: Relative protein expression levels of LC3 and LC3 net Flux in N2aswe cells following 
treatment with medium (Con), LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + 
LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs before and after Bafilomycin A1 (BafA1;400nM : 4 hrs). 
Beta-actin (β-actin) was used as a loading control. All data is expressed as means ± SEM (* p-value 
<0.05 vs control, #p-value <0.05 vs C+BAfA1, $ p-value <0.05 vs corresponding BafA1 negative 
group. (A.3) A representative blot is shown. 
(Fig 3.2.1 B) p62 targets ubiquitinated proteins marked for degradation and thus when 
autophagy is inhibited using BafA1, an increase in p62 protein level is indicative of its protein 
clearance through the autophagic pathway. If p62 protein levels do not change upon BafA1 
treatment, no clearance and hence no autophagy activity takes place. Hence, like LC3-II, an 
accumulation of p62 following BafA1 treatment is associated with increased protein 
degradation through autophagy. Significantly increased p62 protein levels were observed for 
the GB high (↑:200µg/ml) [170.8 ± 10.60% (p<0.05)] when compared to its corresponding 
BafA1 negative group. This result suggests an induction of autophagy by GB high 
(↑:200µg/ml). Interestingly, we observed that p62 protein levels were even more elevated 
when exposed to GB high (↑:200µg/ml) in the presence of LiCl followed by BafA1 treatment 
when compared to cells treated with GB high (↑:200µg/ml) only [176.6 ± 6.77%) p<0.05)]. 
These results indicate that GB in the presence of LiCl further enhances autophagy compared 
to GB on its own.  
  
(A.3) 
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Figure 3.2.1 B: Relative protein expression levels of p62 and p62  net Flux  in N2aswe cells following 
treatment with medium (Con), LiCl 10mM, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low 
(↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs before and after Bafilomycin A1 
(BafA1;400nM : 4hrs). Beta-actin (β-actin) was used as a loading control. All data is expressed as 
means ± SEM (* p-value <0.05 vs control, #p-value <0.05 vs C+BAfA1, $ p-value <0.05 vs 
corresponding BafA1 negative group. A representative blot is shown. 
3.2.2 Immunofluorescence analysis of p62  
In order to further investigate the modulatory role of GB in the absence and presence of LiCl, 
immunofluorescence analysis of the autophagy adapter protein p62 was conducted. The 
protein abundance of p62 can serve as a marker to monitor autophagy flux. Suppression of 
autophagy manifests with increased p62 levels, whereas induction of autophagy results in 
decreased p62 abundance. Untreated cells served as control cells and displayed a notable 
abundance of p62 (Fig 3.2.2). Upon exposure to Bafilomycin A1 (BafA1), an increase in red 
fluorescent signal intensity correlating to higher abundance of p62 clusters was evident (Fig 
3.2.2). Thus, the abundance of p62 was increased in BafA1 treated cells compared to control 
cells indicating the state of basal autophagy of the cells.  The results indicate that exposure 
to GB high (↑:200µg/ml) and a combination treatment of GB high (↑:200µg/ml) + LiCl, 
followed by four hrs of BafA1, presented the highest abundance of p62 compared to control 
cells treated with BafA1. Importantly, GB high (↑:200µg/ml) + BafA1 treatment revealed 
greater abundance of p62 compared to GB low (↓:10µg/ml) + BafA1. This strongly indicates 
a dose dependent effect of GB on autophagic activity, with the high concentration inducing 
autophagy more robustly than the low concentration. Moreover, a combination treatment of 
GB high (↑:200µg/ml) + LiCl followed by four hrs of BafA1 revealed greater abundance of 
p62, compared to GB low (↓:10µg/ml) + LiCl + BafA1. 
(B.3) 
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Figure 3.2.2: Fluorescence micrographs of p62 abundance of N2aswe cells that were either untreated, 
treated with LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, or GB high 
(↑:200µg/ml) + LiCl for 24 hrs and subsequently treated without (left), or with BafA1 (right) (400nM, 4 
hrs). First panel represent Single cell and second panel represent single cell zoomed. ROI represents 
region of interest. Red signal represents p-62 linked to Alexa 561, blue signal represents Hoechst 
Scale bar: 10 µm. Arrow head indicate p62 clusters. 
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Section 3.3 The effects of Gingko biloba treatment on lysosome abundance  
Western blot analysis probing for of LAMP2a protein levels was performed to assess whether 
GB supplementation effects the lysosomal compartment and the abundance of lysosomes in 
the context of APP overexpression. LAMP2a is a specific lysosomal membrane associated 
protein and its protein expression correlates with the lysosomal abundance in a cell 
(Eskelinen, 2006). No significant changes were observed in the expression levels of 
LAMP2a, however, strong trends can be observed (Fig 3.3.1). Relative expression of 
LAMP2a compared to control was increased with butyric acid treatment [1.08 ± 0.40], 
decreased in the presence of LiCl [0.33 ± 0.07], GB low (↓:10µg/ml) [0.41 ± 0.16], GB high 
(↑:200µg/ml) [0.38 ± 0.10], GB low (↓:10µg/ml) +LiCl [0.54 ± 0.22], GB high (↑:200µg/ml) + 
LiCl [0.64 ± 0.12] and appear increased compared to BA treated cells, when cells were 
treated with LiCl (10mM) [0.54 ± 0.13] and GB low (↓:10µg/ml) [0.81 ± 0.28] in the presence 
and absence [1.28 ± 0.47] of LiCl prior exposure to BA. Interestingly, no changes were 
consistently observed between cells treated with GB high (↑:200µg/ml) and cells co-treated 
with butyric acid and GB high(↑:200µg/ml) [0.40 ± 0.10], suggesting some, yet, through this 
method not well quantifiable effect.  
  
 
 
 
 
Figure 3.3.1: Relative protein expression levels of LAMP2a in N2aswe cells (C), following treatment 
with LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) 
+ LiCl, for 24 hrs and subsequently treated without or with Butyric acid (BA 5 mM; 48H). Beta-actin (β-
actin) was used as a loading control. All data are expressed as mean ± SEM. A representative blot is 
shown. 
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3.3.2 The effects of Gingko biloba treatment on the lysosomal acidic compartment 
under neurotoxic conditions  
Acridine orange (AO) binds to DNA which emits green fluorescence and fluoresces red in 
acidic vesicular organelles (AVOs), including lysosomes and autolysosomes. Lysosomes are 
characterized by an acidic lumen (pH 5) as a result of the concentrated presence of various 
hydrolase enzymes necessary for cargo degradation. AO has been used as a rapid means to 
detect the acidic compartment, like lysosomes (Thomé et al., 2016), and indicate lysosomal 
function. A decrease in red fluorescence emission suggests a decrease in the acidic 
compartment and hence lysosomal function. Therefore, the AO stain was used to assess the 
overall lysosomal acidic compartment (LAC) upon treatment with Gingko biloba in the 
presence and absence of LiCl supplementation under neurotoxic conditions. Untreated 
N2aswe cells stained with 5 µM of AO for 20 minutes showed clear red puncta and hot spots 
in the cytoplasm and appeared to be located perinuclear (Fig 3.3.2). All the treatment groups 
displayed a similar morphology, although a relative decrease in the red signal was 
demonstrated. Since AO is sensitive to pH changes, exposure to BA is hypothesized to alter 
the response of AO, as BA causes the cellular condition to become less acidic compared to 
control conditions. Indeed, treatment with BA (5 mM; 48 hrs) showed changes in nuclear 
signal and a relative decrease in AO red signal, and hence a reduction in LAC compared to 
control cells, suggesting decreased lysosomal function. 24 hrs exposure to LiCl prior to BA 
treatment manifested in a robust increase in AO red signal compared to BA-only treated 
cells. This was however not the case when the cells were exposed to both GB 
concentrations prior to BA treatment. The AO red signal under these conditions was similar 
to BA-only treated conditions. These results suggest that lysosomes are most sensitive to 
LiCl treatment. Interestingly, a combination pre-treatment of GB and LiCl prior to BA 
treatment did not affect the AO red signal, in comparison with LiCl-pre-treated cells. 
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Figure 3.3.2: Lysosomal acidic compartment (LAC) detection using Acridine Orange (AO) staining. (A) 
Representative micrographs of AO-stained (20min, 5µM) N2aswe cells that were untreated, treated 
with LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) 
+ LiCl, for 24 hrs and subsequently treated without  (left) or with BA (right) (5mM, 48 hrs). Red 
(lysosomal acid compartments). Green (DNA). Blue (Hoechst). Scale bar =10µM.  
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3.3.3 The effects of Gingko biloba treatment on the neuronal ultrastructure under 
neurotoxic conditions  
The ultrastructural morphology of N2aswe cell vacuolar structures,  was observed by 
Transmission electron microscopy (TEM) following treatment with LiCl, GB low (↓:10µg/ml), 
GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs and 
subsequently treated without or with Butyric acid (BA 5 mM; 48 hrs).  
Under control conditions, the micrographs revealed regular cytoplasmic components and 
intact nuclei with distinct chromatin network. Exposure to LiCl, GB low (↓:10µg/ml), GB high 
(↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl revealed a similar 
morphology to control conditions respectively.  Moderate vacuolar structures and moderate 
swirl-like structures with a low electron density was observed under control conditions (Fig 
3.3.3). An increase in the number and size of vacuolar structures was observed when the 
cells were treated with LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + 
LiCl, GB high (↑:200µg/ml) + LiCl. Moreover, treatment with GB high (↑:200µg/ml) in the 
absence and presence of LiCl revealed most robust and very large vacuolar structure and 
the presence of clear distinct electron dense structure (i.e. lysosomes).  
BA-treated cells reveal more prominent and larger swirl-like structures compared to control 
cells, fewer and less defined vacuolar structures and loss of membrane and nuclear integrity. 
Exposure to LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB 
high (↑:200µg/ml) + LiCl prior BA treatment, revealed a more intact nuclear, a mixture of 
(light and darker vacuolar structures) and increased number of vacuolar structures. 
Importantly, treatment with GB high (↑:200µg/ml) in the absence and presence of LiCl 
revealed large vacuolar structures which could contain Aβ peptides targeted for degradation.  
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Figure 3.3.3: Representative Transmission electron micrographs of N2aswe cells (Con) that were treated with 
LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl, for 24 
hrs and subsequently treated without  (left) or with BA (right) (5mM, 48 hrs). First panel represent Single cell and 
second panel represent single cell zoomed ROI. Arrows indicate structures of interest. Scale bar =5000 nm.   
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Section 3.4 The effect of Gingko Biloba treatment on the clearance of 
amyloidogenic proteins under neurotoxic conditions  
Western blot analysis was performed to assess whether GB treatment, both in the presence 
and absence of LiCl, has an effect on the protein expression levels of APP, BACE and Aβ, 
which are involved in amyloid processing (Kellett and Hooper, 2009).  
As shown in Figure 3.4 A The results indicate a significant increase in APP protein levels in 
cells treated with BA compared to control cells [1.43 ± 0.24 (p<0.05)]. Similarly, the results 
indicate a significant increase in BACE [0.68 ± 0.06 (p<0.05)] and Aβ [0.66± 0.05 (p<0.05)].  
protein levels in cells treated with BA compared to control cells (Fig 3.4 B & C). These results 
indicate that the increase in APP due to the overexpression also translate in increased BACE 
protein levels as well as a significant increase in Aβ protein synthesis in cells treated with BA 
compared to control cells. Importantly, the results indicate a significant reduction in APP 
protein levels following 24 hrs treatment of LiCl [0.77 ± 0.13 (p<0.05)], GB low (↓:10µg/ml) 
[0.68 ± 0.14 (p<0.05)], GB high (↑:200µg/ml) [0.77 ± 0.17 (p<0.05)], GB low (↓:10µg/ml) + 
LiCl [0.41 ± 0.08 (p<0.05)], GB high (↑:200µg/ml) + LiCl [0.66 ± 0.30 (p<0.05)] compared to 
cells only treated with BA (5 mM, 48 hrs) (Fig 3.4 B & C). Similarly, the results indicate a 
significant decrease in BACE and Aβ protein levels following 24 hrs treatment of GB low 
(↓:10µg/ml) [0.25 ± 0.02 (p<0.05)], GB high (↑:200µg/ml) [0.32 ± 0.05 (p<0.05)] in the 
presence and absence of LiCl [0.38 ± 0.01 (p<0.05)]  prior to BA exposure compared to cells 
only treated with BA (5 mM, 48 hrs (B&C). However, no concentration dependent difference 
in the clearance of the proteins is observed. All autophagy inducing drugs appear to clear the 
proteins of interest relatively 
equally. 
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Figure 3.4: Relative protein expression levels of (A) APP and (B) BACE (C) Aβ in N2aswe cells (C) 
following treatment with LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, 
GB high (↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated without or with Butyric acid (BA;5 
mM; 48 hrs). Beta-actin (β-actin) was used as a loading control. All data are expressed as mean ± 
SEM (* p < 0.05 vs C, # p <0.05 vs C+BA). (D) A representative blot for each protein is shown. 
  
(D) 
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Section 3.5 The effect of Gingko biloba treatment on apoptosis onset under 
neurotoxic conditions 
Both cytochrome-c and cleaved-caspase-3 play immediate roles in the induction and 
execution of cell death via apoptosis. An increase in the relative expression of both proteins 
is indicative of active apoptosis. Western blot analysis of cytochrome-c and cleaved-caspase 
3 protein expression levels was performed to assess the potential protective role of GB 
supplementation in the context of APP overexpression.   
A significant increase in cytochrome-c [3.12 ± 0.67 (p<0.05)] and cleaved-caspase 3 [3.26 ± 
0.83 (p<0.05)]  protein expression following 48 hrs of butyric acid (BA, 5mM) treatment was 
observed when compared to control (Fig 3.5 A&B). This indicates that APP overexpression 
indeed leads to the release of cytochrome-c. Notably, a significant decrease in cytochrome-c 
protein levels was observed in 24 hrs pre-treatment with LiCl [2.62 ± 0.61 (p<0.05)], GB low 
(↓:10µg/ml) [2.47 ± 0.30 (p<0.05)] and  GB high (↑:200µg/ml) in the presence [2.21 ± 0.65 
(p<0.05)] and absence of LiCl [2.40 ± 0.68 (p<0.05)] before 48 hrs BA (5 mM,48 hrs) 
treatment compared to cells only treated with BA. These results indicate protective effects of 
all the treatment interventions, in the context of APP-induced neuronal toxicity. However, 
relatively unchanged cleaved caspase-3 expression was observed following 24 hrs pre-
treatment with LiCl [0.55 ± 0.13], GB low (↓:10µg/ml) [0.33 ± 0.18] and GB high (↑:200µg/ml) 
in the presence [0.60 ± 0.13] and absence of LiCl [0.60 ± 0.24] before 48 hrs BA (5 mM,48 
hrs) treatment compared to cells only treated with BA (Fig 3.5 B). 
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Figure 3.5: Relative protein expression levels of (A) Cytochrome-c and (B) Cleaved-Caspase-3 in 
N2aswe cells following treatment LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) 
+ LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated without or with Butyric acid 
(BA;5 mM; 48 hrs. Beta-actin (β-actin) was used as a loading control. All data is expressed as means 
± SEM (* p<0.05 vs C, # p <0.05 vs C+BA. (n=3). (A.1 & B.1) A representative blot is shown. 
Section 3.6 The effect of Gingko Biloba treatment on mitochondrial fission and 
fusion dynamics 
Western blot analysis of MNF1 and DRP1 protein expression levels were performed to 
assess whether GB supplementation enables the preservation of mitochondrial function in 
the context of APP overexpression.  MNF1 is a protein primarily responsible for the 
regulation of the fusion events and is localized on the outermost mitochondrial membrane. 
DRP1 is prominently found in the cytoplasm, however, the fragmentation of mitochondria is 
promoted by the interaction of DRP1 with the outer membrane of mitochondria (Fig 3.6.1 A). 
The results revealed that LiCl [1.30 ± 0.04 (p<0.05)] and GB low (↓:10µg/ml) [1.37 ± 0.07 
(p<0.05)] & GB high (↑:200µg/ml) [ 1.47 ± 0.31 (p<0.05)] in the presence of LiCl significantly 
increased the protein expression of MNF1. Interestingly, combination treatment of GB high 
(↑:200µg/ml) + LiCl (10mM) [1.55 ± 0.03 (p<0.05)] showed significantly increased more 
MNF1 protein levels compared to cells treated with GB (↑200µg/ml) only. This suggests that 
GB high (↑:200µg/ml) in the presence of LiCl favours the fusion state of a mitochondrial 
network as compared to GB-treated cells only. Exposure to butyric acid (BA, 48 hrs, 5 mM) 
led to a significant decrease in MNF1 protein levels in control cells [0.67 ± 0.03 (p<0.05)]. 
Importantly however, pre-treatment with LiCl, GB low (↓:10µg/ml) [0.65 ± 0.04], GB high 
(↑:200µg/ml) [0.68 ± 0.4], GB low (↓:10µg/ml) + LiCl [0.67 ± 0.35], GB high (↑:200µg/ml) + 
LiCl [0.72 ± 0.04] for 24 hrs followed by BA exposure, and had no effect on MFN1 expression 
compared to BA-treated cells.  
(B.1) 
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Exposure to both GB concentrations (10µg/ml) [0.52 ± 0.08 (p<0.05)] & GB high (200µg/ml) 
[0.47 ± 0.10 (p<0.05)] and a combination treatment of GB low (↓:10µg/ml) +LiCl [0.05 ± 0.20 
(p<0.05)] caused a significant decrease in DRP1 protein expression compared to control (Fig 
3.6.1B). We hypothesised that exposure to butyric acid (BA, 48 hrs, 5nM) would significantly 
increase the protein expression of DRP1, however, this was not the case. Surprisingly, 
untreated cells displayed relatively greater although non-significant protein expression of 
DRP1 compared to BA-treated cells [0.56 ± 0.09]. Importantly, pre-treatment with GB low 
(↓:10µg/ml) [0.32 ± 0.10 (p<0.05)] and GB high (↑:200µg/ml) [0.29 ± 0.05 (p<0.05)] in the 
absence and presence of LiCl followed by BA treatment caused a significant decrease in 
DRP1 protein expression compared to BA treated cells.  
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Figure 3.6.1: Relative protein expression levels of (A) MNF1 (B) DRP1 in N2aswe cells following 
treatment with LiCl, GB low (↓:10 µg/ml), GB high (↑:200 µg/ml), GB low (↓:10 µg/ml) + LiCl, GB high 
(↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated without or with Butyric acid (BA;5 mM; 48 
hrs). Beta-actin (β-actin) was used as a loading control. All data are expressed as means ± SEM (* 
p<0.05 vs C, # p <0.05 vs C+BA, @ p <0.05 vs GB high (↑:200 µg/ml). (A.1 & B.1) A representative 
blot is shown. 
  
(B) 
(B.1) 
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3.6.2 The effect of Gingko biloba treatment on mitochondrial morphology  
The function of cells can, at least in part, be assessed by the network organization or 
morphology of mitochondria. A network of elongated, fused mitochondria is usually 
associated with healthy viable cells (Chan, 2006). Staining cells with Tetra-methyl-
rhodamine-ethyl-esther TMRE revealed that control cells displayed elongated mitochondria 
that form a highly interconnected network. A 24-hr supplementation with all treatment groups 
including: LiCl (10 mM, GB low (↓:10 µg/ml), GB high (↑:200 µg/ml) and combination 
treatments GB low (↓:10 µg/ml) + LiCl, GB high (↑:200 µg/ml) + LiCl, displayed elongated 
fused mitochondria, very similar to control cells. 
On the other hand, cells subjected to butyric acid (BA, 5mM, 48 hrs) treatment exhibited a 
complete loss of network connectivity, portrayed by the fragmented mitochondrial 
morphology. Cells subjected to 24 hrs pre-treatment with all treatment groups including: LiCl 
(10 mM), GB low (↓:10µg/ml), GB high (↑:200 µg/ml) and combination treatments GB low 
(↓:10 µg/ml) + LiCl, GB high (↑:200 µg/ml) + LiCl, prior to BA exposure exhibited a network of 
both fused and fragmented mitochondria; however, a larger degree of mitochondrial 
connectivity and a reduction in fragmented mitochondria was evident compared to BA-only 
treated cells (Figure 3.6.2).  
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Figure 3.6.2: Representative micrographs of N2aswe cells stained with TMRE at control conditions (Con), with 
LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl, for 24 
hrs and subsequently treated without  (left) or with Butyric acid (BA, 5mM, 48 hrs) (right) . Red = TMRE, blue = 
Hoechst. Scale bar = 5 µm/10µm/20µm. Arrowheads indicate mitochondria morphology (fused vs fragmented 
network). 
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Section 3.7 Autophagy activity (flux) under neurotoxic conditions 
In order to assess the effects of the treatment interventions on autophagy activity, i.e. the 
rate of protein degradation through autophagy (autophagy flux), cells were treated with 
saturating concentrations bafilomycin. Protein expression of p62 is shown to increase upon 
BafA1 treatment, suggesting that the autophagic process is indeed active under the 
examined conditions (Fig 3.7 A). Significantly increased p62 protein levels were observed for 
the GB high (↑:200µg/ml) + BA + BafA1 [1.87 ± 0.68 (p<0.05)] treatment group compared to 
its corresponding BafA1 negative group, indicating upregulation of autophagy activity under 
this treatment condition. A significant increase p62 protein levels was also observed when 
cells were exposed to GB high (↑:200µg/ml) [1.89 ± 0.68 (p<0.05)] followed by BA and BafA1 
treatment, in comparison with control and GB low (↓:10µg/ml) treated cells followed by BA 
and BafA1 treatment, respectively. This further suggests that autophagy flux is highest when 
cells are exposed to GB high (↑:200µg/ml) and again highlights the dose-dependent 
modulation of GB on autophagy flux. In this context, a combination treatment of GB high 
(↑:200µg/ml) + LiCl [1.93 ± 0.20 (p<0.05)] followed by BA and BafA1 treatment, displayed a 
increase in p62 protein levels compared to control and LiCl treated cells followed by BA and 
BafA1 treatment respectively. These results, therefore, in the case of neuronal damage, 
suggest that a combination treatment also further enhances the autophagic flux compared to 
exposure to one drug only. 
 
 
 
 
 
 
 
 
 
 
  
 
(A) 
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Figure 3.7 A: Relative protein expression levels of p62 and p62 Net Flux in N2aswe cells following 
treatment with medium (C), LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + 
LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated with Butyric acid  (BA;5 mM; 48 
hrs) followed by Bafilomycin A1 (BafA1, 400nM, 4hrs). Beta-actin (β-actin) was used as a loading 
control. All data are expressed as means ± SEM (* p <0.05 vs C+BA, # p <0.05 vs C+BA+BafA1, + vs 
GB low (↓:10µg/ml) +BA+BafA1), $ p<0.05 vs its relative control) (n=3). (A.2) A representative blot is 
shown. 
 
(A.1) 
(A.2) 
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These results are supported by the LC3-II protein expression data (Fig 3.7 B), which 
demonstrated that LC3-II protein levels significantly increased when the cells were treated 
with GB high (↑:200µg/ml) + BA + BafA1 [2.25 ± 0.25 (p<0.05)], compared to its 
corresponding BafA1 negative group. This result indicates an increase in the LC3 abundance 
and autophagosome pool size, hence suggesting upregulation of autophagy under these 
treatment conditions. Furthermore, a significant increase in LC3-II protein levels was 
observed when the cells were exposed to GB high (↑:200µg/ml) [2.25 ± 0.20 (p<0.05)]  
followed by BA and BafA1 treatment, compared to control cells treated with BA (hence basal 
autophagy) This further suggests that autophagy flux is highest when cells are exposed to 
GB high (↑:200µg/ml) as compared to GB low (↓:10µg/ml). Overall, our findings suggest that 
high autophagy flux can be achieved and is crucial to decrease proteotoxicity by favoring the 
degradation of accumulated protein aggregates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Figure 3.7 B: Relative protein expression levels of LC3-II and LC3-II Net Flux in N2aswe cells 
following treatment with medium (C), LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low 
(↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated with Butyric acid  
(BA;5 mM; 48 hrs) followed by Bafilomycin A1 (BafA1, 400nM, 4hrs). Beta-actin (β-actin) was used as 
a loading control. LC3-II blot shows the concersion of LC3-I to LC3-II. All data are expressed as 
means ± SEM (# p-value <0.05 vs C+BA+BafA1, $ p <0.05 vs its relative control, + vs GB low 
(↓:10µg/ml) +BA+BafA1). (n=3). (B.2) A representative blot is shown. 
(B.2) 
(B.1) 
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Section 3.8 The effect of Gingko Biloba treatment on autophagy flux and APP 
processing  
3.8.A Inhibition of autophagy leads to the accumulation of APP 
Western blot analysis was performed to assess whether GB’s dose dependent effect on 
autophagic activity translates in distinct, flux dependent removal of APP and Aβ. In the 
previous section, our results demonstrated that GB reduces the protein expression APP, 
BACE and Aβ, which are all involved in the amyloidogenic pathway. We hypothesise that the 
clearance of these proteins is facilitated through the autophagy process. In order to assess 
this hypothesis, cells were treated with bafilomycin to determine whether the particular 
proteins are targeted and degraded through the autophagy pathway. Upon bafilomycin 
treatment, cargo targeted for degradation by the autophagy system would accumulate. Under 
basal conditions, control cells treated with BA (5mM, 48 hrs) and post-treated with BafA1 
displayed a decrease in APP protein expression [0.70 ± 0.03 (p<0.05)] compared to cells 
only treated with BA (Fig 3.8 A), suggesting that indeed autophagy is involved APP 
processing.  
Our results indicate that treatment with BafA1 caused strong trends of elevated APP protein 
levels in most treatment conditions besides GB low (↓:10µg/ml) [0.56 ± 0.41] (Figure 3.8 A). 
In addition, exposure to GB high (↑:200µg/ml) [0.70  ± 0.03 (p<0.05)] prior to BA and BafA1 
treatment caused a significant increase in APP protein levels compared to control and GB 
low (↓:10µg/ml) conditions This further supports a GB concentration-dependent modulation of 
autophagy activity and hence degradation of target proteins. Accordingly, a decrease in APP 
protein levels, when treated with GB high (↑:200µg/ml) [0.70 ± 0.03] prior to BA exposure, 
appears to be significantly increased in the presence of GB high (↑:200µg/ml), BA and BafA1 
compared to cells treated with GB high (↑:200µg/ml) and BA. This further suggest that APP is 
targeted as cargo for autophagy degradation. Since GB high (↑:200µg/ml) has the highest 
autophagy and is therefore clearing APP the strongest, inhibiting its autophagy leads to APP 
accumulating in a most robust manner (Fig 3.8 A).  
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Figure 3.8 A: Relative protein expression levels of APP in N2aswe cells (C) following treatment with 
LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + 
LiCl, for 24 hrs and subsequently treated with Butyric acid in the presence and absence of BafA1 
(BA;5 mM; 48 hrs). Beta-actin (β-actin) was used as a loading control. All data are expressed as 
means ± SEM (# p<0.05 vs C+BA, $ p<0.05 vs its relative control, + p<0.05 vs GB low (↓:10µg/ml) 
+BA+BafA1). (n=3). (A.1) A representative blot is shown.  
  
(A) 
(A.1) 
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3.8.B Inhibition of autophagy leads to the accumulation of BACE 
Similar to the effect observed of autophagy on APP processing under basal conditions, cells 
treated with BA (5mM, 48 hrs) [0.80 ± 0.05] and post-treated with BafA1 displayed a 
decrease in BACE protein expression. Our results (Fig 3.8 B) indicate that treatment with 
BafA1 caused strong trends of accumulation in BACE protein levels in most treatment 
conditions, although this effect was non-significant (Figure 3.8 B). Exposure to GB high 
(↑:200µg/ml) [1.38 ± 0.21 (p<0.05)] prior to BA and BafA1 treatment caused the most robust 
increase in BACE protein levels compared to control and GB low (↓:10µg/ml) conditions [1.05 
± 0.157]. Interestingly, exposure to GB high (↑:200µg/ml) in the presence of LiCl showed a 
significant increase in BACE when co-treated with BA+BafA1, compared to control cells 
treated with BA and BafA1 and GB high (↑:200µg/ml) and BA. This further supports the 
notion of a GB concentration-dependent modulatory effect on autophagy and hence 
degradation of target protein. This further suggest that BACE is targeted as cargo. 
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Figure 3.8 B: Relative protein expression levels of BACE in N2aswe cells (C) following treatment with 
LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + 
LiCl, for 24 hrs and subsequently treated with Butyric acid in the presence and absence of BafA1 
(BA;5 mM; 48 hrs). Beta-actin (β-actin) was used as a loading control. All data are expressed as 
means ± SEM (# p<0.05 vs C+BA, $ p<0.05 vs its relative control, + p<0.05 vs GB low (↓:10µg/ml) 
+BA+BafA1). (n=3). (B.1) A representative blot is shown.  
 3.8.C Inhibition of autophagy leads to the accumulation of Aβ 
Since Aβ is the product of APP cleavage by BACE, the protein expression of BACE is 
expected to translate in the protein expression of Aβ. Thus, a decrease in BACE following BA 
exposure would also result in a decrease in Aβ protein expression. To our surprise, no 
significant changes were observed in the protein expression of Aβ, however, strong trends of 
increased Aβ protein expression can be observed with exposure to BafA1 particularly under 
conditions of GB high (↑:200µg/ml) and both in the presence [0.42 ± 0.2] and absence [0.52 
± 0.1] of LiCl. 
  
(B.1) 
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Figure 3.8 C: Relative protein expression levels of Aβ in N2aswe cells (C) following treatment with 
LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high (↑:200µg/ml) + 
LiCl, for 24 hrs and subsequently treated with Butyric acid in the presence and absence of BafA1 
(BA;5 mM; 48 hrs). Beta-actin (β-actin) was used as a loading control. All data are expressed as 
means ± SEM (# p-value <0.05 vs C+BA, $ p-value <0.05 vs its relative control, +p<0.05 vs GB low 
(↓:10µg/ml) +BA+BafA1). (n=3). (C.1) A representative blot is shown.  
(C) 
(C.1) 
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Section 3.9 The effect of Gingko Biloba treatment on autophagy and apoptosis 
3.9.A The role of Autophagy inhibition on cell death onset  
In the following section we aimed to assess whether the observed neuroprotective effects of 
GB treatment were dependent on the modulation of autophagy. We subsequently aimed to 
assess how the modulation of autophagy by GB, when blocking autophagy, would affect cell 
death susceptibility. Thus, western blot analysis was performed to assess the protein 
expression of cytochrome-c and cleaved-caspase-3. Cytochrome-c protein expression was 
significantly increased in cells exposed to GB high (↑:200µg/ml) [1.401 ± 0.52 (p<0.05)] 
followed by BA and BafA1 treatment compared to cells treated BA + BafA1 and with GB low 
(↓:10µg/ml) followed by BA and BafA1 treatment. These results further demonstrate the 
dose-dependent effect of GB on autophagy and its protective role. Moreover, these results 
suggest that since GB high (↑:200µg/ml) caused the highest autophagy flux, when its 
autophagy activity is inhibited, the onset of apoptosis will increase, as shown by the 
increased cytochrome-c release. This suggests how highly dependent these cells are on high 
autophagy activity to delay the onset of cell death. Thus, autophagy has a protective effect in 
these conditions. 
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Figure 3.9 A: Relative protein expression levels of cytochrome-c in N2aswe cells following treatment 
with medium (Con), LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB 
high (↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated with Butyric acid  (BA;5 mM; 48hrs) 
followed by Bafilomycin A1 (BafA1, 400nM, 4 hrs). Beta-actin (β-actin) was used as a loading control. 
All data are expressed as means ± SEM (# p <0.05 vs C+BA, $ p<0.05 vs its relative control, +p<0.05 
vs GB low (↓:10µg/ml) +BA+BafA1). (n=3). A representative blot is shown.  
3.9 B The role of Autophagy on oxidative stress 
In order to further measure neuronal injury, 4-Hydroxynonenal (4HNE) was utilized, to 
assess lipid peroxidation. 4HNE has been shown to increase during states of oxidative stress 
which is a result of increased cellular stress events that in turn cause higher rates of lipid 
peroxidation. The neuroprotective role of GB high (↑:200µg/ml) and its associated high 
autophagy flux was further demonstrated through western blot analysis of 4HNE. 4HNE 
protein expression was significantly increased when cells were treated with GB high 
(↑:200µg/ml) + BA+ BafA1 [1.90 ± 0.81 (p<0.05)] compared to cells exposed to GB low 
(↓:10µg/ml) +BA+ BafA1 and control cells treated with BA and BafA1 respectively. These 
results suggest that, when the upregulation of autophagy by GB is high (↑:200µg/ml), yet 
autophagosome fusion is inhibited, the cells manifest in high lipid peroxidation. Moreover, 
these findings demonstrate how highly dependent cells are on high autophagy activity to 
resist cellular stress. Furthermore, pre-treatment with LiCl [1.50 ± 0.10 (p<0.05)] and GB high 
(↑:200µg/ml) [1.90 ± 0.81 (p<0.05)] prior to BA + BafA1 exposure presented with an increase 
in 4HNE protein levels, in comparison to their relative BafA1 negative groups  
  
(A.1) 
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Figure 3.9 B: Relative protein expression levels of 4HNE in N2aswe cells following treatment with 
medium (C), LiCl, GB low (↓:10µg/ml), GB high (↑:200µg/ml), GB low (↓:10µg/ml) + LiCl, GB high 
(↑:200µg/ml) + LiCl, for 24 hrs and subsequently treated with Butyric acid  (BA;5 mM; 48 hrs) followed 
by Bafilomycin A1 (BafA1, 400nM, 4 hrs). Beta-actin (β-actin) was used as a loading control. All data 
are expressed as means ± SEM (* p-value <0.05 vs C+BA+BafA1, $ p-value <0.05 vs its relative 
control, + vs GB low (↓:10µg/ml) +BA+BafA1). (n=3). A representative blot is shown.  
 
(B) 
(B.1) 
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Section 3.10 The compositional analysis of GB  
The Liquid chromatography–mass spectrometry (LC-MS) Q-TOF technique was utilized 
to identify the specific components including, terpene lactones and flavonoid glycosides 
present in GB. The table 3.10 below represents a summary of the compounds identified in 
the GB extract used in the study:  
Table 3.10: The Liquid chromatography–mass spectrometry of GB 
Name Formula Retention Time Mass (g/mol)  
 
Ginkgolide A C20H24O9 19.49 408.1425 
Ginkgolide B C20H24O10 14.5 424.1374 
Ginkgolide C C20H24O11 1409 440.1317 
Ginkgolide J C20H24O10 19.5 424.1362 
Bilobalide C15H18O8 13.7 326.1001 
Kaempferol-3-[6’’’-p-
coumaroylglucosyl-β-
(1→4)-rhamnoside] 
C36H36O17 19.5 740.1957 
Kaempferol 3-(2G-
rhamnosylrutinoside) 
C33H40O19 19.7 740.218 
Kaempferol 3-O-
glucoside 
C21H20O11 13.94 448.101 
Luteolin 3’-O-
glucoside 
C21H20O11 16.1 448.101 
Isorhamnetin 3-O-
rutinoside 
C28H32O16 16.1 624.168 
Kaempferol 3-O-
rutinoside 
C27H30O15 16.1 594.1583 
Kaempferol-3-O-β-D-
glucorhamnoside 
C27H30O15 14.74 594.1584 
Rutin C27H30O16 15.6 609 
Quercetin-3-o-
robinobiside 
C15H10O7 14.2 609 
Our results reveal the presence of major active components in Ginkgo biloba extract 
including:  a) flavonoid glycoside (Kaempferol and glucose glycoside) and b) Ginkgolides A, 
B, C and J, Bilobalide which are terpene lactones. 
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CHAPTER 4: DISCUSSION 
Autophagy is a vital process in cellular survival, as it is essential for organelle and long-lived 
protein turnover. As such, it is widely accepted that autophagy impairment is a major 
contributing factor in the development of AD (Nixon, 2007). This impairment is associated 
with a rise in the vulnerability of the cell to undergo cell death (Ntsapi et al., 2018).  
Conversely, autophagy inhibition has been shown to modulate APP processing and causes 
the deposition of Aβ (Pickford et al., 2008). The implication of the presence of Aβ has been 
shown to become toxic when its levels increase above physiological levels, due to the 
imbalance in production and clearance, as evidenced in AD. The modulation, in particular the 
increase of autophagic activity is therefore thought to be a promising therapeutic strategy 
aimed towards the alleviation of Aβ-associated neurotoxicity in AD, which is often 
accompanied by extensive mitochondrial and lysosomal damage (Nixon, 2007). Although 
significant insight has been gained regarding AD pathology, limited progress has been made 
in the development of pharmaceutical therapeutics that modify or reverse the debilitating 
effects of this disease.  Currently, all approved treatment options for AD are primarily 
symptomatic, these include acetylcholine inhibitors, as well as N-methyl-D-aspartate 
(NMDA)-receptor antagonist, which address symptoms but not the underlying cause or 
defect (Anand et al., 2014). Despite advances in unravelling the biological underpinnings of 
AD pathology, to date there are still no disease-modifying therapies available for those 
affected. 
Gingko biloba (GB) and lithium chloride (LiCl) have been reported to be neuroprotective in 
the context of neurodegenerative diseases (Kanowski, et al., 1996; Baldessarini et al., 1999). 
These neuroprotective effects include the preservation of synaptic plasticity (Hong et al., 
1997), enhancing mitochondrial function (Forlenza et al., 2012), inhibition of apoptosis, 
decreasing the deposition of Aβ (Su et al., 2004) and improving cognitive defects (Fornai et 
al., 2008). Some of these beneficial effects have been translated into the clinical context 
through supplementation with GB (EGb 761), which was shown to improve the 
neuropsychiatric symptoms in dementia patients when compared to a placebo group 
(Schneider et al., 2005). Even though some countries readily prescribe GB and LiCl to 
individuals suffering from AD, their mechanism of action remains largely unclear. Both these 
drugs have shown promising autophagy modulating properties (Liu et al., 2015; Sarkar et al., 
2005) and thereby play a role in the removal of toxic protein aggregates. However, this role 
has not been fully explored for translation to a clinical level, largely due to limited knowledge 
around the ranges of drug concentration that affect and control autophagy finely 
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The aim of the proposed study was therefore to investigate the effect of both GB and LiCl as 
a single or combination treatment intervention on the modulation of autophagy activity, and 
the mitigation of Aβ proteotoxicity in an in vitro model of AD. We hypothesized that treatment 
with GB will exhibit a dose dependent effect on autophagic activity, and this effect will be 
further enhanced through combination treatment with LiCl. This effect may then translate in 
the distinct removal of APP and Aβ, preserving lysosomal function and mitochondrial 
integrity.  
4.1 Gingko biloba pre-treatment confers neuroprotection against Aβ 
proteotoxicity 
The N2aswe cell line has extensively been utilized to study disease pathologies related to Aβ 
mediated neurotoxicity (Park et al., 2016b). The early accumulation of extracellular Aβ 
peptides in AD susceptible neurons of the brain has been shown to be the main contributor 
to the pathogenesis of AD (Hardy and Higgins, 1992). We hypothesized that GB would have 
a concentration dependent effect on the cellular viability of APP overexpressing N2aswe 
cells, and that this effect would be further potentiated in the presence of LiCl. In an attempt to 
assess the neuroprotective role of GB against Aβ mediated proteotoxicity, WST1 assays 
were utilized. Our results indicate that the use of 5 mM of BA for 48 hrs significantly reduced 
the relative reductive capacity of cells compared to control conditions (Fig 3.1.4). Since BA 
induces the expression of APP, and hence enhanced production of Aβ, our results indicate 
that 48 hrs expression of APP impacts the viability of the cells. Importantly, this Aβ induced 
reduction in cellular viability was markedly suppressed by 24 hrs exposure to LiCl 10 mM, 
GB 10 µg/ml & 200 µg/ml and a combination treatment of GB↓ (10 µg/ml) + LiCl 10 mM prior 
BA exposure. Indeed, the comparison of concentrations is however poorly described, and we 
observed protective effects with both low and high concentrations of GB in the context Aβ 
proteotoxicity. Our results revealed that both GB and LiCl confer neuroprotective properties. 
This is consistent with current literature findings which have demonstrated that pre-treatment 
with GB extract (EGb761) increased the cell viability of oxygen and glucose-deprived human 
neuroblastoma cells (Ba and Min, 2015). Conversely, 24 hr pre-treatment with 3 mM of LiCl 
has been shown to increase the cell viability of rat pheochromocytoma cells which were 
exposed to Aβ peptide for 24 hrs (Wei et al., 2000). This led to a suppression in Aβ-induced 
loss of redox activity. Together with our results, these findings suggest that both GB and LiCl 
are neuroprotective under proteotoxic conditions. The possible mechanism underlying LiCl’s 
neuroprotective role is potentially by increasing the activity of Bcl-2 which in turn regulates 
cell survival by inhibiting apoptotic genes such as p53 and Bax protein (Wei et al., 2000). 
Interestingly, administration of both combination treatment of GB↓10 µg/ml & GB↑200 µg/ml 
with LiCl also demonstrated an additive protective effect compared to BA-only treated cells 
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(Fig 3.1.4). However, this effect was only significant under GB↓10 µg/ml + LiCl conditions 
and was not markedly higher compared to the scenario when cells were exposed to the 
single treatments. To our best knowledge, this is the first time that these two drugs have 
been administrated in combination, in which case our findings warrant further investigation in 
the future. Thus, pre-treatment with GB in the presence and absence of LiCl prior to Aβ 
aggregate accumulation would potentially ameliorate Aβ-induced cytotoxicity. This is 
important because the early accumulation of extracellular Aβ peptides in AD susceptible 
neurons of the brain has been shown to be the main contributor to the pathogenesis of AD 
(Hardy and Higgins, 1992). 
4.2 Gingko biloba treatment and LiCl modulate autophagic flux 
To elucidate potential mechanisms underlying the neuroprotective effects of LiCl and GB, we 
measured the protein levels of p62 and LC3-II in the presence and absence of BafA1. It is 
known that the administration of an autophagy inhibitor such as Bafilomycin A1 (BafA1) 
translates to elevated levels of LC3-II in association with increased p62 protein levels, since 
fusion of autophagosomes and lysosomes is inhibited (Mizushima and Yoshimori, 2007).. We 
hypothesised that the protective role of both LiCl and GB was brought about through their 
respective modulatory role on autophagy. We further hypothesized that GB would exhibit a 
concentration-dependent effect on autophagy, an effect that would further be potentiated in 
the presence of LiCl. 
The expression of LC3-II is indicative of the abundance of autophagosomes, whereas an 
increase in p62 protein levels measures functional autophagy, following BafA1 treatment. 
Our results reveal that BafA1 had no effect in control cells, displayed by the non-significant 
changes in LC3-II and p62 protein expression compared to BafA1 untreated cells (Fig 3.2.1 
A &B). This suggests that these cells have a relatively low basal autophagy flux. The non-
significant increase in p62 levels following BafA1 treatment could be explained by the fact 
that p62 is also required for the selective binding of ubiquitinated tagged proteins and marks 
the proteins for degradation by either the UPS system or the autophagy system (Ding et al. 
2007). Therefore, blocking autophagy may result in cellular compensation through the UPS 
process.  
However, treatment with both concentrations of GB in the presence and absence of LiCl lead 
to a robust accumulation of autophagosomes (LC3-II levels) compared to their respective 
BafA1 negative group and control cells only treated with BafA1. Similarly, an elevation of p62 
protein levels was demonstrated when the cells were exposed to GB high (↑:200 µg/ml) in 
the presence of BafA1, compared to its corresponding BafA1 negative group. This effect was 
enhanced when GB high (↑:200 µg/ml) was combined with LiCl (Fig 3.2.1B). Taken together, 
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these results indicate that GB, in the presence and absence of LiCl, upregulates autophagy 
and induces autophagy above basal autophagy levels. This is consistent with current 
literature that demonstrated that GB dietary supplementation results in robust autophagic 
induction, as revealed by an increase in LC3-II protein levels and beclin1 expression in the 
brains of APP-transgenic mice (Liu et al., 2015). Similarly, in microglia cells, the protein 
expression of LC3-II and beclin1 was elevated and associated with decreased p62 levels 
following GB EGb761 treatment, suggesting that GB treatment upregulates autophagy 
activity.  In contrast, another GB extract (EGb1212), consisting of a greater quantity of 
bilobalide and ginkgolide B, has been reported to inhibit autophagy in the ischemic brain (Yin 
et al., 2013). These data suggest that the different components found in GB influence the 
overall modulation of GB on autophagy. Moreover, these data demonstrate that indeed 
autophagic activity may differ, depending on the drug concentration used. This may have 
important implications in drug screening as well as in treatment intervention approached, 
allowing to match autophagy dysfunction with a most suitable autophagy enhancing drug. A 
reverse transcription-polymerase chain reaction assay study demonstrated that Lewis lung 
cancer cells exposed to different concentrations of GB exocarp extracts (10, 20 and 40 
mg/ml) displayed a significant upregulation in ATG 5 mRNA (Cao et al., 2017). Moreover, the 
higher concentration of GB exocarp extracts (20 and 40 mg/ml) markedly increased Beclin1 
mRNA. Since the upregulation of ATG 5 and Beclin1 is associated with high autophagy 
activity, these data suggest that higher concentration of GB exhibit indeed a greater effect on 
the modulation of autophagy activity. These findings highlight that a concentration-dependent 
modulation of GB on autophagy indeed exists, as we had proposed. This study further 
demonstrates that GB exocarp extracts elevated the protein expression of p-AMPK and p-
mTOR through western blot analysis, which could potentially be the underlying mechanism 
by which GB upregulates autophagy (Cao et al., 2017). However, these parameters were not 
investigated in this present study and thus warrant further investigation. Although a recent 
study showed that GB exocarp extracts increase the abundance of autophagosomes in 
Lewis lung cancer cells using TEM analysis (Cao et al., 2017), little is known about the effect 
of GB’s on autophagic flux. Autophagic flux is defined as the rate of protein degradation 
through the entire autophagy pathway (du Toit et al., 2014; Klionsky et al., 2016) and can 
only be investigated using an autophagy inhibitor such as BafA1 (Mizushima and Yoshimori, 
2007). Thus, to our best knowledge, this is the first time that the extent of autophagic flux 
modulation in response to GB treatment is presented. 
Although LiCl treatment on its own did not significantly increase the pool size of 
autophagosomes following BafA1, a strong trend of increased LC3-II protein expression was 
demonstrated (Fig 3.2.1 A). This is consistent with a study that demonstrated that N2aswe 
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cells exposed to LiCl for 24 hrs manifested in an increased amount of LC3-II protein levels 
(Heiseke et al., 2009).  Moreover, the abundance of LC3-II protein levels in the presence of 
BafA1 was larger, indicating that LiCl indeed upregulates autophagic activity above basal 
levels. The underlying mechanism by which LiCl upregulates autophagy is suggested to be 
through its inhibitory action on inositol monophosphatase (IMPase), which results in the 
depletion of free inositol (Sarkar et al., 2005). On the other hand, we believe that since LiCl 
has an inhibitory effect on GSK3β, which results in the activation of mTORC1 and the 
consequent suppression of autophagy, this could potentially counteract the upregulation of 
autophagy by LiCl through IMpase inhibition (Sarkar et al., 2008). This may serve as an 
indication for our findings, revealing a non-significant induction of autophagy by LiCl. Another 
study also showed that LiCl (10 mM) induced autophagy in COS-7 cells but did not increase 
the accumulation of LC3-II in neuronal cells (Tsvetkov et al., 2009). 
Given that both GB and LiCl upregulate autophagy, we found that a combination treatment of 
GB and LiCl manifested in an upregulation of autophagy, in which GB high (↑:200 µg/ml) + 
LiCl had a larger increase in the accumulation of autophagosomes, compared to GB low 
(↓:10 µg/ml) + LiCl (Fig 3.2.1). Although we hypothesized that the extent of autophagic flux 
modulation, in response to GB treatment in the presence of LiCl, would confer additive 
protective effects, this was not confirmed in the study. To our surprise, the response of LC3-II 
protein levels in the presence of BafA1 was similar when the cells were exposed to both low 
and high concentration of GB alone or in the presence of LiCl (Fig 3.2.1 A). Our results differ 
from a study that investigated the combination effect of LiCl and rapamycin (Sarkar et al., 
2005). This study showed that co-treatment with rapamycin and LiCl revealed greater 
reduction of pathological prion proteins in murine neuroblastoma cells compared to cells 
treated with either drug on its own (Sarkar et al.,2005). Furthermore, this effect was due to 
enhanced autophagy flux of the combinatorial treatment.  
Corresponding fluorescence microscopy of p62 was employed to further characterise the 
extent of GB modulation of autophagy flux. Our results revealed a low abundance of p62 
aggregates under normal conditions, which remained unaltered when exposed to GB in the 
presence or absence of LiCl (Fig 3.2.2). Indeed, low p62 expression under normal conditions 
is indicative of high protein degradation through autophagy, which is common in neurons 
(Mizushima and Yoshimori, 2007). As expected, treated with BafA1 resulted in a marked 
increase in p62 aggregates compared to untreated cells (Fig 3.2.2). Importantly, 
fluorescence micrographs demonstrated that exposure to GB high (↑:200 µg/ml) and a 
combination treatment of GB high (↑:200 µg/ml) + LiCl 10 mM in the presence of BafA1 
presented with the highest abundance of p62 compared to control cells treated with BafA1 
and GB low (↓:10 µg/ml) in the presence of BafA1. These results further suggest that GB 
Stellenbosch University  https://scholar.sun.ac.za
  98 
may have a dose-dependent effect on the abundance of p62 and hence, an effect on the 
functional activity of autophagy.  
4.3 Gingko biloba treatment preserves lysosome function 
The internalization of Aβ has been described to cause instability of lysosomes (Zuroff et al., 
2017). Therefore, we proposed that GB treatment in the presence or absence of LiCl would 
preserve lysosome function under Aβ-induced cytotoxicity. Since LAMP2a is a specific 
lysosomal membrane associated protein, we assessed whether its protein expression 
correlates with the abundance of lysosomes with intact membranes (Eskelinen, 2006).   
Although no significant changes were observed in the expression levels of LAMP2a, strong 
trends can be observed (Fig 3.3.1). Firstly, it is apparent that exposure to LiCl and GB 
reduces the protein levels of LAMP2a (Fig.3.3.1). Our results differ from a study that used 
the mono-dansyl-cadaverine staining method to detect the generation of acidic vacuoles 
(including lysosomes) in cells, showing that the fluorescence intensity of untreated cells was 
weaker and displayed fewer acidic vacuoles (Cao et al., 2017). However, exposure to GB 
exocarp extracts resulted in enhanced mono-dansyl-cadaverine fluorescence intensity and 
prominent aggregated particles. Thus, the authors concluded that GB treatment increased 
the activation and generation of acidic vacuoles (Cao et al., 2017). Since our results reported 
that LiCl and GB induce autophagy (Fig 3.2.1), and it is known that lysosomes are the 
organelles that carry out the cargo degradation, it could be plausible that these lysosomes 
are rapidly fusing with autophagosomes to form auto-lysosomes.  Moreover, it is possible 
that both LiCl and GB also target chaperone-mediated autophagy. This notion is supported 
by a study that showed that LAMP2a levels directly correlate with the activity of the 
proteolytic pathway, particularly chaperone-mediated autophagy (Kaushik and Cuervo, 
2015). On the other hand, it can be argued that the reduction of LAMP2a protein expression 
observed in our study, when exposed to GB and LiCl, potentially resulted from a reduction in 
lysosomal pool size or biogenesis compared to control conditions. However, we doubt that 
this is the case in our scenario, as LAMP2a does not directly correlate to the biogenesis state 
of lysosomes and the high rate of degradation through the autophagy-lysosomal-pathway 
following GB treatment would not be possible. Indeed, lysosomal vesicles have been shown 
to be vital in the functional execution of protein/organelle degradation through the autophagy 
pathway (Settembre et al.,  2015). Our TEM micrographs (Fig 3.3.3) support the notion that 
both GB and LiCl treatment increase the size and number a vaculaor structures which we 
believe represent autophagosomes, lysosomes and autolysosomes.  
Secondly, and of particular interest, treatment with BA revealed an elevation in LAMP2a 
protein levels (Fig 3.3.1). Since BA induces the overexpression of APP and thus, enhanced 
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production of Aβ, we believe that the increase in LAMP2a could have been as a result of Aβ 
accumulation in the lysosomes, resulting in the destabilization of lysosomes and 
consequently inhibiting the cathepsin enzymes in lysosomes necessary to degrade Aβ. The 
TEM micrographs support this notion, revealed by disrupted vaculoar structures following BA 
treatment (Fig 3.3.3). In support of this notion, suppression of lysosomal enzymes has 
previously been reported to trigger the accumulation of Aβ within the lysosomal lumen 
(Zheng et al., 2006). However, it is also plausible that Aβ damaged the lysosomal membrane 
and caused subsequent rupture, resulting in the leakage of cellular contents, including the 
cathepsins from the lysosomal lumen into the cytosol (Boya and Kroemer, 2008). A decrease 
in LAMP2a in response to BA could also be expected in this regard. However, for future 
studies and to fully elucidate the role of the damaged lysosome pool in comparison to healthy 
lysosomes, the protein expression of Galectin-3, which is reported to accumulate in damaged 
lysosomes, could be compared with the protein expression of LAMP2a (Maejima et al., 
2013). Interestingly, it has been reported that damaged lysosomes themselves can be 
targeted for autophagy degradation (Maejima et al., 2013). We therefore suggest that GB in 
the presence and absence of LiCl would attenuate the damages caused by BA exposure, 
potentially by inducing the degradation of these damaged lysosomes through lysophagy.  
Pre-treatment with GB high (↑:200 µg/ml) prior to BA exposure caused a decrease in 
LAMP2a expression, whereas pre-treatment with LiCl, GB low (↓:10 µg/ml) both GB (low↓:10 
µg/m + (↑:200 µg/ml) in the presence of LiCl revealed an elevation in LAMP2a protein 
expression (Fig 3.3.1). The reduction in LAMP2a expression in response to GB high (↑:200 
µg/ml) prior to BA exposure potentially suggests that GB high (↑:200 µg/ml) decreases the 
damaged lysosomes as a result of BA treatment and hence, preserves the functioning of 
lysosomes. This notion can also be supported by GB high (↑:200 µg/ml) associated high 
autophagy flux (Fig 3.2.1), sequestering damaged lysosomes robustly, potentially through 
lysophagy. Therefore, Aβ triggers lysosomal damage, which in turn leads to an increase in 
LC3-II expression, suggesting that lysosomal rupture contributes to the induction of 
autophagy (Maejima et al., 2013). However, we suggest that further experiments like 
confocal microscopy analysis could be conducted to study the colocalization of LC3 and 
LAMP1, which would reveal the possibility of damaged lysosomes being selectively targeted 
by the autophagy process (Maejima et al., 2013). It might be conceivable that GB sequesters 
damaged lysosomes in an autophagy dependent manner and hence prevents the release of 
the cytosolic contents which could trigger events such as apoptosis. However, before a 
therapeutic strategy can be implemented, it is important that the steps and extent of 
autophagy dysfunction is fully identified. Merely increasing autophagy initiation may be 
detrimental if the clearance by lysosomes is defective. Therefore, a treatment intervention 
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would have to improve any defects in the lysosomes and re-establish the acidification of 
lysosomes, followed by the stimulation of autophagy. In this context, since LiCl and GB 
(low↓:10 µg/ml) displayed the same LAMP2a expression as BA-treated cells, this would 
suggest that their autophagic activity is not high enough to sequester the damaged 
lysosomes. Overall, induction of autophagy by GB in the presence and absence of LiCl prior 
to Aβ aggregate accumulation would potentially ameliorate Aβ-induced lysosomal damage. 
To further validate the effect of GB in the presence and absence of LiCl on lysosomal 
function, acridine orange (AO) stain was employed (Fig 3.3.2).  AO binds to DNA which 
fluoresces green but emits red fluorescence in acidic vesicular organelles (AVOs), including 
lysosomes, endosomes and autolysosomes. Since lysosomes are the most acidic organelles 
in cells, we employed AO as a rapid staining technique to assess the acidic compartments, 
particularly lysosomes (Thomé et al., 2016).  It is important to highlight a major weakness 
when assessing lysosomal function using AO stain, which is the fact that AO associates with 
all acid compartments and hence is unable to differentiate between functional and non-
functional lysosomes or endosomes and other acidic vacuoles.  
Lysosomal detection using AO staining revealed similar findings to that observed using 
LAMP2a western blot analysis (Fig 3.3.1). Under control conditions, untreated control cells 
displayed a clear abundance of lysosomal acid compartments (LAC), whereas exposure to 
GB and LiCl displayed the same morphology as the untreated control cells, although a 
relative decrease in LAC was demonstrated (Fig 3.3.2). Treatment with BA revealed a 
marked reduction in LAC compared to control condition, indicating that BA treatment 
contributes to the deacidifcation of organelles. These results suggest that BA exposure 
resulted in the damage of lysosomes or decrease in lysosome function. However, to fully 
elucidate the difference between damaged and healthy lysosomes, we propose that 
additional analyses are conducted such as antibody-based fluorescence microscopy against 
LAMP2a which can be used as a lysosomal marker and Galectin-3 antibody which can be 
used as a marker for damaged lysosomes (Maejima et al., 2013). Furthermore, the uses of 
GFP-Galectin-3 transfected cells to could be used to better assess the distribution of 
damaged versus healthy lysosomes. Similarly, to the results revealed with western blot 
analysis, pre-treatment with LiCl prior to BA exposure caused a robust increase in LAC 
compared to BA-only treated cells. In this context, it is possible that LiCl increases the 
biogenesis and lysosomal pool size which regulates many cellular processes. In fact, 
literature has shown that LiCl induces lysosomal dependent processes such as the Wnt/β-
catenin signalling and increases the degradation by cathepsin H (Kishimoto and EItoi, 2013). 
However, pre-treatment with GB in the absence and presence LiCl prior to BA exposure did 
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not alter the LAC abundance. This may indicate that these cells maintained the overall LAC 
volume in the cytoplasm even under BA exposure.  
4.4 Gingko biloba treatment clears amyloidogenic proteins under neurotoxic 
conditions 
The ability of compounds or drugs to clear toxic protein aggregates in the context of 
neurodegeneration has received major attention. Exposure to both, high and low 
concentrations of GB manifested in a significant reduction of APP, BACE and Aβ prior to BA 
treatment (Fig 3.4. A, B &C). These findings suggest active clearance of the amyloidogenic 
proteins by both GB concentrations. Although statistically there are no GB dose-dependent 
differences in the reduction of amyloidogenic proteins between the low treatment groups, the 
immunoblot data reveal that GB high (↑:200 µg/ml) reduces BACE protein levels robustly 
more than GB low (↓:10 µg/ml). These data further point to a concentration-dependent 
clearance of BACE by GB, where the highest GB concentration clears the amyloidogenic 
proteins strongest. This is in line with a study that performed Aβ aggregation assays in 
response to different concentrations of GB [EGB 761 (1- 100 µg/ml)] (Luo et al. 2002). This 
study reported that the anti-Aβ aggregation properties of GB (EGB 761) was only evident at 
the highest concentration (GB 100 µg/ml) by directly inhibiting the generation of Aβ fibrils 
(Luo et al. 2002). Unfortunately, however, no autophagy assessment was performed. 
Another study showed that a duration of 5 months and not 2 months of treatment with GB 
(EGb 761) decreased phosphorylated-tau protein levels in a tau-mutant transgenic mouse 
(Qin et al., 2018). Since tau phosphorylation is known to be a downstream effect of Aβ 
pathology, this finding suggests that long-term treatment with GB is more beneficial in 
ameliorating AD pathology. We believe that other protein expression tests such as ELISA 
should be conducted to more finely assess these observed differences. In the brain tissue of 
transgenic mice, chronic treatment with EGb761 (300 mg/kg) has been shown to differentially 
influence protein levels involved in the processing and metabolism of APP (Augustin et al., 
2009). The same study also revealed that long-term EGb761 dietary supplementation leads 
to a significant decrease in human APP levels in the cortex and hippocampus region, which 
could indicate a role for APP to be molecularly targeted by EGb761. Overall, our results 
demonstrated that GB results in the clearance of amyloidogenic proteins. 
Exposure of cells to 24 hrs LiCl significantly decreased the protein levels of APP, suggesting 
that LiCl affects the general synthesis of APP by supressing the expression of APP (Fig 3.4 
A). Our results are however conflicting, since another study demonstrated that the protein 
expression of APP and CTFß (C99) was unaltered by 24 hrs LiCl (10 mM) treatment, 
suggesting that LiCl does not influence Ɣ-secretase activity (Esselmann et al., 2004). Our 
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results further demonstrate that LiCl reduces the expression of BACE and Aβ (Fig 3.4 B &C). 
This finding is of importance since Aβ has been shown to increase the activity of GSK3β, 
which leads to an increase in phosphorylation of tau and apoptotic cell death, further 
exacerbating AD pathology (Diniz et al., 2013). Thus, since it is generally acknowledged that 
LiCl Inhibits GSK3β, treatment with LiCl would potentially abolish Aβ mediated cell death and 
tau hyper-phosphorylation. Moreover, our findings are consistent with a study showing that 
LiCl inhibits the generation of Aβ peptide in neuronal cells and animal models that 
overexpress APP (Phiel et al., 2003). Notably, the combination treatment of GB and LiCl also 
leads to a reduction in APP, BACE and Aβ protein expression. However, the combination 
treatments did not necessarily manifest an additional clearance effect compared to the single 
treatments. This can be explained, at least in part, by the fact that administrated in isolation, 
GB and LiCl resulted in a reduction of the amyloidogenic proteins. Overall, induction of 
autophagy by GB in the presence and absence of LiCl prior to Aβ aggregation would 
potentially ameliorate Aβ-induced cytotoxicity. Therefore, if autophagy is induced by GB in 
the presence and absence of LiCl, prior to the manifestation of cellular stress, it may indeed 
act against Aβ-mediated cytotoxicity and display neuroprotective effects. Our results support 
this notion.  
4.5 Gingko biloba treatment prevents Aβ induced apoptosis 
The release of cytochrome-c from mitochondria is a vital step in the generation of the 
apoptosome, which in turn initiates the apoptosis caspase cascade. As a result, assessment 
of cytochrome-c can serve as an indication for the engagement of the upstream apoptotic 
machinery (Galluzzi et al., 2017), while assessment of caspase-3 is indicative of the 
execution step of apoptosis, since caspase-3 is a key effector protease. Our results 
presented a marked increase in cleaved caspase-3 and cytochrome-c after BA exposure, 
signifying induction of apoptosis (Fig 3.5 A & B). This is line with a study that showed a 
similar activation of caspase 3 and release of cytochrome-c following exposure to BA (Luo et 
al., 2002). This data supports the notion that the activation of apoptosis is due to the 
enhanced synthesis of Aβ in the N2aswe mutant cells. Our TEM data also support this 
notion, demonstrated by the disruption of the nuclear integrity and loss of regular cytoplasmic 
content. Indeed, nuclei fragmentation, membrane blebbing, chromosomal DNA cleavage, 
and cell shrinkage are characteristics of apoptosis (Fig 3.3.3) (Edinger and Thompson, 
2004). However, exposure to both GB and LiCl significantly reduced the release of 
cytochrome-c and slightly decreased the cleavage of caspsase-3 (Fig 3.5 A & B). It is thus 
reasonable to conclude that both GB and LiCl impact the apoptotic machinery upstream of 
cytochrome-c release and fail, at the time point of investigation, to alter the pro-apoptotic 
caspase cascade, demonstrated by the non-significant effect on protein expression of 
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cleaved-caspase-3. Since cytochrome-c is initially released, followed by caspase 3 
activation, hence, the effects we observe may indicate the cascade events of apoptosis. 
Later time points may be utilized in future work to confirm this. These findings further suggest 
that both GB and LiCl play a role in the preservation of the mitochondrial membrane 
potential. This is consistent with the finding that PC12 cells treated with GB (EGB 761) 
resulted in the prevention of cytochrome-c release from the mitochondria and fragmentation 
of DNA (Smith et al., 2002).  Smith et al also found that GB (EGB 761) significantly inhibited 
the cleavage and activation of caspase-3, whereas in our study GB treated cells slightly 
suppressed the cleavage of caspase-3. GB Extract (EGB71) has also been shown to block 
apoptosis through the apoptosis-inducing factor signal transduction pathway and 
transcription Bcl-2 anti-apoptotic protein (Ba and Min, 2015). Luo et al. (2002) demonstrated 
that 48 hrs exposure to EGb761 prior to the induction of APP expression by BA, apoptosis 
was attenuated in neuroblastoma Swedish cells (Luo et al., 2002). LiCl has been shown to 
increase the activity of Bcl-2 which in turn regulates cell survival by inhibiting apoptotic genes 
such as p53 and Bax protein (Wei et al., 2000). Moreover, since LiCl increases the activity of 
Bcl-2, this protein to able to prevent the release of cytochrome-c and thereby prevent 
apoptosis. These findings raise the possibility that both LiCl and GB prevent the induction of 
the apoptosis cascade at multiple levels and cellular pathways. 
4.6 Gingko biloba treatment preserves mitochondrial fission and fusion 
dynamics 
It is well established that Aβ protein aggregates impair mitochondrial function (Diana et al., 
2008). For this reason, we aimed to assess the effect of GB treatment in the presence and 
absence of LiCl treatment on mitochondrial fission and fusion dynamics. When the 
mitochondria are healthy, an equilibrium exists between the fusion and fission state, which 
enables their intracellular movement (Laura et al., 2014). Interestingly, under control 
conditions, our cells appear to favour a fission state revealed by the higher protein 
expression of DRP1 compared to MNF1 (Fig 3.6.1 A & B). However, TMRE micrographs 
demonstrated that morphologically, the cells display a mitochondrial network that is highly 
fused, yet, DRP1 levels are high. These data indicate strongly that protein levels that control 
mitochondrial equilibrium states between fission and fusion do not by themselves dictate a 
particular morphology. Although this result was unexpected, they are, however, in 
accordance with a study that reported that fibroblasts collected from AD sporadic patients 
expressed less DRP1 levels and displayed a network of elongated mitochondria (Wand et 
al., 2008). We believe that these cells were under conditions where the removal of damaged 
mitochondria was achieved through the fission process. During this process, damaged 
mitochondria are separated into smaller fragments, thereby making it more likely for these 
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organelles to be targeted for degradation through autophagy, in a process referred to as 
mitophagy (Laura et al., 2014). Importantly, under control conditions, we found that exposure 
to LiCl and GB favored the fusion state of the mitochondrial network and decreased the 
expression of DRP1 fission protein, indicating that these treatment interventions promote 
healthy functioning mitochondria (Fig 3.6.1B). This effect was however only statistically 
significant when the cells were exposed to LiCl and GB +LiCl. This is important since in 
sporadic AD, the impairment of mitochondria is reported to be the primary event that causes 
the deposition of Aβ (Swerdlow et al., 2010). Hence, the preservation of mitochondria by GB 
and LiCl is important to prevent Aβ deposition.  In addition, these findings raise the possibility 
that LiCl greatly impacts the functioning of mitochondria. Since mitochondrial fusion favours 
the distribution of ATP in metabolically active cells (Westermann, 2010), this could also 
suggest that LiCl favours the production of ATP. This finding is of importance, since 
mitochondrial function is necessary for cellular metabolism, as sustained ATP synthesis is 
integral part to maintaining normal cellular function, cellular viability and homeostasis. 
Exposure to BA significantly reduced the protein expression of MNF1 compared to control 
cells which corresponded to the marked increase in the protein levels of DRP1 (Fig 3.6.1 
A&B). These results indicate the induction of the APP transgene, resulting in the 
overexpression of Aβ, negatively impacting the functioning of mitochondria.  This is 
consistent with a study reporting that neuroblastoma cells overexpressing APP displayed 
mitochondria that were predominantly fragmented with reduced DRP1 and OPA1 levels 
(Wang et al., 2008). This is also in accordance with a study that investigated the effect of Aβ 
on the mitochondria of neuroblastoma cells expressing APP and PS1 assessed using a 
Mitosensor (Luo et al., 2002). This study demonstrated that cells treated with BA 
predominately fluoresced green, indicating mitochondria undergoing apoptosis, whereas 
untreated cells fluoresced red indicative of mitochondria that are healthy and functional (Luo 
et al., 2002). Thus, this study demonstrated that BA induces Aβ-mediated damage to 
mitochondria.  Under Aβ proteotoxicity, pre-treatment with LiCl and GB seemed to have 
minor effects on the fusion state of the mitochondrial network, however, the fission state was 
drastically reduced compared to BA only conditions. This is important, since a decrease in 
fission would also indicate and lead to an increase in fusion. Indeed, observations in 
literature suggest that supplementation with GB in neuroblastoma cells amends the 
performance of mitochondrial oxidative phosphorylation and attenuates Aβ toxicity (Eckert, 
2012). GB was also reported exert protective effects by enhancing the production of ATP in 
these neurons. 
The functionality of cells can be assessed by the network organization or morphology of 
mitochondria. Elongated, fused mitochondrial networks are associated with healthy viable 
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cells, while fragmented morphology is usually associated with stressed cells (Chan, 2006). 
Thus, the study of mitochondrial network dynamics is critical, since the morphology of 
mitochondria is associated with crucial cellular activities (Fig 3.6.2). Under control conditions, 
treatment with GB in the presence and absence of LiCl displayed a similar morphology 
(fused elongated mitochondria) compared to untreated cells.  These results indicate that GB 
and LiCl do not alter the normal mitochondrial network organization (Fig 3.6.2) but only effect 
the diseased/proteotoxic state.  
In contrast, exposure to BA displayed a dominant state of fragmented mitochondria, 
suggesting that BA favours the fission state of the mitochondrial network (Fig 3.6.2). This is 
consistent with another study that demonstrated that neuronal cells exposed to conditioned 
media from cells overexposing mutant APP lead to elevated mitochondrial fission states 
(Wang et al., 2008). Several studies have demonstrated that cells deficient in fusion proteins 
(i.e. MNF1) are susceptible to apoptotic cell death, and such cells display mitochondria that 
favour the fission state, hence extensive fragmentation (Lee et al., 2004). Moreover, Aβ 
protein aggregates have been shown to impair mitochondrial function (Diana et al., 2008). 
Rhein et al. (2010) showed that neuroblastoma cells overexpressing APP, displayed a strong 
decrease in the mitochondrial electron transport chain coupling and the respiratory capacity. 
However, we observed that GB treatment in the presence and absence of LiCl prior to BA 
exposure improved the morphology of mitochondria by displaying a mitochondrial population 
that is more fused and elongated (Fig 3.6.2). These findings suggest that GB and LiCl rescue 
and preserve the functionality of mitochondria. This is in accordance with a study 
demonstrating that neuronal cells supplemented with GB EGb761 were protected from 
hydrogen peroxide induced toxicity (Shi et al., 2010). Exposure to GB has been shown to 
enhance energy homeostasis and reduce the levels of ROS in neuroblastoma cells 
overexpressing APP (Rhein et al., 2010). Taken together, these results suggest that GB and 
LiCl have regulatory effects on mitochondria and their function. 
4.7 Robust autophagy flux is vital under neurotoxic conditions to maintain 
cellular homeostasis 
In an attempt to validate that autophagy is essential to maintain cellular functions and 
degrade toxic proteins such as Aβ and damaged organelles, we assessed how GB in the 
presence and absence of LiCl modulates autophagy during APP overexpression. Treatment 
with BA and BafA1 resulted in an increase in p62 and LC3-II protein levels compared to BA-
only treated cells (Fig 3.7 A & B). This result suggests that autophagy is still functional even 
in the context of APP overexpression. In accordance with Nixon et al. (2005), an elevation of 
large autophagic vacuoles appeared to accumulate in dystrophic neurites in an electron 
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microscopy study on post mortem human brain samples from patients with AD. Our results, 
however, indicate that the presence of autophagic vesicles is indeed reflective of a still 
functional autophagy flux.  
We observed that treatment with GB high (↑:200 µg/ml) followed by BA and BafA1 exposure 
manifested in a significant elevation of p62 and LC3-II protein expression compared to its 
relative BafA1 negative group and cells exposed to only BA and BafA1 (Fig 3.7 A &B). These 
results suggest that GB high (↑:200 µg/ml) induces autophagy in the context of APP 
overexpression and additionally upregulates autophagy beyond the basal autophagy of the 
cells under APP overexpression. This result suggests that treatment with GB (↑:200 µg/ml) 
leads to the highest autophagy flux, which is still functional even under APP overexpression. 
Importantly, cells treated with GB (↑:200 µg/ml) followed by BA and BafA1 treatment, 
resulted in a significant increase in p62 protein levels compared to cells treated with GB low 
(↓:10 µg/ml) followed by BA and BafA1 treatment.  This is in accordance with a recent study 
by Qin et al. (2018) reporting that treatment with 5 g/ml of GB (EGb761), but not at a lower 
concentration (2.5 g/ml), significantly increased the protein level of LC3B-II in the cell lysate. 
4.8  Inhibition of autophagy leads to the accumulation of amyloidogenic 
proteins 
Under normal physiological conditions, generated and aggregated Aβ can be targeted for 
degradation by the autophagy system. However, defects in this system result in the 
accumulation of Aβ since it will no longer be removed. Moreover, the accumulation of Aβ 
within autophagosome vesicles has been reported to be exacerbated by the defective 
clearance of autophagosomes containing APP in AD, thereby inducing Aβ neurotoxicity and 
resulting in neuronal impairment (Yu et al., 2005). Therefore, in this sense, the ability of GB 
in the presence and absence of LiCl to enhance autophagy would be neuroprotective by 
facilitating the removal of Aβ aggregates. 
In order to elucidate whether the amyloidogenic proteins, including APP, BACE and Aβ, are 
targeted by autophagy, western blot analysis was conducted to evaluate how the 
suppression of the autophagy pathway would impact the processing of APP in the presence 
and absence of BafA1 treatment. We anticipated that the elevation of APP, BACE and Aβ in 
response to BA exposure would be further increased when autophagy was inhibited with 
BafA1 treatment, and thereby suggesting that the turnover of these proteins is mediated by 
autophagy. To our surprise, the protein expression of APP, BACE and Aβ decreased in the 
presence of BA and BafA1 treatment compared to cells only treated with BA (Fig 3.8 A, B 
and C). These findings suggest that the basal autophagy of these cells is too low to degrade 
the accumulated amyloidogenic proteins, which are clearly generated in excess when 
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overexpressed. The system may hence be overloaded with protein cargo. However, it could 
also suggest that basal autophagy is not fully functional during APP overexpression, thereby 
being unable to clear APP, BACE and Aβ sufficiently. This is, however, unlikely the case, 
since we observed that LC3-II and p62 protein levels were increased during APP 
overexpression and inhibition of autophagosome turnover. Another study also demonstrated 
that APP protein levels were unaltered in beclin deficient AD transgenic mice (Pickford et al., 
2008). However, others have reported that during APP overexpression, the accumulation of 
Aβ has been shown to increase mTOR signalling, which in turn may further increase Aβ 
accumulation by blocking autophagy (Caccamo et al., 2017). It has also been reported that 
autophagic vacuoles may be a source of Aβ production and that autophagic vacuoles 
accumulate in AD brains and in APP/PS1 transgenic mice, thus suggesting that an increase 
in autophagy may in fact lead to a further accumulation of Aβ (Boland et al., 2008; Yu et al., 
2005). In contrast, other, and most reports show that autophagy protects neurons from Aβ 
toxicity (Hung et al., 2009; Pickford et al., 2008).  
Pickford et al. (2008), showed that increasing autophagy by overexpressing beclin-1, a key 
protein involved in autophagy induction, reduces Aβ deposits in a transgenic model of AD. 
Since GB (↑:200 µg/ml) yielded the highest upregulation of autophagy in the context of APP 
overexpression (Fig. 3.8 A & B), we hypothesised that it would therefore clear APP, BACE 
and Aβ the strongest, and hence the inhibition of autophagy would cause these proteins to 
accumulate most. Indeed, exposure to GB (↑:200 µg/ml) plus BA and BafA1 presented with a 
significant increase in APP and BACE protein expression and a non-significant increase in 
Aβ protein levels compared to cells treated with BA and BafA1 (Fig 3.8). Thus, these 
aggregate-prone proteins are distinct confirmed autophagy substrates. Interestingly, in an in 
vitro study of Huntingtin disease, treatment with BafA1 did not influence the expression of 
polyglutamin aggregates and protein levels of LC3-II, when treated with GB (EGb761) in 
HEK293 cells expressing htt Q103 (soluble polyQ proteins) (Stark and Beh, 2014). The 
authors suggest that autophagy had no impact on polyglutamin aggregate levels.  
Importantly, cells treated with GB (↑:200 µg/ml) followed by BA and BafA1 treatment resulted 
in an increase in APP protein levels compared to cells treated with GB low (↓:10 µg/ml) 
followed by BA and BafA1 treatment. These results suggest that GB (↑:200 µg/ml) clears 
APP through autophagy stronger than GB low (↓:10 µg/ml), suggesting a concentration 
dependent effect of GB on protein clearance via autophagy. These findings are consistent 
with another study reporting that 0.5 g/ml of rapamycin was insufficient to completely abolish 
p70S6K phosphorylation and significantly reduced mTOR activity, and that the biggest 
decrease in Aβ levels was detected when rapamycin was used at a much higher 
concentration (50 g/ml) (Caccamo et al., 2010). Interestingly, in our study, the protein 
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expression of Aβ remained unaltered even in the presence of BafA1, although exposure to 
GB (↑:200 µg/ml) in the absence and presence of LiCl and GB low (↓:10µg/ml) only in the 
presence of LiCl displayed a trend of increased Aβ protein levels. This is consistent with a 
study showing that although rapamycin was successful in decreasing intracellular Aβ42 
levels, this effect was abolished in the presence of an autophagy inhibitor and in the 
presence of 3-methyladenine (autophagy inhibitor) (Xue  et al., 2013 ). Overall, our results 
suggest that APP, BACE and Aβ are targeted by the autophagic machinery, serving as 
substrates for protein degradation through autophagy. Moreover, we have shown that GB 
ameliorates Aβ pathology by increasing autophagy. Thus, our data support the theory that an 
increase in autophagy may have a beneficial effect in AD pathogenesis. 
4.9  Autophagy upregulation by GB attenuates Aβ mediated cell death  
The role of autophagy in chronic neurodegeneration appears to be complex. Autophagy, 
when too high and highly active for too long, represents a bona fide programmed cell death 
pathway, and could thereby theoretically contribute to neuronal loss in chronic 
neurodegeneration (Mok et al., 2007). In fact, autophagy has been implicated as a 
mechanism of neurodegeneration in prion disease (Sikorska et al., 2004). However, since 
autophagy is most often protective (Hara et al., 2006; Komatsu et al., 2006), we 
hypothesized that the inhibition of autophagy by BafA1 would result in the elevation of 
cytochrome-c release during APP overexpression. To our surprise, exposure to BA results in 
a degree of cell death which was, however, not augmented by BafA1 exposure (Fig 3.9 A). 
However, a trend of increased cytochrome-c protein expression was displayed when 
autophagy was inhibited by BafA1, suggesting that the cells are dependent on the autophagy 
pathway to delay the onset of cell death. Exposure to GB high (↑:200 µg/ml) during APP 
overexpression in the presence of BafA1, resulted in more release of cytochrome-c 
compared to cells treated with BA and BafA1 (Fig 3.9 A). Importantly, this effect was also 
apparent in cells treated with GB low (↓:10 µg/ml) during APP overexpression in the 
presence of BafA1. Taken together, these results suggest that autophagy induction by GB 
high (↑:200 µg/ml) is essential to prevent the trigger of apoptosis This is consistent with 
studies that reported that impairment of autophagy is associated with neuronal death and 
neurological abnormalities (Hara et al., 2006; Komatsu et al., 2006). Hence, autophagy is 
essential for maintenance of normal CNS functions. Therefore, if autophagy is induced by 
GB in the presence and absence of LiCl, before the manifestation of cellular stress, it acts 
against Aβ-mediated cytotoxicity and displays neuroprotective effects. 
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4.10 The role of autophagy in oxidative stress 
Since it is a generally acknowledged phenomenon that oxidative stress is linked to AD, and 
since GB displays well established anti-oxidative properties, we propose that GB would relay 
neuroprotective effects by attenuating oxidative stress (i.e. lipid peroxidation) (Chan et al., 
2007). Aβ targets microglia to induce a neuro-inflammatory response, and modulates its own 
metabolism (Huang and Mucke, 2012). Therefore, exposure to BA would indeed initiate 
oxidative stress and cytotoxicity, and subsequently increase peroxidation of proteins. In fact, 
exposure to BA caused an increase in 4HNE protein expression which was further 
augmented when autophagy was inhibited (Fig 3.9 B). Pre-treatment with LiCl and GB high 
(↑:200 µg/ml) showed a degree of oxidative stress which was further elevated in the 
presence of BafA1. Importantly, GB high (↑:200 µg/ml) together with BA and BafA1 revealed 
increased 4HNE protein expression compared to GB low (↓:10 µg/ml) plus BA and BafA1 
treatment. These results signify that during the high autophagy induction by GB high (↑:200 
µg/ml) manifestation of cellular stress is involved, likely acting against Aβ-mediated 
cytotoxicity and displaying neuroprotective effects. This finding is consistent with a study that 
demonstrated that GB (EGB761) confers anti-oxidative properties in in vitro and in vivo 
models by directly attenuating ROS levels and increasing the resistance of model organisms 
to oxidative stress (Smith and Luo 2003; Wu et al., 2002). Additionally, work by Schindowski 
et al., (2001) demonstrates that treatment with EGb761 in vivo and in vitro model systems 
has anti-inflammatory and antioxidant properties and enhances cerebral blood flow. In AD 
transgenic mice, Aβ aggregation and oxidative stress induced by Aβ has been shown to be 
attenuated by EGb761 supplementation (Shi, 2010). Another study has shown how GB (EGb 
761) dose-dependently (10-100µg/ml) protects hippocampal neurons against Aβ-induced 
toxicity (impacting ROS and apoptosis), with highest and complete protection at the highest 
dose (Bastianetto et al., 2000). Taken together, these results indicate that GB’s 
neuroprotective role is partly related to its antioxidant properties, demonstrating its potential 
effect in Aβ-induced neurodegenerative diseases such as AD. 
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CHAPTER 5: SUMMARY AND CONCLUSION 
Although research efforts have intensified in the last decade, AD remains greatly 
understudied and poorly documented, especially in the context of South Africa. Moreover, 
despite advances in unravelling the biological underpinnings of AD pathology, to date there 
are no disease-modifying therapies available for those affected. This highlights the 
substantial need for dedicated research efforts toward the development of better targeted AD 
therapeutic interventions that are strongly aligned with the molecular defect and may 
potentially modify the progression of the disease. Recently, the role of proteotoxicity and 
autophagy dysfunction in the context of neurodegeneration has received major attention. As 
such, defects within the autophagic system is associated with the onset of 
neurodegenerative diseases, including AD (Wong and Cuervo, 2010). However, the 
relationship between candidate drugs of interest and autophagy activity remains unclear. 
This study therefore aimed to investigate the effect of both GB and LiCl as a single or 
combined treatment intervention on the modulation of autophagy activity, and the effect on 
Aβ proteotoxicity in an in vitro model of AD. It was hypothesized that treatment with GB will 
exhibit a concentration-dependent effect on autophagic activity, which can be further 
enhanced through combination treatment with LiCl. This effect will translate in the distinct 
removal of APP and Aβ, by preserving lysosomal function and mitochondrial integrity.  
Our results indicated that GB induces autophagy in the presence and absence of LiCl, 
moreover indeed in a concentration-dependent manner, specifically with GB (↑:200 µg/ml) 
displaying highest induction of autophagy. Although we hypothesized that this effect will be 
further enhanced through combination treatment with LiCl, this was not always the case. 
Thus, more research is required to study the interaction of these two drugs. The induction of 
autophagy by GB further translated in the clearing of APP, BACE and Aβ, thus preventing 
Aβ-induced toxicity, which has been shown to be the main contributor of AD pathology. The 
assessment of the mitochondrial network and its morphology revealed that exposure to LiCl 
and GB in combination with LiCl favoured fusion states. Indeed, healthy mitochondria 
present a morphology of equilibrium between the fusion and fission states, which enables 
their intracellular movement (Laura et al., 2014). We also observed that APP overexpression 
impairs mitochondrial and lysosomal function, which was improved by GB treatment in the 
absence and presence of LiCl. Although the effect of GB in the presence and absence of LiCl 
on lysosomes is not fully verified, our results suggest that through the modulation of 
autophagy, the lysosomal abundance is somewhat impacted by GB exposure. We suggest 
that more specific techniques be used to assess lysosomal function, specifically to 
differentiate between damaged and healthy lysosomes.  
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In addition, GB pre-treatment resulted in the attenuation of Aβ-induced apoptosis by 
reduction in the release of cytochrome-c, hence serving as a protective mechanism. We 
hypothesised that this protective mechanism was brought about through the upregulation of 
autophagy. This notion was supported, since the release of cytochrome-c and lipid 
peroxidation was stronger when autophagy was inhibited. Moreover, APP, BACE and Aβ 
aggregates were elevated when the induction of autophagy by GB (↑:200 µg/ml) was 
inhibited.  
In conclusion, the results presented here provide a molecular basis for Aβ -induced cell 
death, showing that GB, and more specifically, GB in combination with LiCl, an FDA 
approved drug, reduces Aβ pathology, preserves lysosomal and mitochondrial function and 
thereby attenuates Aβ-induced cell death by upregulating autophagy. This finding may 
constitute a novel therapeutic approach to AD. In addition, even though both concentrations 
of GB result in a similar degree of protection, their effect on protein clearance through 
autophagy, and autophagy activity is different. We therefore recommend that the individuals 
suffering from AD, or those susceptible to AD, are supplemented with the dose of GB which 
provides the highest clearance, highest protection and highest flux, which we reported as GB 
(↑:200µg/ml). For example, consumption of two capsules instead of one capsule would be 
the most beneficial. Hence a suitably high, yet non-toxic concentration may be recommended 
as adjuvant treatment. This notion can be tested in patients by using patient derived cells, 
such as fibroblasts, to screen and choose the best suitable drug. 
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5.1  Summary diagram 
5.1.1 Molecular defects in AD  
 
5.1.2 Proposed protective mechanism of GB in the presence and absence of LiCl.  
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FUTURE RECOMMENDATIONS AND LIMITATIONS OF THE STUDY 
It must be noted that the model system utilized is not without limitations. Firstly, the in vitro 
model of AD used in this study only represented late disease states, as APP overexpression 
was induced for 48 hrs. However, to better elucidate the scenario of the progression of AD, 
we propose that the investigation of early AD pathology (12 hrs APP overexpression) versus 
late AD pathology (48 hrs APP overexpression) be included, since this would have been 
better to mimic disease progression. However, the model system holds strength, as the 
deposition of Aβ peptide in the brain is an early event of AD progression and occurs years 
before AD symptoms manifest.  
Although our study has demonstrated the importance of employing GB and LiCl supplements 
before any signs of AD may manifest, AD could be delayed or prevented by targeting Aβ 
peptide. Secondly, although a liquid chromatography–mass spectrometry was conducted in 
order to identify the composition of GB, we suggest that for further studies, each component 
is purified and assessed for its autophagy properties, as studies have shown that the 
different components of GB activate distinct pathways.  Indeed, studies have demonstrated 
that the ginkgolides have several physiological properties (Yagmur et al., 2005). Moreover, 
we suggest that the molecular interaction between GB and LiCl be better evaluated, in order 
to more finely describe how their combination exerts protective effects. In addition, since 
extensive literature focused on the standardised GB leave extract EGb761, we suggest the 
assessment of the difference between the GB used in our study and the standard GB extract.  
Although we believe that the GB used in our study, is a product available in health care and 
pharmacies in South Africa, mimics well what people indeed consume, and hence the results 
presented here are likely closely associated to what would be observed in an in vivo human 
response, caution should be taken when LiCl is administrated because it is also a mood 
disorder modulator (Baldessarini et al., 1999). Likewise, caution should be exercised with 
GB, as it is a platelet-activating factor antagonist which could have side effects for individuals 
with blood disorders (Yagmur et al., 2005). Ntsapi Although this study demonstrated that GB 
induces autophagy in the presence and absence of LiCl, the precise rate of autophagy, i.e. 
autophagic flux as described recently remains unclarified (du Toit et al., 2018). This could be 
done through a combination of life cell imaging and through TEM analysis, measuring the 
number of autophagosomes that are produced and then also quantifying the surface area of 
autolysosomes (Eskelinen et al., 2011). Alternatively, the GFP-LC3-RFP-LC3ΔG probe could 
be used, which is a fusion protein of GFP-LC3 and RFP-LC3 and was developed by Kaizuka 
et al. (2016) to better assess autophagic flux. We also recommend that the BafA1 incubation 
time to be longer, to allow more time for autophagosome accumulation to take place.  
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We also suggest that the defects in the autophagy-lysosomal pathway be localized, to 
precisely identify which step of the autophagy process the treatment intervention needs to 
target. For future studies, to fully elucidate the pool of damaged lysosomes versus healthy 
lysosomes, the protein expression of Galectin-3, which is reported to accumulate in damaged 
lysosomes, could be compared with the protein expression of LAMP2a protein levels 
(Maejima et al., 2013). In addition, in an attempt to elucidate the effect of APP over 
expression on mitochondria, additional mitochondrial parameters, such as mitochondrial 
respiration in response to APP overexpression, could be conducted. Finally, the assessment 
of changes in the shape, size, distribution and movement of mitochondria through life-cell 
time lapse analysis would provide additional context as to how APP overexpression impacts 
mitochondria.  
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Supplementary results 
 
Figure S1: Representative micrographs of N2a cells transfected with GFP-Galectin3 (GFP-Gal3) and 
counterstained with lysotracker red. Under control conditions (Con) and following treatment with 
Butyric acid (BA: 48H 5mM), Lithium chloride (Licl: 24 hrs 10 mM), Ginkgo biloba (GB 10ug/ml or 
200ug/ml)  or Butyric acid in the presence of Lithium chloride or Ginkgo biloba (BA + Licl: 48 H 5mM + 
Post-24H 10 mM). Red = Lysotracker, green = GFP-Galectin-3 . 60X magnification. Scale bar = 5 µm. 
Arrowheads indicate Gal3 positive lysosomes. 
 
Protocols 
Neuronal reductive capacity following ketone body treatment  
With the guidance by literature, a dose response of Gingko biloba (GB) and lithium chloride 
(LiCl) was established. This was done to verify that the desirable concentration of both 
treatment groups was not toxic to the cells. Under control conditions, the reductive capacity 
was considered as 100% and no significant differences in cells treated with both GB and LiCl 
was yielded in comparison to control conditions. 
Wst-1 assay 
 The WST-1 should be warmed to 37 °C 
 5% of WST-1 of the well volume should be added to pre-warmed complete medium 
 Discard the medium all the wells of 48-well plates 
 Using a sterile P200 pipette tip, 200 µl of pre-warmed medium comprising of WST-1 
should be placed in each well  
 Plate should be wrapped in foil 
 Incubate for 2 hrs at 37 °C (5% CO2) 
 The absorbance measured at 450 nm using a microplate reader  
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Transfection with ATeam indicator 
 Seed cells at a density of 500 cells per well in NUNC 8-well chamber dishes 
 Allow to adhere overnight 
 Refresh the medium 
 Make up Mix 1 and Mix 2 in two separate 0.5 ml eppies 
 Mix 1: Add 1µL DNA (to obtain 800 ng DNA concentration), 100 µL serum-free 
medium, and 2 µL P3000 reagent to Eppendorf tube  
 Mix 2: Add 1 µL lipofectamine and 100 µL serum-free medium to eppie (cold 
re  
 vortex both eppies Briefly 
 Add Mix 1 to Mix 2 and vortex 
 Incubate for 5 min at room temperature 
 Add 50 µL of the transfection medium to each well 
 Incubate for 48 hrs at 37 °C, 5% CO2, refreshing medium 1 h after addition of the 
transfection medium to minimize exposure to the toxic transfection reagent 
 Image cells 48 - 72 hrs after transfection 
 Discard media 
 Wash chamber twice with fresh media  
 Add lysotracker (light sensitive) and fresh media  
 Wrap 8-chamber plate with foil and incubate for 2H 
 Add 2ul of Hoechst to each well in the 8-chamber plate for 10min (remember to cover 
with foil).  
Compounds  EPPIE 1 EPPIE 2 
GFP-galectin3 (1/773,8 ng/ul) X (800 
DNA concentration) = 1ul  
NA 
P3000 1ul per well NA 
Serum free 
media  
50ul per well  50ul per well 
Lipofectamine  NA 0.5ul per well 
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Seeding densities 
 
Consumable  Cells per well Media volume  Time 
T-25    
T-75 (blots) 500000 cells  48 H treatment 
24well-plate   500ul  
48well-plate 2500 cells 500ul 48 H treatment  
96well plate 1000 cells 150ul 48H treatment  
48well-plate 5000 cells 500ul 24H treatment  
8-well chamber  500 cells 200ul 48 H treatment 
 
Treatment  STOCK Working Concentration  
BA 10.94M 5mM 
GB  (Current) 3150ug  
(2) 23000ug  
(3) 1388ug   
(4) 14620ug 
100ug (low) 
400ug (high) 
LiCl 1M 10mM 
BAF 200uM 400nM 
Treatment  Working 
Concentration  
Treatment 
volume  
Media  Time 
BA 5mM 22.85ul 50ml 48 H 
LiCl 10mM 500ul 50ml 24H 
BAF 400nM    
Lysotracker 75nM 0.0150ul in 
200ul 
(8-well 
chamber=200ul/well) 
2H 
Hoechst   1ul (8-well 
chamber=200ul/well) 
10min 
(before 
imaging) 
Silica 250mg/ml   3Hrs 
TMRE 500 nM   20min before 
imaging) 
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Lysotracker (light 
sensitive) 
1mM 75nM 
Hoechst  0.5μg/ml  
Silica 500mg/ml 250mg/ml 
TMRE 25mM 500 nM 
 
Lysotracker : Media 
 0.075ul: 1000ul Media 
Hoescht: Media  
 1ul:200ul Media 
TMRE: Media  
 1ul:1000ul  
 1ul:1000ul  
 Add 1ul of TMRE to 1000ul Media 
 From this solution take 1ul and add it to another 1000ul of media  
Conversions 
 1mM=1000000nM 
 1ml=1000ul 
 1ug=1000mg 
 C1V1=C2V2 
 1um=1000nM 
Media usage  
Experiment  Confluency 
treatment  
Total Media  Treatment  Total treatment 
volume  
Western Blot  70% (12 T-75 X 12ml) 
=144ml 
(three 50ml Tubes of 
media) 
GB 
(400ug) 
GB 
(100ug) 
LiCl 
(10mM) 
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PROTEIN EXTRACTION  
Base Constituents 
 Tris-HCl (buffering agent prevents protein denaturation) 
 NaCl (salt prevents non-specific protein aggregation)  
 NP-40 (non-ionic detergent to extract proteins; 10% stock solution in H2O) or use 
Triton X-100 
 Na-deoxycholate (ionic detergent to extract proteins; 10% stock solution in H2O; 
protect from light) 
 pH to 9.0. Boil, cool, pH again to 9.0. Repeat until colourless 
RIPA Protease Inhibitors 
 Phenylmethylsulfonyl fluoride (PMSF) (200 mM stock solution in isopropanol; store at 
room temperature) 
 EDTA (calcium chelator; 100 mM stock solution in H2O, pH 7.4) 
 Leupeptin (store frozen in aliquots, 1 mg/ml in H2O) 
 Aprotinin (store frozen in aliquots, 1 mg/ml in H2O) 
 Pepstatin (store frozen in aliquots, 1 mg/ml in methanol) 
RIPA Phosphatase Inhibitors 
 Activated Na3VO4 (200 mM stock solution in H2O; see Sodium Orthovanadate 
Activation Protocol) 
 NaF (200 mM stock solution: store at room temperature) 
 Reminder: Do not add phosphatase inhibitors when preparing lysates for 
phosphatase assays. 
 RIPA Trypsin Inhibitors 
 Soyabean Trypsin Inhibitor (SBTI) (1 mg/ml in 0.01 M phosphate buffer, pH 6.5 with 
0.15M NaCl- freeze aliquots at -20OC) 
 Benzamidine (200mM stock solution -dissolve in distilled H2O – store at -200C) 
Procedure:  
Prepare 100 ml modified RIPA buffer as follows:  
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 Add 790 mg Tris base to 75 ml distilled H2O. Add 900 mg NaCl and stir the solution 
until all solids are dissolved. Using HCl, adjust the pH to 7.4. 
 Add 10 ml of 10% NP-40 to the solution. 
 Add 2.5 ml of 10% Na-deoxycholate and stir until solution is clear. 
 Add 1 ml of 100 mM EDTA to the solution. Adjust the volume of the solution to 100 ml 
using a graduated cylinder.  
 Preferably, the remaining protease/ phosphatase inhibitors should be added to the 
solution on the same day you are running the assay Therefore, it is best to aliquot the 
buffer in 10ml aliquots without the protease inhibitors and store at 2-8° C. 
 
RIPA with inhibitors 
On day of use, thaw the required amount of RIPA buffer and add the appropriate volume of 
protease/phosphatase inhibitor cocktail to the amount of RIPA buffer. If metalloproteases are 
present in the tissue, add an appropriate volume of 0.5M EDTA if not included in the cocktail 
itself. Halt Protease & Phosphatase Inhibitor Cocktail is supplied, ready- made and 10ul is 
added to 10ml RIPA on day of tissue lysis. A vial of 0.5M EDTA is also supplied and it is 
added if necessary, also 10ul/10ml RIPA buffer on day of use. 
Causation: PMSF is extremely unstable in aqueous solutions, with a half-life of 
approximately 30 minutes, and it should be added immediately before use. 
Preparation of RIPA Buffer (modified RadioImmunoPrecipitAtion buffer) per T-75 Flask 
 PI  42ul 
 Sodium Orthovanadate (Na3VO4, 200 mM stock solution)  5ul 
 NaF 200 mM stock solution: store at room temperature) 5ul 
 Phenylmethylsulfonyl fluoride (PMSF, 200 mM stock solution)  10ul (add last to 
cocktail, just before adding the RIPA cocktail to cell) 
Materials & equipment 
 Ice (Remember to always put samples on ice) 
 1.5ml eppendorf tubes (18) 
 Aluminium Foil 
 Homogenising tubes 
 Scalpel blade 
 Fine tweezers (forceps) 
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 Tissue homogeniser 
 Sonicator 
 RIPA buffer 
Sample preparation and Protein determination  
Direct Detect Infrared Spectrometer protein determination 
Description 
Catalogue 
Number 
DDHW00010-WW 
Trade Name Direct Detect 
Description Direct Detect Spectrometer 
Overview The Direct Detect™ infrared (IR)-based quantification system is an innovative 
combination of software-controlled instrumentation and EMD Millipore 
Corporation’s advanced membrane technology, optimized for the detection and 
quantification of proteins. Biomolecules are applied directly to a card-based 
hydrophilic polytetrafluoroethylene (PTFE) membrane that is transparent in most 
of the infrared spectral region. The Direct Detect™ system measures amide 
bonds in protein chains, accurately quantifying an intrinsic component of every 
protein without relying on amino acid composition, dye binding properties, or 
redox potential. Protein concentrations from 0.2 to 5 mg/mL can accurately be 
determined from a minimal sample volume (2 μL) without bio- or immuno-
chemical staining. Sample analysis takes only minutes and in most cases can be 
performed directly from the buffered or native solution. 
Applications 
Application By measuring amide bonds in protein chains, the Direct Detect Spectrometer 
system accurately determines an intrinsic component of every protein without 
relying on amino acid composition, dye binding or redox potential. 
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Applications 
Key 
Applications 
Protein Quantitation 
Components of Direct Detect Infrared Spectrometer  
 
Direct Detect Spectrometer- Sample measuring 
 Place the Assay-free cards on the spotting tray or another clean surface 
 Designate one spot for blank measurement (the blank is the buffer (RIPA buffer) used 
to prepare the protein, but there is no protein in it). By default, the Direct Detect 
software designates position 1 as the blank 
 Pipette 2µL of blank into the centre of spot designated as the blank position. Pipette 
2µL of samples to be analysed into the centre of remaining spots  
 Insert Assay-free card vertically into the instrument card holder with the instrument 
and card arrows aligned. The instrument will move the card up and down and sound 
a tone. The green light illuminates to confirm proper insertion  
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 Input samples details into software measurements set up screen. Select method 
(three calibration methods are preloaded), input sample names 
 Click on the measure card button  
 If the Dry sample card option is chosen (recommended), the indicator light will remain 
yellow until the sample is dry 
 The sample concentration will appear on the screen, along with the statistical analysis 
and spectrum plot 
 After all, four positions on the card have been read, the instrument will sound a tone. 
The second card will rise to the initial position and can be removed 
Below is the figure representing exact protocol   
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Sample Preparation 
Laemmli’s loading buffer 
Solution A 
 38ml dH2O 
 10ml 0.5M Tris (pH6.8) use HCl to pH. 
 8ml glycerol 
 16ml 10% SDS 
 4ml 0.05% (w/v) Bromophenol blue 
Materials: 
 Heat box (95°C) 
 Syringe needle 
 Β-mercaptoethanol 
 Ice and 1.5 mL 
 eppendorf  
 tubes 
 Vortex 
 Centrifuge 
Protocol: 
 Work out volume needed for samples (volume should be 40µg/µL) and then: 
 Prepared in 2:1 ratio of protein sample + 3X Laemli’s buffer (Sbuffer). Add Laemli’s 
buffer should be added first followed by the protein sample (place tube on ice)   
 Vortex the protein sample and the boil at 95°C for 5min   
 Spin down samples for 10 seconds and place on ice 
 Samples can now either be stored at -20°C for future use, or loaded onto the gels 
Preparation of 12% BioRad Fast Cast Stain-Free gels according to instructions  
 Assemble the gel casting stand using spacer and short plates 
 Fill the gap between plates to the top with dH2O using a disposable pipette 
 Wait 5 min to check for leaks and readjust if necessary until watertight 
 Remove the dH2O by tipping the rig and use paper towel if necessary 
 Make up the resolving and stacking gel according to the manufacturer’s instructions 
 Resolving gel (for one gel): 
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 Add 3 ml of both Buffer A and Buffer B into a small glass beaker 
 30 µl APS 
  
 Stacking gel (for one gel): 
 Add 1 ml of Buffer A and Buffer B into a separate small glass beaker 
 10 µl APS 
 2 µl TEMED 
 Mix the contents of both beakers thoroughly by swirling their contents 
 Pour Resolver into the gel rig using a disposable pipette to approximately 1 cm from 
the top 
 Pour the Stacker to the top using a new disposable pipette 
 mb(s) gently, avoiding air bubbles 
 Allow the gel(s) to set (30 min – 1 h) 
 Use within three weeks 
 Store at 4 °C and keep moist until use 
Day 1 
 Put on heat box (It takes 20min to reach 95°C)  
 Before you start with the experiment verify if all the solutions are available in the lab 
 Prepare 12% BioRad Fast Cast Stain-Free gels according to instructions  
 (If it’s not stain-free remember to add TCE) 
 Gels can also be prepared in advance and kept in the fridge, by wrapping them in 
soaked paper towels and sealed in cling wrap  
 Protein samples should be thawed on ice (NB proteins samples should always be on 
ice) 
 Prepared in 2:1 ratio of protein sample + 3X Laemli’s buffer (Sbuffer). Add Laemli’s 
buffer should be added first followed by the protein sample (place tube on ice)   
 Vortex the protein sample and the boil at 95°C for 5min   
 Spin down samples for 10 seconds  
 Assemble the gasket 
 Gels should be assembled onto the gasket making sure the comb is facing inward  
 Gasket should Fill the gasket with running buffer – check for leaks 
 Carefully remove the combs and rinse out wells with P200 pipet (set to approx. 100 
ul) and yellow tip 
 Load ladder (4 ul BLUeye) 
 Load samples 
Stellenbosch University  https://scholar.sun.ac.za
  138 
 Place gasket into tank and fill with running buffer (10x: dilute 900ml H20 + 100ml 
running buffer). Re-fill gasket if necessary.  
 Attach lid (black on black, red on red) and plug into power pack 
 Run at 120 V for until you see blue dye runs down to bottom of the tank (this may 
take approximately 1h:45min 
 When finished, activate the gel on ChemiDoc  
 Gel activation protocol, 2.5 min 
 Prepare for transfer (few min beforehand) on TurboBlot tray 
 Place bottom part and roll out any bubbles 
 Place the gel carefully on the bottom transfer pack 
 Place top part of transfer pack 
 Close with lid – be careful not to move lid while closing 
 Transfer on TurboBlot according to desired settings 
 Biorad defined LMWsetting generally works fine 
 After transfer, disassemble stack 
 Activate membrane on chemidoc 
 Select Blots : Chemi : Stain-Free-Blot 
 Mini-protein-gel 
 Rinse in 100% methanol 
 Air-dry membrane  
 Becomes white 
 Hold in fumehood for quicker drying 
 Re-hydrate membrane in 100% methanol 
 Until translucent, 10-15 sec 
 Wash membrane in TBS-T 3x for 5 min 
 Block membrane in 5% milk (prepared in TBS-T) for 1 hr with gentle shaking 
 Wash membrane 3x for 5 min in TBS-T 
 Incubate membrane on primary antibody O/N at 4°C 
 Prepared in 50 ml centrifuge tube 
 Dilute antibody in TBS-T to desired concentration, normally 1:1000 
 5ml TBS-T (5000ul) + 5ul primary AB 
 Attach to rotators in walk-in fridge 
 Make sure tube/s are straight and rotor is balanced 
 
Day 2 
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 Retrieve membranes 
 Stored primary antibody in fridge/freezer 
 Wash membrane 3x 5 min in TBS-T 
 Incubate membrane on secondary antibody for 1 hr at RT 
 Prepared in 50 ml centrifuge tube 
 Dilute antibody in TBS-T to desired concentration, normally 1:5000 
 Place on roller in WB room 
 Wash membrane 3x 5 min in TBS-T 
 Develop 
 Prepare minimum amount of ECL needed in eppie in 1:1 ratio  
 Place membrane on Chemidoc and check position 
 Add ECL to the desired area and roll to ensure even spread. Roll away excess ECL 
 Expose using desired settings 
 Place membrane on tray of Biorad Chemidoc, taking care to remove bubbles. 
 
 
Image analysis:Image analysis on Chemi-Doc: 
 Select “Image Lab” program from desktop on computer 
 The start page will pop up – can choose an existing protocol or create a new one 
 All protocol settings can be modified by selecting the item on the left under “Protocol 
Set Up”  
 For self-poured gels: Select “Blot” and then select “Chemi” from drop down window. 
 Next, set the imaging area to 12 x 9 
 Specify the optimum exposure eg – “intense bands”  
 Default colour is auto selected – you can change this if you want 
 Select “Lane and Band Detection” 
 Select either “Low” or “High” for intense or faint bands or use the “custom” slider to 
set exact sensitivity 
 Select “Analyse MW” then select MW standard used, the lane it is in and the 
regression method (linear, semi-log)- if using Bio-Rad marker can analyse against 
this 
 Generate a report: Specific output, then give a customised name and specify as to 
whether you want it printed or just displayed 
 Get a protocol summary – if ok, save 
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 Load the gel into the imager and position it on the stage using the “position gel” 
button – this will show a live image of the gel’s position – can adjust by opening the 
top door of Chemi-doc (not the drawer where the gel is) -can adjust the zoom 
settings and position to get image exactly as you want it 
 When happy with gel position, Click on “Run Protocol” 
 Once protocol has run, the images and report will be displayed with all selected 
analyses applied 
 Save the images wanted to an appropriate folder in documents. 
 
Day 3 
 Prepare Stripping Buffer 
 15g Glycine 
 10ml 10% SDS 
 10ml Tween-20 
 800ml dH2O 
 Set pH at 2.2 and adjust to final volume of 1l with dH2O 
 Stripping buffer protocol 
 Wash membrane 2 x 10min with TBS-T 
 Add stripping buffer and shake for 15min at RT 
 Replace stripping buffer and shake for another 15min at RT 
 Rinse membrane vigorously in TBS-T twice 
 Wash membrane in TBS-T for ±15min 
 Apply a final wash step of 3 x 5min in TBS-T 
 Block membrane and continue with Ab probing 
 
Base Constituents 
 Tris-HCl (buffering agent prevents protein denaturation) 
 NaCl (salt prevents non-specific protein aggregation)  
 NP-40 (non-ionic detergent to extract proteins; 10% stock solution in H2O) or use 
Triton X-100 
 Na-deoxycholate (ionic detergent to extract proteins; 10% stock solution in H2O; 
protect from light) 
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